Amneal Pharmaceuticals (AMRX) 10-K 3 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Feb. 14, 2023	Jun. 30, 2022
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-38485
Entity Registrant Name	Amneal Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0546926
Entity Address, Address Line One	400 Crossing Boulevard
Entity Address, City or Town	Bridgewater
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08807
City Area Code	908
Local Phone Number	947-3120
Title of 12(b) Security	Class A Common Stock, par value $0.01 per share
Trading Symbol	AMRX
Security Exchange Name	NYSE
Entity Well-Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 470,754,286
Documents Incorporated by Reference	Certain information required to be furnished pursuant to Part III of this Form 10-K will be set forth in, and is hereby incorporated by reference herein from, the registrant’s definitive proxy statement for its 2023 Annual Meeting of Stockholders, to be filed by the registrant with the Securities and Exchange Commission pursuant to Regulation 14A no later than 120 days after December 31, 2022 (the “2023 Proxy Statement”).
Amendment Flag	false
Document Fiscal Period Focus	FY
Entity Central Index Key	0001723128
Document Fiscal Year Focus	2022
Class A Common Stock
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		151,500,830
Class B Common Stock
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		152,116,890

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Iselin, NJ
Auditor Firm ID	42

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net revenue	$ 2,212,304	$ 2,093,669	$ 1,992,523
Cost of goods sold	1,416,485	1,302,004	1,329,551
Cost of goods sold impairment charges	11,111	22,692	34,579
Gross profit	784,708	768,973	628,393
Selling, general and administrative	399,700	365,504	326,727
Research and development	195,688	201,847	179,930
In-process research and development impairment charges	12,970	710	2,680
Intellectual property legal development expenses	4,358	7,716	10,655
Acquisition, transaction-related and integration expenses	709	8,055	8,988
Restructuring and other charges	1,421	1,857	2,398
Change in fair value of contingent consideration	731	200	0
(Insurance recoveries) charges for property losses and associated expenses, net	(1,911)	5,368	0
Charges related to legal matters, net	269,930	25,000	5,860
Other operating income	(3,960)	0	0
Operating (loss) income	(94,928)	152,716	91,155
Other (expense) income:
Interest expense, net	(158,377)	(136,325)	(145,998)
Foreign exchange (loss) gain, net	(12,364)	(355)	16,350
Loss on refinancing - Revolving Credit Facility	(291)	0	0
Gain on sale of international businesses	0	0	123
Other income, net	17,833	15,330	2,590
Total other expense, net	(153,199)	(121,350)	(126,935)
(Loss) income before income taxes	(248,127)	31,366	(35,780)
Provision for (benefit from) income taxes	6,662	11,196	(104,358)
Net (loss) income	(254,789)	20,170	68,578
Less: Net loss (income) attributable to non-controlling interests	125,241	(9,546)	22,481
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest	(129,548)	10,624	91,059
Accretion of redeemable non-controlling interest	(438)	0	0
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.	$ (129,986)	$ 10,624	$ 91,059
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:
Basic (in dollars per share)	$ (0.86)	$ 0.07	$ 0.62
Diluted (in dollars per share)	$ (0.86)	$ 0.07	$ 0.61
Weighted-average common shares outstanding:
Basic (in shares)	150,944	148,922	147,443
Diluted (in shares)	150,944	151,821	148,913

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Other Comprehensive Income [Abstract]
Net (loss) income	$ (254,789)	$ 20,170	$ 68,578
Less: Net loss (income) attributable to non-controlling interests	125,241	(9,546)	22,481
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest	(129,548)	10,624	91,059
Accretion of redeemable non-controlling interest	(438)	0	0
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.	(129,986)	10,624	91,059
Other comprehensive (loss) income:
Foreign currency translation adjustments arising during the period	(26,891)	(8,618)	(13,500)
Unrealized gain (loss) on cash flow hedge, net of tax	97,059	42,430	(70,276)
Less: Other comprehensive (income) loss attributable to non-controlling interests	(35,292)	(17,095)	42,573
Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc.	34,876	16,717	(41,203)
Comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc.	$ (95,110)	$ 27,341	$ 49,856

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 25,976	$ 247,790
Restricted cash	9,251	8,949
Trade accounts receivable, net	741,791	662,583
Inventories	530,735	489,389
Prepaid expenses and other current assets	103,565	110,218
Related party receivables	500	1,179
Total current assets	1,411,818	1,520,108
Property, plant and equipment, net	469,815	514,158
Goodwill	598,853	593,017
Intangible assets, net	1,096,093	1,166,922
Operating lease right-of-use assets	56,121	60,370
Other assets	103,217	20,614
Total assets	3,799,341	3,939,664
Current liabilities:
Accounts payable and accrued expenses	538,199	525,345
Current portion of liabilities for legal matters	107,483	58,000
Revolving credit facility	60,000	0
Current portion of long-term debt, net	29,961	30,614
Related party payables - short term	2,479	47,861
Total current liabilities	752,800	677,243
Long-term debt, net	2,591,981	2,680,053
Note payable - related party	39,706	38,038
Related party payable - long term	9,649	9,619
Other long-term liabilities	87,468	38,903
Total long-term liabilities	2,837,613	2,878,541
Commitments and contingencies (Notes 5 and 21)
Redeemable non-controlling interests	24,949	16,907
Stockholders’ equity:
Preferred stock, $0.01 par value, 2,000 shares authorized; none issued at both December 31, 2022 and 2021	0	0
Additional paid-in capital	691,629	658,350
Stockholders' accumulated deficit	(406,183)	(276,197)
Accumulated other comprehensive income (loss)	9,939	(24,827)
Total Amneal Pharmaceuticals, Inc. stockholders' equity	298,421	360,340
Non-controlling interests	(114,442)	6,633
Total stockholders' equity	183,979	366,973
Total liabilities and stockholders' equity	3,799,341	3,939,664
Common Class A
Stockholders’ equity:
Common stock	1,514	1,492
Common Class B
Stockholders’ equity:
Common stock	1,522	1,522
Excluding Related Party
Current assets:
Operating lease right-of-use assets	38,211	39,899
Financing lease right of use assets	63,424	64,475
Current liabilities:
Current portion of operating lease liabilities	8,321	9,686
Current portion of financing lease liabilities	3,488	3,101
Operating lease liabilities	32,126	32,894
Financing lease liabilities	60,769	60,251
Related Party
Current assets:
Operating lease right-of-use assets	17,910	20,471
Current liabilities:
Current portion of operating lease liabilities	2,869	2,636
Current portion of operating lease liabilities - related party	2,869	2,636
Operating lease liabilities	$ 15,914	$ 18,783

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Class A Common Stock
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	900,000,000	900,000,000
Common stock, shares issued (in shares)	151,490,000	149,413,000
Class B Common Stock
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	152,117,000	152,117,000

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Puniska Healthcare Pvt Ltd	Kashiv Specialty Pharmaceuticals, LLC	Rondo Partners LLC	Subsequent To Combination	Common Stock Class A Common Stock	Common Stock Class B Common Stock	Additional Paid-in Capital	Stockholders’ Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income	Non- Controlling Interests	Non- Controlling Interests Subsequent To Combination
Shares beginning balance (in shares) at Dec. 31, 2019						147,070,000	152,117,000
Stockholders' equity beginning balance at Dec. 31, 2019	$ 346,788					$ 1,470	$ 1,522	$ 606,966	$ (377,880)	$ (68)	$ 114,778
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	67,791								91,059		(23,268)
Foreign currency translation adjustments	(13,500)									(6,643)	(6,857)
Stock-based compensation	$ 20,750							20,750
Exercise of stock options (in shares)	116,681					117,000
Exercise of stock options	$ 321					$ 1		323		(15)	12
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)						487,000
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	(863)					$ 4		268		(32)	(1,103)
Tax distributions, net					$ (2,779)							$ (2,779)
Unrealized gain (loss) on cash flow hedge, net of tax	(70,276)									(34,560)	(35,716)
Non-controlling interests from KSP Acquisition	(3,300)							106			(3,406)
Non-controlling interests from the acquisition				$ 0
Shares ending balance (in shares) at Dec. 31, 2020						147,674,000	152,117,000
Stockholders' equity ending balance at Dec. 31, 2020	344,932					$ 1,475	$ 1,522	628,413	(286,821)	(41,318)	41,661
Redeemable non-controlling interest, beginning balance at Dec. 31, 2019	0
Increase (Decrease) in Temporary Equity [Roll Forward]
Net (loss) income	787
Tax distributions, net	(458)
Non-controlling interests from the acquisition	11,475
Redeemable non-controlling interest, ending balance at Dec. 31, 2020	11,804
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	13,163								10,624		2,539
Foreign currency translation adjustments	(8,618)									(4,255)	(4,363)
Stock-based compensation	$ 28,412							28,412
Exercise of stock options (in shares)	342,350					342,000
Exercise of stock options	$ 853					$ 3		901		(44)	(7)
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)						1,397,000
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	(2,713)					$ 14		624		(182)	(3,169)
Tax distributions, net					(53,486)							(53,486)
Unrealized gain (loss) on cash flow hedge, net of tax	42,430									20,972	21,458
Non-controlling interests from KSP Acquisition											2,000
Non-controlling interests from the acquisition		$ 0	$ 2,000
Shares ending balance (in shares) at Dec. 31, 2021						149,413,000	152,117,000
Stockholders' equity ending balance at Dec. 31, 2021	366,973					$ 1,492	$ 1,522	658,350	(276,197)	(24,827)	6,633
Increase (Decrease) in Temporary Equity [Roll Forward]
Net (loss) income	7,007
Tax distributions, net	(3,646)
Non-controlling interests from the acquisition	1,742
Redeemable non-controlling interest, ending balance at Dec. 31, 2021	16,907
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(270,584)								(129,548)		(141,036)
Foreign currency translation adjustments	(26,891)									(13,394)	(13,497)
Stock-based compensation	$ 31,847							31,847
Exercise of stock options (in shares)	207,452					207,000
Exercise of stock options	$ 662					$ 2		615			45
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)						1,870,000
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	(3,562)					$ 20		817		(110)	(4,289)
Tax distributions, net					$ (10,642)							$ (10,642)
Unrealized gain (loss) on cash flow hedge, net of tax	97,059									48,270	48,789
Reclassification of redeemable non-controlling interest	(883)								(438)		(445)
Acquisition of non-controlling interest from Puniska Acquisition		$ 0
Shares ending balance (in shares) at Dec. 31, 2022						151,490,000	152,117,000
Stockholders' equity ending balance at Dec. 31, 2022	183,979					$ 1,514	$ 1,522	$ 691,629	$ (406,183)	$ 9,939	$ (114,442)
Increase (Decrease) in Temporary Equity [Roll Forward]
Net (loss) income	15,795
Tax distributions, net	(6,914)
Reclassification of redeemable non-controlling interests	883
Acquisition of non-controlling interest from Puniska Acquisition	(1,722)
Redeemable non-controlling interest, ending balance at Dec. 31, 2022	$ 24,949

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net (loss) income	$ (254,789)	$ 20,170	$ 68,578
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	240,175	233,406	235,387
Unrealized foreign currency loss (gain)	15,190	175	(16,728)
Amortization of debt issuance costs and discount	8,595	9,203	8,678
Loss on refinancing - Revolving Credit Facility	291	0	0
Gain on sale of international businesses, net	0	0	(123)
Intangible asset impairment charges	24,081	23,402	37,259
Non-cash restructuring and asset-related (benefit) charges	0	0	(536)
Change in fair value of contingent consideration	731	200	0
Stock-based compensation	31,847	28,412	20,750
Inventory provision	51,096	54,660	75,236
Insurance recoveries for property and equipment losses	(1,000)	(5,000)	0
Non-cash property losses	0	5,152	0
Other operating charges and credits, net	8,828	5,633	11,818
Changes in assets and liabilities:
Trade accounts receivable, net	(79,717)	(23,621)	16,787
Inventories	(102,396)	(49,015)	(113,782)
Prepaid expenses, other current assets and other assets	9,882	(21,981)	33,312
Related party receivables	646	7,311	412
Accounts payable, accrued expenses and other liabilities	109,568	(43,932)	307
Related party payables	2,072	(2,355)	1,646
Net cash provided by operating activities	65,100	241,820	379,001
Cash flows from investing activities:
Purchases of property, plant and equipment	(46,407)	(47,728)	(56,445)
Acquisition of intangible assets	(41,800)	(1,700)	(4,350)
Deposits for future acquisition of property, plant, and equipment	(2,388)	(3,211)	(5,391)
Acquisitions of businesses, net of cash acquired	(84,714)	(146,543)	(251,360)
Proceeds from insurance recoveries for property and equipment losses	1,000	5,000	0
Net cash used in investing activities	(174,309)	(194,182)	(317,546)
Cash flows from financing activities:
Payments of deferred financing and refinancing costs	(1,663)	0	(4,102)
Proceeds from issuance of debt	0	0	180,000
Payments of principal on debt, revolving credit facility, financing leases and other	(123,272)	(78,086)	(35,933)
Borrowings on revolving credit facility	85,000	0	0
Proceeds from exercise of stock options	662	853	321
Employee payroll tax withholding on restricted stock unit vesting	(3,571)	(2,664)	(863)
Payments of deferred consideration for acquisitions - related party	(44,498)	0	0
Acquisition of redeemable non-controlling interests	(1,722)	0	0
Distribution of earnings to and acquisition of non-controlling interest	0	0	(3,300)
Tax distributions to non-controlling interest	(17,556)	(57,132)	(3,237)
Payments of principal on financing lease - related party	0	(93)	(1,079)
Repayment of related party note	0	(1,000)	0
Net cash (used in) provided by financing activities	(106,620)	(138,122)	131,807
Effect of foreign exchange rate on cash	(5,683)	102	1,037
Net (decrease) increase in cash, cash equivalents, and restricted cash	(221,512)	(90,382)	194,299
Cash, cash equivalents, and restricted cash - beginning of period	256,739	347,121	152,822
Cash, cash equivalents, and restricted cash - end of period	35,227	256,739	347,121
Cash and cash equivalents - end of period	25,976	247,790	341,378
Restricted cash - end of period	9,251	8,949	5,743
Supplemental disclosure of cash flow information:
Cash paid for interest	142,722	121,747	130,186
Cash (paid) received, net for income taxes	(12,649)	(15,558)	100,141
Supplemental disclosure of non-cash investing and financing activity:
Notes payable for acquisitions - related party	0	14,162	36,033
Deferred consideration for acquisition - related party	0	30,099	0
Contingent consideration for acquisition	8,796	0	0
Contingent consideration for acquisition - related party	0	5,700	0
Payable for acquisition of product rights and licenses	$ 0	$ 300	$ 0

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations Amneal Pharmaceuticals, Inc. (the “Company”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including complex generics and specialty branded pharmaceuticals. The Company operates principally in the United States, India, and Ireland, and sells to wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies, either directly or indirectly. The Company is a holding company, whose principal assets are common units (“Amneal Common Units”) of Amneal Pharmaceuticals, LLC (“Amneal”). The group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members” or the “Amneal Group”) held 50.1% of Amneal Common Units and the Company held the remaining 49.9% as of December 31, 2022.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Accounting Principles The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated. Principles of Consolidation Although the Company has a minority economic interest in Amneal, it is Amneal’s sole managing member, having the sole voting power to make all of Amneal’s business decisions and controls its management. Therefore, the Company consolidates the financial statements of Amneal and its subsidiaries. The Company records non-controlling interests for the portion of Amneal’s economic interests that it does not hold. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates. Revenue Recognition When assessing its revenue recognition, the Company performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the performance obligation. The Company recognizes revenue when it transfers control of its products to customers, in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those products. From time to time, the Company may enter into arrangements where it licenses certain products to a third-party distributor. Licensing arrangement performance obligations generally include intellectual property (“IP”) rights and research and development (“R&D”) and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company’s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company’s IP. Revenue from sales-based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. For further details on the Company’s revenue recognition policies, refer to Note 4. Revenue Recognition. Stock-Based Compensation The Company’s stock-based compensation consists of stock options, restricted stock units (“RSUs”) and market performance-based restricted stock units (“MPRSUs”) awarded to employees and non-employee directors. Stock options are measured at their fair value on the grant date or date of modification, as applicable. RSUs, including MPRSUs, are measured at the stock price on the grant date or date of modification, as applicable. The Company recognizes compensation expense on a straight-line basis over the requisite service and/or performance period, as applicable. Forfeitures of awards are accounted for as a reduction in stock-based compensation expense in the period such awards are forfeited. The Company's policy is to issue new shares upon option exercises and the vesting of RSUs and MPRSUs. Contingent consideration Business acquisitions may include future payments that are contingent upon the occurrence of certain pharmaceutical regulatory milestones or net sales of pharmaceutical products. For acquisitions that are accounted for as a business combination, the obligations for such contingent consideration payments are recorded at fair value on the acquisition date. For contingent milestone payments, the Company uses a probability-weighted income approach utilizing an appropriate discount rate. For contingent tiered royalties on net sales, the Company uses a Monte Carlo simulation model. Contingent consideration liabilities are revalued to fair value at the end of each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in fair value of contingent consideration in the consolidated statements of operations. Refer to Note 3. Acquisitions and Note 19. Fair Value Measurements for additional information. Foreign Currencies The Company has operations in the U.S., India, Ireland, and other foreign jurisdictions. Generally, the Company’s foreign operating subsidiaries’ functional currency is the local currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Translation adjustments are included in accumulated other comprehensive income (loss) and non-controlling interests in the consolidated balance sheets and are included in comprehensive (loss) income. Transaction gains and losses are included in net (loss) income in the Company’s consolidated statements of operations as a component of foreign exchange (loss) gain, net. Such foreign currency transaction gains and losses include fluctuations related to long term intercompany loans that are payable in the foreseeable future. Translation gains and losses on intercompany balances of a long-term investment nature are included in foreign currency translation adjustments in accumulated other comprehensive income (loss) and non-controlling interests, and comprehensive (loss) income. Business Combinations Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, the acquiring entity in a business combination records the assets acquired and liabilities assumed at the date of acquisition at their fair values. Any excess of the purchase price over the fair value of net assets and other identifiable intangible assets acquired is recorded as goodwill. Acquisition-related costs, primarily professional fees, are expensed as incurred. Cash and Cash Equivalents Cash and cash equivalents consist of cash on deposit and highly liquid investments with original maturities of three months or less. A portion of the Company’s cash flows are derived outside the U.S. As a result, the Company is subject to market risk associated with changes in foreign exchange rates. The Company maintains cash balances at both U.S.-based and international-based commercial banks. At various times during the year, cash balances in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation. Restricted Cash At December 31, 2022 and 2021, respectively, the Company had restricted cash balances of $9.3 million and $8.9 million, respectively, in its bank accounts primarily related to the purchase of certain land and equipment in India. Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary. The Company does not require collateral to secure amounts owed to it by its customers. Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects the best estimate of expected credit losses of the accounts receivable portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. The Company determines its allowance methodology by pooling receivable balances at the customer level. The Company consider various factors, including its previous loss history, individual credit risk associated to each customer, and the current and future condition of the general economy. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent that any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of such customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, account balances are charged off against the allowance when management believes it is probable the receivable will not be recovered. The Company does not have any off-balance-sheet credit exposure related to customers. Chargebacks Received from Manufacturers When a sale occurs on a contracted item, the difference between the cost the Company pays to the manufacturer of that item and the contract price that the end customer has with the manufacturer is rebated to the Company by the manufacturer as a chargeback. Chargebacks are recorded as a reduction to cost of sales and either a reduction in the amount due to the manufacturer (if there is a right of offset) or as a receivable from the manufacturer. Inventories Inventories consist of finished goods held for sale, raw materials, and work in process. Inventories are stated at net realizable value, with cost determined using the first-in, first-out method. Adjustments for excess and obsolete inventories are established based upon historical experience and management’s assessment of current product demand. These assessments include inventory obsolescence based on its expiration date, damaged or rejected product, and slow-moving products. Property, Plant, and Equipment Property, plant, and equipment are stated at historical cost less accumulated depreciation. Depreciation expense is computed primarily using the straight-line method over the estimated useful lives of the assets, which are as follows: Asset Classification Estimated Useful Life Buildings 30 years Computer equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of asset's useful life or remaining life of lease Machinery and equipment 5 - 10 years Vehicles 5 years Upon retirement or disposal, the cost of the asset disposed and the accumulated depreciation are removed from the accounts, and any gain or loss is reflected as part of operating income (loss) in the period of disposal. Expenditures that significantly increase value or extend useful lives of property, plant, and equipment are capitalized, whereas those for normal maintenance and repairs are expensed. The Company capitalizes interest on borrowings during the construction period of major capital projects as part of the related asset and amortizes the capitalized interest into earnings over the related asset’s remaining useful life. Leases All significant lease arrangements are recognized as right-of-use (“ROU”) assets and lease liabilities at lease commencement. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of the future lease payments using the Company's incremental borrowing rate. Operating lease expense is recognized on a straight-line basis over the lease term. At each balance sheet date, operating and financing lease liabilities continue to represent the present value of the future payments. Financing lease ROU assets are expensed using the straight-line method, unless another basis is more representative of the pattern of economic benefit, to lease expense. Interest on financing lease liabilities is recognized in interest expense. Leases with an initial term of 12 months or less (short-term leases) are not recognized in the balance sheet and the related lease payments are recognized as incurred over the lease term. The Company separates lease and non-lease components. A portion of the Company's real estate leases are subject to periodic changes in the Consumer Price Index ("CPI"). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. For further details regarding the Company's leases, refer to Note 18. Leases . In-Process Research and Development The fair value of in-process research and development (“IPR&D”) acquired in a business combination is determined based on the present value of each research project’s projected cash flows using an income approach. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and the life of each research project’s underlying marketability. In determining the fair value of each research project, expected cash flows are adjusted for certain risks of completion, including technical and regulatory risk. The value attributable to IPR&D projects at the time of acquisition is capitalized as an indefinite-lived intangible asset and tested for impairment until the project is completed or abandoned. Upon completion of the project, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized over the estimated useful life of the asset based on the pattern in which the economic benefits are expected to be consumed or otherwise used up or, if that pattern is not readily determinable, on a straight-line basis. If the project is abandoned, the indefinite-lived intangible asset is charged to expense. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company's outlook and market performance of the Company's industry and recent and forecasted financial performance. Goodwill Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. The Company reviews goodwill for possible impairment annually during the fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable. In order to test goodwill for impairment, an entity is permitted to first assess qualitative factors to determine whether a quantitative assessment of goodwill is necessary. The qualitative factors considered by the Company may include, but are not limited to, general economic conditions, the Company’s outlook, market performance of the Company’s industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. If a quantitative assessment is required, the Company determines the fair value of its reporting unit using a combination of the income and market approaches. If the net book value of the reporting unit exceeds its fair value, the Company recognizes a goodwill impairment charge for the reporting unit equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value. See Note 13. Goodwill and Other Intangible Assets , for further discussion of the Company's quantitative assessment of goodwill. Assumptions and estimates used in the evaluation of impairment may affect the carrying value of long-lived assets, which could result in impairment charges in future periods. Such assumptions include projections of future cash flows and the current fair value of the asset. Amortization of Intangible Assets with Finite Lives Intangible assets, other than indefinite-lived intangible assets, are amortized over the estimated useful life of the asset based on the pattern in which the economic benefits are expected to be consumed or otherwise used up or, if that pattern is not readily determinable, on a straight-line basis. The useful life is the period over which the assets are expected to contribute directly or indirectly to future cash flows. Intangible assets are not written-off in the period of acquisition unless they become impaired during that period. The Company regularly evaluates the remaining useful life of each intangible asset that is being amortized to determine whether events and circumstances warrant a revision to the remaining period of amortization. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over that revised remaining useful life. See Note 13. Goodwill and Other Intangible Assets , for further discussion of the Company's intangible assets. Impairment of Long-Lived Assets (Including Intangible Assets with Finite Lives) The Company reviews its long-lived assets, including intangible assets with finite lives, for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company evaluates assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value which is generally an expected present value cash flow technique. Management’s policy in determining whether an impairment indicator exists comprises measurable operating performance criteria as well as other qualitative measures. See Note 13. Goodwill and Other Intangible Assets , for further discussion of the Company's assessment of intangible asset impairment. Financial Instruments The Company minimizes its risks from interest fluctuations through its normal operating and financing activities and, when deemed appropriate through the use of derivative financial instruments. Derivative financial instruments are used to manage risk and are not used for trading or other speculative purposes. The Company does not use leveraged derivative financial instruments. Derivative financial instruments that qualify for hedge accounting must be designated and effective as a hedge of the identified risk exposure at the inception of the contract. Accordingly, changes in fair value of the derivative contract must be highly correlated with changes in fair value of the underlying hedged item at inception of the hedge and over the life of the hedge contract. All derivatives are recorded on the balance sheet as assets or liabilities and measured at fair value. For derivatives designated as cash flow hedges, the effective portion of the changes in fair value of the derivatives are recorded in accumulated other comprehensive loss, net of income taxes and subsequently amortized as an adjustment to interest expense over the period during which the hedged forecasted transaction affects earnings, which is when the Company recognizes interest expense on the hedged cash flows. Cash flows of such derivative financial instruments are classified consistent with the underlying hedged item. Highly effective hedging relationships that use interest rate swaps as the hedging instrument and that meet criteria under ASC 815, Derivatives and Hedging , may qualify for the “short-cut method” of assessing effectiveness. The short-cut method allows the Company to make the assumption of no ineffectiveness, which means that the change in fair value of the hedged item can be assumed to be equal to the change in fair value of the derivative. Unless critical terms change, no further evaluation of effectiveness is performed for these hedging relationships unless a critical term is changed. For a hedging relationship that does not qualify for the short-cut method, the Company measures its effectiveness using the “hypothetical derivative method”, in which the change in fair value of the hedged item must be measured separately from the change in fair value of the derivative. At inception and quarterly thereafter, the Company formally assesses whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. The Company compares the change in the fair value of the actual interest rate derivative to the change in the fair value of a hypothetical interest rate derivative with critical terms that match the hedged interest rate payments. After the initial quantitative assessment, this analysis is performed on a qualitative basis and, if it is determined that the hedging relationship was and continues to be highly effective, no further analysis is required. All components of each derivative financial instrument's gain or loss are included in the assessment of hedge effectiveness. If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive income (loss) net of income taxes, unless it is probable that the forecasted transaction will not occur. If it is probable that the forecasted transaction will not occur by the originally specified time period, the Company discontinues hedge accounting, and any deferred gains or losses reported in accumulated other comprehensive income (loss) are classified into earnings immediately. The Company is subject to credit risk as a result of nonperformance by counterparties to the derivative agreements. Upon inception and quarterly thereafter, the Company makes judgments on each counterparty’s creditworthiness for nonperformance by counterparties. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes , which requires the recognition of tax benefits or expenses on temporary differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company’s consolidated balance sheets as deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. ASC 740-10 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected to be taken in a tax return that affect amounts reported in the financial statements. The Company has reviewed and will continue to review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company’s assessment of the conclusions reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain tax positions, if applicable, as a component of income tax expense. Comprehensive (Loss) Income Comprehensive (loss) income includes net (loss) income and all changes in stockholders’ equity (except those arising from transactions with stockholders) including foreign currency translation adjustments resulting from the consolidation of foreign subsidiaries’ financial statements and unrealized gains (losses) on cash flows hedges, net of income taxes. Research and Development R&D activities are expensed as incurred. R&D expenses primarily consist of direct and allocated expenses incurred with the process of formulation, clinical research, and validation associated with new product development. Upfront and milestone payments made to third parties in connection with R&D collaborations are expensed as incurred up to the point of regulatory approval or when there is no alternative future use. Intellectual Property Legal Development Expenses The Company expenses external intellectual property legal development expenses as incurred. These costs relate to legal challenges of innovator’s patents for invalidity or non-infringement, which are customary in the generic pharmaceutical industry, and are incurred predominately during development of a product and prior to regulatory approval. Associated costs include, but are not limited to, formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend the intellectual property supporting the Company's regulatory filings. Shipping Costs The Company records the costs of shipping product to its customers as a component of selling, general, and administrative expenses as incurred. Shipping costs were $18.7 million, $18.1 million and $17.4 million for the years ended December 31, 2022, 2021 and 2020, respectively. Advertising Costs Advertising costs are expensed as incurred. Advertising costs are included in selling, general and administrative expenses and were $16.8 million, $15.1 million and $15.6 million for the years ended December 31, 2022, 2021 and 2020, respectively. Recently Adopted Accounting Pronouncements In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832) , Disclosures by Business Entities About Government Assistance (“ASU 2021-10”), which requires entities to provide disclosures on material government assistance transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. ASU 2021-10 is effective for the Company’s annual disclosures as of and for the year ended December 31, 2022, with early adoption permissible. The Company elected to adopt this guidance during the second quarter of 2022 in connection with the recognition of cash incentives related to the India Production Linked Incentive Scheme for the Pharmaceutical Sector (“PLI Scheme”). Refer to Note 6. Government Grants , for additional information. Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. These amendments were effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848) , to expand and clarify the scope of Topic 848 to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU 2020-04. In December 2022, the FASB issued ASU 2022-06, Reference Rate reform (Topic 848): Deferral of the Sunset Date of Topic 848 , which deferred the sunset date of Topic 848, Reference Rate Reform to December 31, 2024. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”) , which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers (“ASC 606”). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. ASU 2021-08 is effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company will adopt ASU 2021-08 effective January 1, 2023 and apply the guidance to subsequent acquisitions. The adoption of ASU 2021-08 will only impact the accounting for the Company’s future acquisitions. Reclassification The prior period balance related to liabilities for legal proceedings of $58.0 million, formerly included in accounts payable and accrued expenses as of December 31, 2021, has been reclassified to the balance sheet caption current portion of liabilities for legal matters to conform to the current period presentation in the consolidated balance sheets.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions Acquisitions Saol Baclofen Franchise Acquisition On December 30, 2021, the Company entered into an asset purchase agreement with certain entities affiliated with Saol International Limited (collectively, “Saol”), a private specialty pharmaceutical company, pursuant to which it agreed to acquire Saol’s baclofen franchise, including Lioresal®, LYVISPAH™, and a pipeline product under development (the “Saol Acquisition”). The Saol Acquisition expanded the Company’s commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market. The transaction closed on February 9, 2022. Consideration for the Saol Acquisition included $84.7 million, paid at closing with cash on hand, and contingent royalty payments based on annual net sales for certain acquired assets, beginning in 2023. Cash paid at closing included $1.1 million for inventory acquired in excess of the normalized level, as defined in the asset purchase agreement (working capital adjustment). For the year ended December 31, 2022, the Company incurred $0.1 million in transaction costs associated with the Saol Acquisition, which was recorded in acquisition, transaction-related and integration expenses. The Saol Acquisition was accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer. The purchase price was calculated as follows (in thousands): Cash $ 84,714 Contingent consideration (royalties) (1) 8,796 Fair value of consideration transferred $ 93,510 (1) The estimated fair value of contingent consideration on the acquisition date wa s $8.8 million and was based on significant Level 3 inputs that were not observable in the market. Key assumptions included the discount rate, projected year of payments and expected net product sales. Refer to Note 19. Fair Value Measurements , for additional information on the methodology and determination of this liability. The following is a summary of the purchase price allocation for the Saol Acquisition (in thousands): Final F air Values as of February 9, 2022 Inventory $ 2,162 Prepaid expenses and other current assets 98 Goodwill 7,553 Intangible assets 83,815 Total assets acquired 93,628 Accounts payable and accrued expenses 118 Fair value of consideration transferred $ 93,510 The acquired intangible assets are being amortized over their estimated useful lives as follows (in thousands): Final Fair Value Weighted-Average Marketed product rights $ 83,815 11.5 The estimated fair value of the identifiable intangible assets was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The assumptions, including the expected projected cash flows, utilized in the purchase price allocation and in determining the purchase price were based on management's best estimates as of the closing date of the Saol Acquisition on February 9, 2022. Some of the more significant assumptions inherent in the development of those asset valuations included the estimated net cash flows for each year for each asset (including net revenues, cost of sales, selling and marketing costs and working capital / contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream, as well as other factors. The underlying assumptions used to prepare the discounted cash flow analysis may change; accordingly, for these and other reasons, actual results may vary significantly from estimated results. Goodwill is calculated as the excess of the consideration transferred over the net assets recognized. Of the total goodwill acquired in connection with the Saol Acquisition, $5.2 million was allocated to the Company’s Generics segment and $2.4 million was allocated to the Company’s Specialty segment, of which $4.9 million was deductible for tax purposes. From the acquisition date of February 9, 2022 to December 31, 2022, the Saol Acquisition contributed net revenue and an operating loss of $19.8 million and $7.1 million, respectively. Puniska Healthcare Pvt. Ltd. On November 2, 2021, the Company entered into a definitive agreement to acquire Puniska Healthcare Pvt. Ltd. (“Puniska”), a privately held manufacturer of parenteral and injectable drugs in India, and land in a transaction valued at $93.0 million (the “Puniska Acquisition”). Upon execution of the agreement, the Company paid $72.9 million with cash on hand to acquire approximately 74% of the equity interests of Puniska on November 2, 2021. Upon approval of the transaction by the government of India in March 2022, the Company paid, with cash on hand, an additional $1.7 million for the remaining 26% of the equity interests of Puniska (included in redeemable non-controlling interests in the Company’s consolidated balance sheet as of December 31, 2021) and $14.2 million for the satisfaction of a preexisting payable to the sellers (included in related party payables-short term in the Company’s consolidated balance sheet as of December 31, 2021). In December 2021, the Company paid $4.3 million with cash on hand for land associated with the Puniska Acquisition. For the year ended December 31, 2021 the Company incurred $1.0 million in transaction costs associated with the Puniska Acquisition, which were recorded in acquisition, transaction-related and integration expenses. The Puniska Acquisition, excluding the land acquired in December 2021, was accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer. The purchase price was calculated as follows (in thousands): Cash (1) $ 72,880 Payable to sellers (2) 14,162 Fair value of consideration transferred $ 87,042 (1) Cash includes the payment made upon execution of the agreement. (2) Due to the short-term nature of the payable to the sellers, the principal amount approximates fair value. The following is a summary of the purchase price allocation for the Puniska Acquisition (in thousands): Final Fair Values as of Cash $ 165 Trade accounts receivable, net 232 Inventories 1,092 Prepaid expenses and other current assets 4,473 Property, plant and equipment 53,423 Goodwill 30,091 Operating lease-right-of-use assets 234 Other assets 1,303 Total assets acquired 91,013 Accounts payable and accrued expenses 1,732 Operating lease liabilities 234 Other long-term liabilities 263 Total liabilities assumed 2,229 Redeemable non-controlling interests 1,742 Fair value of consideration transferred $ 87,042 Goodwill is calculated as the excess of the consideration transferred and fair value of the redeemable non-controlling interests over the net assets recognized. All of the goodwill acquired in connection with the Puniska Acquisition was allocated to the Company’s Generics segment and deductible for tax purposes. From the acquisition date of November 2, 2021 to December 31, 2021, the Puniska Acquisition contributed an operating loss of $1.8 million. Kashiv Specialty Pharmaceuticals, LLC Acquisition On January 11, 2021, the Company and Kashiv Biosciences, LLC (a related party, see Note 24. Related Party Transactions ) (“Kashiv”) entered into a definitive agreement for Amneal to acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“KSP”), a subsidiary of Kashiv focused on the development of innovative drug delivery platforms, novel 505(b)(2) drugs and complex generics (the “KSP Acquisition”). On April 2, 2021, the Company completed the KSP Acquisition. Under the terms of the transaction, the cash portion of the consideration was $104.5 million, comprised of a purchase price of $100.1 million (including initial and deferred consideration) and a working capital adjustment of $4.4 million. The cash purchase price was funded by cash on hand. For further detail of the purchase price, refer to the table below. Transaction costs associated with the KSP Acquisition were $3.1 million f or the year ended December 31, 2021 and were included in acquisition, transaction-related and integration expenses. The KSP Acquisition was accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer. The purchase price was calculated as follows (in thousands): Cash, including working capital payments $ 74,440 Deferred consideration (1) 30,099 Contingent consideration (regulatory milestones) (2) 500 Contingent consideration (royalties) (2) 5,200 Settlement of Amneal trade accounts payable due to KSP (3) (7,117) Fair value of consideration transferred $ 103,122 (1) The deferred consideration is stated at the fair value estimate of $30.1 million, which is the $30.5 million contractually stated amount less a $0.4 million discount. The deferred consideration consists of $30.0 million which was paid on January 11, 2022 and $0.5 million, which was paid during three months ended September 30, 2022. As the deferred consideration is non-interest bearing, the Company, using guideline companies and market borrowings with comparable risk profiles, discounted the deferred consideration at 1.7% over the period from April 2, 2021 to the maturity dates, for a fair value of $30.1 million on the date of acquisition. This discount was amortized to interest expense over the life of the deferred consideration utilizing the effective interest rate method. (2) Kashiv is eligible to receive up to an additional $8.0 million in contingent payments upon the achievement of certain regulatory milestones and potential royalty payments from high single-digits to mid double-digits, depending on the amount of aggregate annual net sales for certain future pharmaceutical products. The estimated fair value of contingent consideration on the acquisition date was $5.7 million and was based on significant Level 3 inputs that were not observable in the market. Key assumptions included the discount rate, probability of achievement of milestones, projected year of payments and expected net product sales. Refer to Note 19. Fair Value Measurements , for additional information on the methodology and determination of this liability. (3) Represents trade accounts payable due to KSP that were effectively settled upon closing of the KSP Acquisition. The following is a summary of the purchase price allocation for the KSP Acquisition (in thousands): Final Fair Values as of Cash $ 112 Restricted cash 500 Prepaid expenses and other current assets 381 Property, plant and equipment 5,375 Goodwill 43,530 Intangible assets 56,400 Operating lease right-of-use assets 9,367 Total assets acquired 115,665 Accounts payable and accrued expenses 1,239 Operating lease liability 9,177 Related party payable 127 Total liabilities assumed 10,543 Non-controlling interests 2,000 Fair value of consideration transferred $ 103,122 Total acquired intangible assets of $56.4 million were comprised of marketed product rights of $29.4 million and IPR&D of $27.0 million. The acquired marketed product rights intangible assets are being amortized over their estimated useful lives as follows (in thousands): Fair Value Weighted-Average Marketed product rights $ 29,400 5.9 The estimated fair value of the IPR&D and identifiable intangible assets was determined using the “income approach”, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The assumptions, including the expected projected cash flows, utilized in the purchase price allocation and in determining the purchase price were based on management's best estimates as of the closing date of the KSP Acquisition on April 2, 2021. Some of the more significant assumptions inherent in the development of those asset valuations included the estimated net cash flows for each year for each asset or product (including net revenues, cost of sales, R&D, selling and marketing costs and working capital / contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream, as well as other factors. The underlying assumptions used to prepare the discounted cash flow analysis may change; accordingly, for these and other reasons, actual results may vary significantly from estimated results. Goodwill is calculated as the excess of the consideration transferred and fair value of the non-controlling interests over the net assets recognized. Of the total goodwill acquired in connection with the KSP Acquisition, $40.8 million was allocated to the Company’s Generics segment and $2.7 million was allocated to the Specialty segment, based on the probability weighted cash flows of the assets acquired as of the date of acquisition. None of the goodwill recognized from the KSP Acquisition was deductible for tax purposes. From the acquisition date of April 2, 2021, to December 31, 2021, the KSP Acquisition contributed an operating loss to the Company’s consolidated statements of operations of $21.3 million, which included approximately $5.8 million of amortization expense from intangible assets acquired in the KSP Acquisition. Offsetting the operating loss was a reduction of third-party consulting services and the elimination of royalties due to KSP. AvKARE and R&S Acquisitions On December 10, 2019, the Company, through its investment in Rondo Partners, LLC (“Rondo”), entered into an equity purchase agreement (“Rondo Equity Purchase Agreement”) and an operating agreement to acquire a 65.1% controlling financing interest in both AvKARE Inc., a Tennessee corporation, and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”) (collectively the “Rondo Acquisitions”). Prior to closing, AvKARE, Inc. converted to a limited liability company, AvKARE, LLC. AvKARE, LLC is one of the largest private label providers of generic pharmaceuticals in the U.S. federal agency sector, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. R&S is a national pharmaceutical wholesaler focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. On January 31, 2020, the Company completed the Rondo Acquisitions. The purchase price of $294.2 million included cash of $254.0 million, the issuance of long-term promissory notes to the sellers with an aggregate principal amount of $44.2 million (estimated fair value of $35.0 million) (the “Sellers Notes”) and a short-term promissory note (the “Short-Term Seller Note”) with a principal amount of $1.0 million to the sellers. The cash purchase price was funded by $76.0 million of cash on hand and debt of $178.0 million of proceeds from a $180.0 million term loan. The remaining $2.0 million consisted of working capital costs. The Company is not party to or a guarantor of the term loan, the Sellers Notes or the Short-Term Seller Note. (Refer to Note 16. Debt ). The Rondo Acquisitions were accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer of AvKARE, LLC and R&S. For the year ended December 31, 2020, the Company incurred $1.0 million in transaction costs associated with the Rondo Acquisitions, which was recorded in acquisition, transaction-related and integration expenses. From the acquisition date of January 31, 2020 to December 31, 2020, the Rondo Acquisitions contributed total net revenue of approximately $311.3 million and operating income of $4.4 million, which included approximately $31.9 million of amortization expense from intangible assets acquired in the Rondo Acquisitions, to the Company’s consolidated statements of operations. Unaudited Pro Forma Information The unaudited pro forma combined results of operations for the years ended December 31, 2021 and 2020 (assuming the closing of the Rondo Acquisitions occurred on January 1, 2019 and the closing of the KSP Acquisition occurred on January 1, 2020) are as follows (in thousands): Year Ended December 31, 2021 2020 Net revenue $ 2,093,861 $ 2,023,609 Net income $ 22,523 $ 54,083 Net income attributable to Amneal Pharmaceuticals, Inc. $ 11,802 $ 80,643 The pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the closing of the Rondo Acquisitions taken place on January 1, 2019 and the closing of the KSP Acquisition taken place on January 1, 2020. Furthermore, the pro forma results do not purport to project the future results of operations of the Company. Adjustments to arrive at the unaudited pro forma information primarily related to increases in selling, general and administrative expenses for amortization of acquired intangible assets, net of the applicable tax impact. Acquisition, Transaction-Related and Integration Expenses For the year ended December 31, 2022, acquisition, transaction-related and integration expenses of $0.7 million primarily consisted of professional services fees associated with the Saol Acquisition. For the year ended December 31, 2021, acquisition, transaction-related and integration expenses of $8.1 million primarily consisted of professional services fees associated with the Puniska Acquisition, the KSP Acquisition, and the Rondo Acquisitions. For the year ended December 31, 2020, acquisition, transaction-related and integration expenses of $9.0 million primarily consisted of professional services fees associated with the then pending KSP Acquisition, the Rondo Acquisitions, and systems integrations associated with the acquisition of Impax.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Pharmaceutical Product Sales Performance Obligations The Company’s performance obligation is the supply of finished pharmaceutical products to its customers. The Company’s customers consist primarily of major wholesalers, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions and pharmaceutical companies. The Company’s customer contracts generally consist of both a master agreement, which is signed by the Company and its customer, and a customer submitted purchase order, which is governed by the terms and conditions of the master agreement. Customers purchase product by direct channel sales from the Company or by indirect channel sales through various distribution channels. Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time. The Company offers standard payment terms to its customers and has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing, since the period between when the Company transfers the product to the customer and when the customer pays for that product is one year or less. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues. The consideration amounts due from customers as a result of product sales are subject to variable consideration, as described further below. The Company offers standard product warranties which provide assurance that the product will function as expected and in accordance with specifications. Customers cannot purchase warranties separately and these warranties do not give rise to a separate performance obligation. The Company permits the return of product under certain circumstances, mainly upon product expiration, instances of shipping errors or where product is damaged in transit. The Company accrues for the customer’s right to return as part of its variable consideration. See below for further details. Variable Consideration The Company includes an estimate of variable consideration in its transaction price at the time of sale, when control of the product transfers to the customer. Variable consideration includes but is not limited to: chargebacks, distribution fees, rebates, group purchasing organization (”GPO”) fees, prompt payment (cash) discounts, consideration payable to the customer, billbacks, Medicaid and other government pricing programs, price protection and shelf stock adjustments, sales returns, and profit shares. The Company assesses whether or not an estimate of its variable consideration is constrained and has determined that the constraint does not apply, since it is probable that a significant reversal in the amount of cumulative revenue will not occur in the future when the uncertainty associated with the variable consideration is subsequently resolved. The Company’s estimates for variable consideration are adjusted as required at each reporting period for specific known developments that may result in a change in the amount of total consideration it expects to receive. Chargebacks In the case an indirect customer purchases product from their preferred wholesaler instead of directly from the Company, and the contract price charged to the indirect customer is lower than the wholesaler pricing, the Company pays the direct customer (wholesaler) a chargeback for the price differential. The Company estimates its chargeback accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to chargebacks, current contract terms and historical experience. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Rebates The Company pays fixed or volume-based rebates to its customers based on a fixed amount, fixed percentage of product sales or based on the achievement of a specified level of purchases. The Company’s rebate accruals are based on actual net sales, contractual rebate rates negotiated with customers, and expected purchase volumes / corresponding tiers based on actual sales to date and forecasted amounts. Group Purchasing Organization Fees The Company pays fees to GPOs for administrative services that the GPOs perform in connection with the purchases of product by the GPO participants who are the Company’s customers. The Company’s GPO fee accruals are based on actual net sales, contractual fee rates negotiated with GPOs and the mix of the products in the distribution channel that remain subject to GPO fees. Prompt Payment (Cash) Discounts The Company provides customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The Company’s prompt payment discount accruals are based on actual net sales and contractual discount rates. Consideration Payable to the Customer The Company pays administrative and service fees to its customers based on a fixed percentage of the product price. These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price. The Company accrues for these fees based on actual net sales, contractual fee rates negotiated with the customer and the mix of the products in the distribution channel that remain subject to fees. Billbacks In the case an indirect customer purchases product from their preferred wholesaler instead of directly from the Company, and the contract price charged to the indirect customer is higher than contractual pricing, the Company pays the indirect customer a billback for the price differential. The Company estimates its billback accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to billbacks, current contract terms and historical experience. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Medicaid and Other Government Pricing Programs The Company complies with required rebates mandated by law under Medicaid and other government pricing programs. The Company estimates its government pricing accruals based on monthly sales, historical experience of claims submitted by the various states and jurisdictions, historical rates and estimated lag time of the rebate invoices. Price Protection and Shelf Stock Adjustments The Company provides customers with price protection and shelf stock adjustments which may result in an adjustment to the price charged for the product transferred, based on differences between old and new prices which may be applied to the customer’s on-hand inventory at the time of the price change. The Company accrues for these adjustments when its expected value of an adjustment is greater than zero, based on contractual pricing, actual net sales, accrual rates based on historical average rates, and estimates of the level of inventory of its products in the distribution channel that remain subject to these adjustments. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Sales Returns The Company permits the return of product under certain circumstances, mainly due to product expiration, instances of shipping errors or where product is damaged in transit, and occurrences of product recalls. The Company’s product returns accrual is primarily based on estimates of future product returns based generally on actual net sales, estimates of the level of inventory of its products in the distribution channel that remain subject to returns, estimated lag time of returns and historical return rates. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Profit Shares For certain product sale arrangements, the Company earns a profit share upon the customer’s sell-through of the product purchased from the Company. The Company estimates its profit shares based on actual net sales, estimates of the level of inventory of its products in the distribution channel that remain subject to profit shares, and historical rates of profit shares earned. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. License Agreements Refer to Note 5. Alliance and Collaboration for further information related to revenue recognition associated with a license agreement with multiple performance obligations. Concentration of Revenue The following table summarizes the percentages of net revenues from each of the Company's customers that individually accounted for 10% or more of its net revenues: For the year ended December 31, 2022 2021 2020 Customer A 21 % 21 % 23 % Customer B 18 % 20 % 17 % Customer C 22 % 24 % 23 % Customer D 10 % 10 % 11 % Disaggregated Revenue The Company's significant therapeutic classes for each of its reportable segments, as determined based on net revenue for each of the years ended December 31, 2022, 2021 and 2020 are set forth below (in thousands): Year ended December 31, 2022 2021 2020 Generics Anti-Infective $ 23,193 $ 30,501 $ 40,381 Hormonal/Allergy 444,909 427,077 355,581 Antiviral (1) 40,601 4,832 25,724 Central Nervous System 393,281 381,110 422,405 Cardiovascular System 118,183 141,866 114,226 Gastroenterology 70,796 76,497 78,165 Oncology 64,285 103,327 61,113 Metabolic Disease/Endocrine 41,128 38,462 45,004 Respiratory 41,085 35,965 37,389 Dermatology 66,553 55,474 58,168 Other therapeutic classes 118,573 69,928 102,721 License agreement (2) 8,018 — — International and other 1,468 1,299 2,333 Total Generics net revenue 1,432,073 1,366,338 1,343,210 Specialty Hormonal/Allergy 91,465 68,397 54,631 Central Nervous System 255,656 277,196 285,737 Other therapeutic classes 27,000 32,726 15,199 Total Specialty net revenue 374,121 378,319 355,567 AvKARE (3) Distribution 260,560 192,921 161,673 Government Label 98,234 118,379 104,054 Institutional 27,742 25,176 18,546 Other 19,574 12,536 9,473 Total AvKARE net revenue 406,110 349,012 293,746 Total net revenue $ 2,212,304 $ 2,093,669 $ 1,992,523 (1) Antiviral net revenue for the year ended December 31, 2021 decreased from the prior year primarily due to a decline in Oseltamivir (generic Tamiflu®) sales from lower demand and increased returns activity above historical levels as a result of decreased influenza activity during the onset of the COVID-19 pandemic. (2) Refer to Note 5. Alliance and Collaboration for information on revenue recognized under a license agreement. (3) The AvKARE segment consists of the businesses acquired in the Rondo Acquisitions on January 31, 2020. Net revenue for the year ended December 31, 2020 represents eleven months of activity. A rollforward of the major categories of sales-related deductions for the years ended December 31, 2022, 2021 and 2020 is as follows (in thousands): Contract Charge- Cash Accrued Accrued Balance at December 31, 2019 $ 829,807 $ 34,308 $ 150,361 $ 114,960 Impact of the Rondo Acquisitions 12,444 944 11,606 10 Provision related to sales recorded in the period 3,930,682 118,525 110,556 133,748 Credits/payments issued during the period (4,144,129) (131,087) (97,539) (117,630) Balance at December 31, 2020 628,804 22,690 174,984 131,088 Provision related to sales recorded in the period 3,164,331 107,810 105,127 137,452 Credits/payments issued during the period (3,289,233) (106,858) (118,133) (182,803) Balance at December 31, 2021 503,902 23,642 161,978 85,737 Provision related to sales recorded in the period 3,416,149 112,609 84,306 129,203 Credits/payments issued during the period (3,346,459) (108,797) (101,224) (128,910) Balance at December 31, 2022 $ 573,592 $ 27,454 $ 145,060 $ 86,030

Alliance and Collaboration

Alliance and Collaboration	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Alliance and Collaboration	Alliance and Collaboration The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements which generally obligate the Company to provide R&D services over multiple periods. The Company's significant arrangements are discussed below. License Agreement On December 28, 2022, Amneal signed a long-term license agreement with Orion Corporation (“Orion”), a globally operating Finnish pharmaceutical company, to commercialize a number of our complex generic products in most parts of Europe, Australia and New Zealand (the “Orion Agreement”). The initial term of the Orion Agreement commences upon commercial launch of the products and will continue for eight years. The Orion Agreement will automatically renew for successive two-year terms unless either party declines such renewal in writing at least one year in advance. Under the terms of the Orion Agreement, Amneal granted Orion licenses to certain generic products commercially available in the U.S. today and select high-value pipeline products currently under development. In addition, Amneal will be responsible for the performance of all R&D activities to be conducted to obtain regulatory approval for each product. Amneal is entitled to be reimbursed for a percentage of mutually agreed upon R&D expenses from Orion. Orion will be responsible for preparing and filing regulatory documentation, along with paying any application fees seeking regulatory approval for the products. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Orion. Orion will be responsible for all commercialization and marketing activities for the territories described above. Amneal will earn revenue for supplying products to Orion at the greater of: (i) cost plus a stated margin, or (ii) a fixed percentage of the net selling price, as defined in the Orion Agreement. Upon signing of the Orion Agreement, Amneal was entitled to an upfront, non-refundable payment of €20.0 million, or $21.4 million, based on the exchange rate as of December 31, 2022. Amneal is eligible to receive certain one-time sales-based milestones in the aggregate of €45.0 million, or $48.2 million, based on the exchange rate as of December 31, 2022, contingent upon whether Orion achieves certain annual sales targets. The Orion Agreement is within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”). The Company identified performance obligations related to: 1) the grant of a license of functional IP, 2.) the performance of R&D activities, and 3.) the supply of products. The Company evaluated that the grant of licenses is in the scope of ASC 606, whereas the performance of R&D activities is in the scope of ASC 730-20, Research and Development Arrangements , because the Company determined that performing R&D activities on behalf of other parties is not part of the ordinary activities of its business. The Company will record reimbursement received from Orion for R&D activities as a reduction of R&D expense. The Company concluded each future purchase order from Orion represents a separate contract. Amneal will record revenue related to each purchase order when it transfers control of the products to Orion. As of December 31, 2022, Amneal has not performed any reimbursable R&D activities under the Orion Agreement or supplied any products to Orion. The Company determined that the transaction price under the arrangement was the upfront payment of $21.4 million, which was allocated to the performance obligations based on their relative standalone selling prices. The remaining sales-based milestones payments of $48.2 million are variable consideration and were not included in the transaction price because they were fully constrained under ASC 606. As of December 31, 2022, the Company recorded a $21.4 million receivable in prepaid expenses and other current assets for the upfront payment due from Orion, which was received in January 2023. For the year ended December 31, 2022, the Company recognized $8.0 million in license revenue related to the delivery of functional IP, which was recorded in net revenues. The remaining $13.4 million of the transaction price was allocated to the R&D activities performance obligation and was recorded as deferred income, of which $6.7 million was recorded in accounts payable and accrued expenses and $6.7 million was recorded in other long-term liabilities as of December 31, 2022. Deferred income related to R&D activities will be recognized, along with the amounts reimbursed by Orion, as reductions to R&D expense in future periods as services are performed. Levothyroxine License and Supply Agreement; Transition Agreement On August 16, 2018, the Company entered into a license and supply agreement with Jerome Stevens Pharmaceuticals, Inc. (“JSP”) for levothyroxine sodium tablets (“Levothyroxine”). This agreement designated the Company as JSP's exclusive commercial partner for Levothyroxine in the U.S. market for a 10-year term commencing on March 22, 2019. Under this license and supply agreement with JSP, the Company accrued the up-front license payment of $50.0 million on March 22, 2019, which was paid in April 2019. The agreement also provides for the Company to pay a profit share to JSP based on net profits of the Company's sales of Levothyroxine, after considering product costs. As a result of significant price erosion associated with the Levothyroxine products licensed from JSP, the Company recorded a $17.7 million cost of goods sold impairment charge for the year ended December 31, 2021 to recognize an impairment on the entire unamortized balance of the up-front license payment (refer to Note 13. Goodwill and Other Intangible Assets for additional information). Biosimilar Licensing and Supply Agreement On May 7, 2018, the Company entered into a licensing and supply agreement with Mabxience S.L., for its biosimilar candidate for Avastin® (bevacizumab). The supply agreement was subsequently amended on March 2, 2021 and the licensing agreement was amended on March 4, 2021. The Company will be the exclusive partner in the U.S. market. The Company will pay up-front, development and regulatory milestone payments as well as commercial milestone payments on reaching pre-agreed sales targets in the market to Mabxience, up to $78.3 million. For the years ended December 31, 2021 and 2020, the Company recognized $11.7 million and $4.5 million, respectively, of milestones in R&D expense related to the agreement (none for the year ended December 31, 2022). On April 13, 2022, the Food and Drug Administration (“FDA”) approved the Company’s biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®. In connection with this regulatory approval and associated activity, the Company paid milestones of $26.5 million during the year ended December 31, 2022, which were capitalized as product rights intangible assets and are being amortized to cost of sales over their estimated useful lives of 7 years. Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited In January 2012, Impax entered into an agreement with AstraZeneca UK Limited (“AstraZeneca”) to distribute branded products under the terms of a distribution, license, development and supply agreement (the “AZ Agreement”). The parties subsequently entered into a First Amendment to the AZ Agreement dated May 31, 2016 (as amended, the “AZ Amendment”). Under the terms of the AZ Agreement, AstraZeneca granted to Impax an exclusive license to commercialize the tablet, orally disintegrating tablet and nasal spray formulations of Zomig® (zolmitriptan) products for the treatment of migraine headaches in the United States and in certain U.S. territories, except during an initial transition period when AstraZeneca fulfilled all orders of Zomig® products on Impax’s behalf and AstraZeneca paid to Impax the gross profit on such Zomig® products. Pursuant to the AZ Amendment, under certain conditions, and depending on the nature and terms of the study agreed to with the FDA, Impax agreed to conduct, at its own expense, the juvenile toxicity study and pediatric study required by the FDA under the Pediatric Research Equity Act (“PREA”) for approval of the nasal formulation of Zomig® for the acute treatment of migraine in pediatric patients ages six through eleven years old, as further described in the study protocol mutually agreed to by the parties (the “PREA Study”). In consideration for Impax conducting the PREA Study at its own expense, the AZ Amendment provided for the total royalty payments payable by Impax to AstraZeneca on net sales of Zomig® products under the AZ Agreement to be reduced by an aggregate amount of $30.0 million to be received in quarterly amounts specified in the Amendment beginning from the quarter ended June 30, 2016 through the quarter ended December 31, 2020. In the event the royalty reduction amounts exceeded the royalty payments payable by Impax to AstraZeneca pursuant to the AZ Agreement in any given quarter, AstraZeneca was required to pay Impax an amount equal to the difference between the royalty reduction amount and the royalty payment payable by Impax to AstraZeneca. Impax’s commitment to perform the PREA Study could have been terminated, without penalty, under certain circumstances as set forth in the AZ Amendment. The Company recognized the amounts received from AstraZeneca for the PREA Study as a reduction of R&D expense. The PREA study was completed during March 2021. In May 2013, Impax’s exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and Impax launched authorized generic versions of those products in the United States. The pediatric exclusivity of the AstraZeneca patent licensed to Impax for Zomig® Spray expired in May 2021 and the Company lost market exclusivity in the fourth quarter of 2021. As discussed above, pursuant to the AZ Amendment, the total royalty payments payable by Impax to AstraZeneca on net sales of Zomig® products under the AZ Agreement was reduced by certain specified amounts beginning from the quarter ended June 30, 2016 through the quarter ended December 31, 2020, with such reduced royalty amounts totaling an aggregate amount of $30.0 million. The Company recorded cost of goods sold for royalties under this agreement of $1.4 million, $12.5 million, and $17.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. Agreements with Kashiv Biosciences, LLC For detail on the Company’s related party agreements with Kashiv Biosciences, LLC, refer to Note 24. Related Party Transactions .

Government Grants

Government Grants	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Government Grants	Government Grants In November 2021, Amneal Pharmaceuticals Private Limited, a subsidiary of the Company in India, was selected as one of 55 companies to participate in the PLI Scheme. The Government of India established the PLI Scheme to make India’s domestic manufacturing more globally competitive and to create global champions within the pharmaceutical sector by encouraging investment and product diversification with a focus on manufacturing complex and high value goods. Under the PLI Scheme, the Company is eligible to receive up to 10.0 billion Indian rupees, or approximately $120.8 million (based on conversion rates as of December 31, 2022), over a maximum six-year period, starting in 2022. To be eligible to receive the cash incentives, Amneal must achieve (i) minimum cumulative expenditures towards developmental and/or capital investments; and (ii) a minimum percentage growth in sales of eligible products. The Company has concluded the PLI Scheme is government assistance in the form of a grant and, in the absence of specific accounting guidance under U.S. GAAP, the Company has analogized to International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance . The Company evaluated the PLI Scheme to be a grant related to income and will recognize the cash incentives on a systematic basis in other operating income. For the year ended December 31, 2022, the Company recognized approximately $4.0 million of income associated with the PLI Scheme, all of which was recorded as a receivable from the government of India in prepaid and other current assets as of December 31, 2022.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Amneal is a limited liability company that is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, Amneal is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by Amneal is passed through to and included in the taxable income or loss of its members, including the Company, on a pro rata basis subject to applicable tax regulations. The Company is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to its allocable share of any taxable income or loss of Amneal, as well as any stand-alone income or loss generated by the Company. Amneal provides for income taxes in the various foreign jurisdictions in which it operates. The Company recorded a deferred tax asset for its outside basis difference in its investment in Amneal on May 4, 2018. The Company recorded a deferred tax asset related to the net operating loss of Impax from January 1, 2018 through May 4, 2018, as well as certain federal and state credits and interest carryforwards of Impax that were attributable to the Company. The Company records its valuation allowances against its deferred tax assets (“DTAs”) when it is more likely than not that all or a portion of a DTA will not be realized. The Company routinely evaluates the realizability of its DTAs by assessing the likelihood that its DTAs will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, the Company considers its historical results and incorporates certain assumptions, including projected new product launches, revenue growth, and operating margins, among others. The Company established a valuation allowance based upon all available objective and verifiable evidence both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. Since first establishing a valuation allowance, the Company has generated cumulative consolidated three year pre-tax losses through December 31, 2022. As a result of the losses through December 31, 2022, the Company determined that it is more likely than not that it will not realize the benefits of its gross DTAs and therefore maintained its valuation allowance. As of December 31, 2022, this valuation allowance was $434.9 million, and it reduced the carrying value of these gross DTAs, net of the impact of the reversal of taxable temporary differences, to zero. In connection with the acquisition of Impax, the Company entered into a tax receivable agreement (“TRA”) for which it is generally required to pay the other holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal Common Units for shares of Class A Common Stock and (ii) tax benefits attributable to payments made under the TRA. In conjunction with the valuation allowance recorded on the DTAs, the Company reversed the accrued TRA liability of $192.8 million, which resulted in a gain recorded in other (expense) income, net for the year ended December 31, 2019. The timing and amount of any payments under the TRA may vary, depending upon a number of factors including the timing and number of Amneal common units sold or exchanged for the Company's Class A Common Stock, the price of the Company’s Class A Common Stock on the date of sale or exchange, the timing and amount of the Company’s taxable income, and the tax rate in effect at the time of realization of the Company’s taxable income (the TRA liability is determined based on a percentage of the corporate tax savings from the use of the TRA’s attributes). Further sales or exchanges occurring subsequent to December 31, 2022 could result in future Amneal tax deductions and obligations to pay 85% of such benefits to the holders of Amneal Common Units. These obligations could be incremental to and substantially larger than the approximate $202.7 million contingent liability as of December 31, 2022 described below. Under certain conditions, such as a change of control or other early termination event, the Company could be obligated to make TRA payments in advance of tax benefits being realized. As noted above, the Company has determined it is more-likely-than-not it will be unable to utilize its DTAs subject to TRA; therefore, as of December 31, 2022, the Company has not recognized the entire contingent liability under the TRA related to the tax savings it may realize from common units sold or exchanged. If utilization of these DTAs becomes more-likely- than-not in the future, at such time, these TRA liabilities (which amounted to approximately $202.7 million at December 31, 2022) will be recorded through charges in the Company’s consolidated statements of operations. Each year, we evaluate the realizability of the deferred tax assets resulting from the sale or exchange of Amneal Common Units for Class A common stock. Although the deferred tax assets are not determined to be realizable, as of December 31, 2022, the Company had assessed that a TRA liability of $0.6 million had become probable. Accordingly, the Company recorded an expense associated with the TRA in other income, net of $0.6 million for the year ended December 31, 2022. In subsequent periods, the Company will continue to evaluate whether any future TRA payments become probable and can be estimated and, if so, the estimate of payment will be accrued. On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the COVID-19 pandemic which, among other things, includes provisions relating to income and non-income-based tax laws. As a result of the CARES Act, the Company carried back approximately $345.0 million in NOLs generated in 2018 to prior taxable income years. In carrying back the 2018 loss to an earlier year, the Company was able to benefit the losses at a 35% tax rate rather than the current U.S. corporate tax rate of 21%. Accordingly, the Company recorded a discrete income tax benefit of $110.0 million for the year ended December 31, 2020. During July 2020, the Company received a cash refund for $106.0 million of the $110.0 million NOL carryback, plus interest of approximately $4.0 million, with an additional $2.0 million received in February of 2021. The remainder of the NOL carryback is expected to be received before December 31, 2023. For the years ended December 31, 2022, 2021 and 2020 the Company's provision for (benefit from) income taxes and effective tax rates were $6.7 million and (2.7)%, $11.2 million and 35.7%, and $(104.4) million and 291.7%, respectively. The Company and its subsidiaries file income tax returns in the U.S. federal, and various state, local and foreign jurisdictions. The Internal Revenue Services (“IRS”) has completed an income tax audit for the 2018 tax return, the year of the Company’s CARES Act carryback. The Company sustained the entire carryback and therefore, the statute is closed for 2018 and prior years. The Company’s 2019 through 2021 tax years remain open to IRS exam. In the U.S., income tax returns are generally subject to examination for a period of three years. Neither the Company nor any of its other affiliates is currently under audit by the IRS. The Amneal partnership is currently under examination in certain states and the Company does not expect any material adjustments as of December 31. 2022. The components of the Company's (loss) income before income taxes were as follows (in thousands): Years Ended December 31, 2022 2021 2020 United States $ (260,616) $ (10,540) $ (99,966) International 12,489 41,906 64,186 Total (loss) income before income taxes $ (248,127) $ 31,366 $ (35,780) The provision for (benefit from) income taxes was comprised of the following (in thousands): Years Ended December 31, 2022 2021 2020 Current: Domestic $ (1,073) $ 1,311 $ (113,754) Foreign 7,735 9,885 9,396 Total current income tax $ 6,662 $ 11,196 $ (104,358) For the years ended December 31, 2022, 2021, and 2020, the Company did not record a provision for deferred income taxes as a result of recording a full valuation allowance on its DTAs. The Company’s effective tax rates were as follows: Years Ended December 31, 2022 2021 2020 Federal income tax at the statutory rate 21.0 % 21.0 % 21.0 % State income tax, net of federal benefit (0.8) 4.2 (2.0) Income not subject to tax (10.7) 6.4 (29.8) Foreign rate differential (3.4) 17.3 (7.1) Permanent book/tax differences (0.3) 4.8 — CARES Act — — 139.9 Valuation allowance (10.3) (13.5) 163.2 Other 1.8 (4.5) 6.5 Effective income tax rate (2.7) % 35.7 % 291.7 % The change in effective income tax rate for the year ended December 31, 2022 compared to the year ended December 31, 2021 was primarily due to the timing and mix of income and to the release of reserves for uncertain tax positions. The change in effective income tax rate for the year ended December 31, 2021 compared to the year ended December 31, 2020 was primarily due to the $110.0 million benefit from the carryback of U.S. Federal DTAs under the CARES Act for the year ended December 31, 2020 described above. The following table summarizes the changes in the Company’s valuation allowance on deferred tax assets (in thousands): Years Ended December 31, 2022 2021 2020 Balance at the beginning of the period $ 416,588 $ 422,812 $ 470,193 Increase (decrease) due to net operating losses and temporary differences 25,589 (10,828) (54,971) Increase due to stock-based compensation 224 5,513 — Decrease recorded against goodwill (1,590) — — Increase (decrease) recorded against additional paid-in capital 2,720 2,842 (1,631) (Decrease) increase recorded against other comprehensive income (8,636) (3,751) 9,221 Balance at the end of the period $ 434,895 $ 416,588 $ 422,812 At December 31, 2022, the Company had approximately $136.4 million of foreign net operating loss carry forwards. These net operating loss carry forwards will partially expire, if unused, between 2029 and 2031. At December 31, 2022, the Company had approximately $253.8 million of federal and $173.8 million of state net operating loss carry forwards. The federal net operating losses are generally allowed to be carried forward indefinitely, and the majority of the state net operating losses will expire, if unused, between 2034 and 2042. At December 31, 2022, the Company had approximately $13.3 million of federal R&D credit carry forwards and $12.3 million of state R&D credit carry forwards. The majority of the federal R&D credit carry forwards will expire if unused, between 2034 and 2042 and the majority of state credits can be carried forward indefinitely. The tax effects of temporary differences that give rise to deferred taxes were as follows (in thousands): December 31, December 31, Deferred tax assets: Partnership interest in Amneal $ 203,336 $ 200,872 Projected imputed interest on TRA 25,255 25,615 Net operating loss carryforward 82,338 73,861 IRC Section 163(j) interest carryforward 54,996 46,407 Capitalized costs 2,505 1,300 Accrued expenses 431 498 Stock-based compensation 5,737 5,513 Intangible assets 23,967 28,380 Tax credits and other 36,330 34,142 Total deferred tax assets 434,895 416,588 Valuation allowance (434,895) (416,588) Net deferred tax assets $ — $ — The Company's Indian subsidiaries are primarily export-oriented and in some cases are eligible for certain limited income tax holiday benefits granted by the government of India for export activities conducted within Special Economic Zones, or SEZs, up to March 31, 2023. Indian profits ineligible for SEZ benefits are subject to corporate income tax at the rate of 34.9%. In addition, all Indian profits, including those generated within SEZs, are subject to the Minimum Alternate Tax (MAT), at the rate of 21.5%. For the years ended December 31, 2022, 2021 and 2020, the effect of income tax holidays granted by the Indian government reduced the overall provision for income taxes, increased the benefit from income taxes and increased net income/decreased net loss by approximately $5.0 million, $3.0 million, and $3.0 million, respectively. After the expiration of SEZ benefit, the Company will claim a reduced tax rate in India of approximately 25.17%. The Company accounts for income tax contingencies using the benefit recognition model. The Company will recognize a benefit if a tax position is more likely than not to be sustained upon audit, based solely on the technical merits. The benefit is measured by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information. The amount of unrecognized tax benefits at December 31, 2022, 2021, and 2020, was $3.6 million, $5.5 million and $5.4 million, respectively, of which $3.5 million, $5.4 million and $5.0 million, respectively, would impact the Company’s effective tax rate if recognized. The Company currently does not believe that the total amount of unrecognized tax benefits will increase or decrease significantly over the next 12 months. Interest expense related to income taxes is included in provision for (benefit from) income taxes. Net interest expense (benefit) related to unrecognized tax benefits for the years ended December 31, 2022, 2021 and 2020 was $(0.7) million, $0.1 million and $(0.3) million, respectively. Accrued interest expense as of December 31, 2022, 2021, and 2020 was $0.1 million, $0.8 million, and $0.8 million, respectively. Income tax penalties are included in provision for (benefit from) income taxes. Accrued tax penalties as of December 31, 2022, 2021 and 2020 were immaterial. A rollforward of unrecognized tax benefits for the years ended December 31, 2022, 2021 and 2020 is as follows (in thousands): Years Ended December 31, 2022 2021 2020 Unrecognized tax benefits at the beginning of the period $ 5,489 $ 5,368 $ 6,176 Gross change for current period positions 110 131 125 Gross change for prior period positions (1,983) (10) 443 Decrease due to settlements and payments — — (1,376) Unrecognized tax benefits at the end of the period $ 3,616 $ 5,489 $ 5,368 In India, the income tax return for the fiscal year ending March 31, 2019 is currently being reviewed by tax authorities as part of the normal procedures, and the Company is not expecting any material adjustments. There are no other income tax returns in the process of examination, administrative appeal, or litigation. Income tax returns are generally subject to examination for a period of 3 years, 5 years, and 4 years after the tax year in India, Switzerland, a nd Ireland, respectively. Applicable foreign taxes (including withholding taxes) have not been provided on the approximately $111.0 million of undistributed earnings of foreign subsidiaries as of December 31, 2022. These earnings have been and currently are considered to be indefinitely reinvested. Quantification of additional taxes that may be payable on distribution is not practicable.

(Loss) Earnings per Share

(Loss) Earnings per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
(Loss) Earnings per Share	(Loss) Earnings per ShareBasic (loss) earnings per share of Class A common stock is computed by dividing net (loss) earnings attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted (loss) earnings per share of Class A common stock is computed by dividing net (loss) earnings attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period, adjusted to give effect to potentially dilutive securities. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted (loss) earnings per share of Class A common stock (in thousands, except per share amounts): Years Ended December 31, 2022 2021 2020 Numerator: Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (129,986) $ 10,624 $ 91,059 Denominator: Weighted-average shares outstanding - basic 150,944 148,922 147,443 Effect of dilutive securities Stock options — 767 348 Restricted stock units — 2,132 1,122 Weighted-average shares outstanding - diluted 150,944 151,821 148,913 Net (loss) earnings per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: Basic $ (0.86) $ 0.07 $ 0.62 Diluted $ (0.86) $ 0.07 $ 0.61 Shares of the Company’s Class B common stock do not share in the earnings or losses of the Company and, therefore, are not participating securities. As such, separate presentation of basic and diluted (loss) earnings per share of Class B common stock under the two-class method has not been presented. The following table presents potentially dilutive securities excluded from the computations of diluted (loss) earnings per share of Class A common stock (in thousands). Years Ended December 31, 2022 2021 2020 Stock options 2,648 (1) 347 (3) 671 (3) Restricted stock units 10,755 (1) — — Performance stock units 7,174 (1) 5,055 (4) 2,973 (4) Shares of Class B common stock 152,117 (2) 152,117 (2) 152,117 (2) (1) Excluded from the computation of diluted loss per share of Class A common stock for the years ended December 31, 2022 because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company for the year ended December 31, 2022. (2) Shares of Class B common stock are considered potentially dilutive shares of Class A common stock. Shares of Class B common stock have been excluded from the computations of diluted (loss) earnings per share of Class A common stock for each of the years ended December 31, 2022, 2021 and 2020 because the effect of their inclusion would have been anti-dilutive under the if-converted method. (3) Excluded from the computation of diluted earnings per share of Class A common stock for the years ended December 31, 2021 and 2020 because the exercise price of the stock options exceeded the average market price of the Class A common stock during the period (out-of-the-money). (4) Excluded from the computation of diluted earnings per share of Class A common stock for the years ended December 31, 2021 and 2020 because the performance vesting conditions were not met.

Trade Accounts Receivable, Net

Trade Accounts Receivable, Net	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Trade Accounts Receivable, Net	Trade Accounts Receivable, Net Trade accounts receivable, net is comprised of the following (in thousands): December 31, December 31, Gross accounts receivable $ 1,344,959 $ 1,191,792 Allowance for credit losses (2,122) (1,665) Contract charge-backs and sales volume allowances (1) (573,592) (503,902) Cash discount allowances (27,454) (23,642) Subtotal (603,168) (529,209) Trade accounts receivable, net $ 741,791 $ 662,583 (1) Refer to Note 4. Revenue Recognition for additional information. Concentration of Receivables Trade accounts receivables from customers representing 10% or more of the Company’s total trade accounts receivable were as follows: December 31, 2022 December 31, 2021 Customer A 41 % 37 % Customer B 25 % 24 % Customer C 21 % 25 %

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are comprised of the following (in thousands): December 31, December 31, Raw materials $ 224,607 $ 214,508 Work in process 58,522 47,802 Finished goods 247,606 227,079 Total inventories $ 530,735 $ 489,389

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are comprised of the following (in thousands): December 31, December 31, Deposits and advances $ 1,821 $ 1,174 Prepaid insurance 8,090 7,962 Prepaid regulatory fees 5,298 3,710 Escrow deposits for legal settlements (1) — 33,000 Income and other tax receivables 12,881 8,850 Prepaid taxes 16,593 16,085 Other current receivables (2) 33,133 9,770 Other prepaid assets 17,144 17,309 Chargebacks receivable (3) 8,605 12,358 Total prepaid expenses and other current assets $ 103,565 $ 110,218 (1) Escrow deposits for legal settlements included preliminary settlement escrow deposits by the Company’s insurers of $33.0 million as of December 31, 2021, associated with insured securities class action lawsuits. Refer to Note 21. Commitments and Contingencies for additional details regarding these matters. This escrow deposit was used to satisfy the securities class action Fleming v. Impax in 2022. (2) Other current receivables as of December 31, 2022 include a $21.4 million receivable for an upfront payment associated with the Orion Agreement which was collected in January 2023. Refer to Note 5. Alliance and Collaboration for additional information. (3) When a sale occurs on a contract item, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback (rebate) receivable and a reduction to cost of goods sold in the same period as the related sale.

Property, Plant, and Equipment,

Property, Plant, and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant, and Equipment, Net	Property, Plant, and Equipment, Net Property, plant, and equipment, net was comprised of the following (in thousands): December 31, December 31, Land $ 10,706 $ 11,540 Buildings 225,630 230,994 Leasehold improvements 124,668 123,508 Machinery and equipment 411,572 414,098 Furniture and fixtures 13,823 12,745 Vehicles 1,699 1,485 Computer equipment 58,344 56,087 Construction-in-progress 69,344 58,263 Total property, plant, and equipment 915,786 908,720 Less: Accumulated depreciation (445,971) (394,562) Property, plant, and equipment, net $ 469,815 $ 514,158 Depreciation recognized by the Company was as follows (in thousands): Years Ended December 31, 2022 2021 2020 Depreciation $ 68,112 $ 60,705 $ 60,420

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The changes in goodwill were as follows (in thousands): Years Ended December 31, 2022 2021 Balance, beginning of period $ 593,017 $ 522,814 Goodwill acquired during the period 7,553 70,584 Adjustment during the period for the Puniska Acquisition 3,075 — Currency translation (4,792) (381) Balance, end of period $ 598,853 $ 593,017 As of December 31, 2022, $366.3 million, $163.1 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. As of December 31, 2021, $363.9 million, $159.6 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. For the year ended December 31, 2022, goodwill acquired during the period was associated with the Saol Acquisition. For the year ended December 31, 2021, the addition to goodwill was associated with the Puniska Acquisition and the KSP Acquisition. Refer to Note 3. Acquisitions for additional information about the Saol Acquisition, Puniska Acquisition and the KSP Acquisition. Annual Goodwill Impairment Test The Company performed a quantitative annual goodwill impairment test for each reporting unit on October 1, 2022, the measurement date. The analysis performed included estimating the fair value of each reporting unit using both the income and market approaches. Based on the results of the annual impairment test, the Company determined that the estimated fair values of the Generics, Specialty and AvKARE reporting units exceeded their respective carrying amounts as of the measurement date; therefore, the Company did not record an impairment charge for the year ended December 31, 2022. There were no indicators of goodwill impairment during the year ended December 31, 2022, including the period subsequent to the measurement date. In performing the annual goodwill impairment test, the Company utilized long-term growth rates for its reporting units ranging from no growth to 1.0% and discount rates ranging from 11.5% to 15.1% in its estimation of fair value. As of December 31, 2022, the estimated fair value of the Generics reporting unit was in excess of its carrying value by approximately 57%, the estimated fair value of the Specialty reporting unit was in excess of its carrying value by approximately 28% and the estimated fair value of the AvKARE reporting unit was in excess of its carrying value by approximately 148%. A 500-basis point increase in the assumed discount rates utilized in each test would not have resulted in a goodwill impairment charge in any of the Company's reporting units. While management believes the assumptions used were reasonable and commensurate with the views of a market participant, changes in key assumptions for these reporting units, including increasing the discount rate, lowering forecasts for revenue and operating margin or lowering the long-term growth rate, could result in a future impairment. Intangible assets were comprised of the following (in thousands): December 31, 2022 December 31, 2021 Weighted- Cost Accumulated Net Cost Accumulated Amortization Net Amortizing intangible assets: Product rights 7.5 $ 1,222,762 $ (573,281) $ 649,481 $ 1,122,612 $ (436,902) $ 685,710 Other intangible assets 4.1 133,800 (77,943) 55,857 133,800 (58,013) 75,787 Total 1,356,562 (651,224) 705,338 1,256,412 (494,915) 761,497 In-process research and development 390,755 — 390,755 405,425 — 405,425 Total intangible assets $ 1,747,317 $ (651,224) $ 1,096,093 $ 1,661,837 $ (494,915) $ 1,166,922 For the year ended December 31, 2022, the Company recognized a total of $24.1 million of intangible asset impairment charges, of which $11.1 million was recognized in cost of goods sold and $13.0 million was recognized in in-process research and development. The impairment charges for the year ended December 31, 2022 primarily related to three currently marketed products and two IPR&D products. Cost of sales impairment charges for the year ended December 31, 2022 of $11.1 million related to currently marketed products of which (i) one product experienced significant price erosion during 2022, resulting in significantly lower than expected future cash flows and negative margins, (ii) the supply agreement of one product was terminated during 2022 and therefore the asset was not recoverable and (iii) one product was no longer expected to be sold to a key customer, and therefore the asset was not recoverable. IPR&D impairment charges for the year ended December 31, 2022 of $13.0 million related to (i) one asset that experienced a delay in its expected launch date and (ii) one asset that experienced significant expected price erosion, both of which resulted in significantly lower than expected future cash flows. For the year ended December 31, 2021, the Company recognized a total of $23.4 million of intangible asset impairment charges, of which $22.7 million was recognized in cost of goods sold and $0.7 million was recognized in in-process research and development. The impairment charges for the year ended December 31, 2021 were primarily related to seven currently marketed products and one IPR&D product. For the currently marketed products, five products experienced significant price erosion during 2021, resulting in significantly lower than expected future cash flows and negative margins. Of the five currently marketed products that experienced significant price erosion during 2021, Levothyroxine contributed $17.7 million of the $22.7 million in cost of goods sold impairment charges ( refer to Note 5. Alliance and Collaboration for additional information about the Company’s Levothyroxine license with JSP) . Additionally, the supply agreements for two currently marketed products were terminated early due to market conditions. The IPR&D impairment charge of $0.7 million was related to one product that experienced a delay in its expected launch date, resulting in significantly lower than expected future cash flows. For the year ended December 31, 2020, the Company recognized a total of $37.3 million of intangible asset impairment charges, of which $34.6 million was recognized in cost of goods sold Amortization expense related to intangible assets recognized was as follows (in thousands): Years Ended December 31, 2022 2021 2020 Amortization $ 172,063 $ 172,701 $ 174,967 The following table presents future amortization expense for the next five years and thereafter, excluding $390.8 million of IPR&D intangible assets (in thousands). Future 2023 $ 163,473 2024 161,169 2025 122,478 2026 71,743 2027 50,180 Thereafter 136,295 Total $ 705,338

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2022
Other Assets [Abstract]
Other Assets	Other Assets Other assets are comprised of the following (in thousands): December 31, December 31, Interest rate swap (1) $ 85,586 $ — Security deposits 3,523 3,895 Long-term prepaid expenses 3,711 5,896 Deferred revolving credit facility costs 2,206 1,603 Other long-term assets 8,191 9,220 Total $ 103,217 $ 20,614 (1) Refer to Note 19. Fair Value Measurements and Note 20. Financial Instruments

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Accounts Payable and Accrued Expenses Accounts payable and accrued expenses were comprised of the following (in thousands): December 31, December 31, 2021 (2) Accounts payable $ 165,980 $ 131,084 Accrued returns allowance (1) 145,060 161,978 Accrued compensation 54,038 62,098 Accrued Medicaid and commercial rebates (1) 86,030 85,737 Accrued royalties 19,309 20,893 Commercial chargebacks and rebates 10,226 10,226 Accrued professional fees 11,386 9,926 Taxes payable 359 2,523 Accrued other 45,811 40,880 Total accounts payable and accrued expenses $ 538,199 $ 525,345 (1) Refer to Note 4. Revenue Recognition for additional information. (2) The prior period balance related to liabilities for legal proceedings of $58.0 million (refer to Note 21. Commitments and Contingencies ), formerly included in accounts payable and accrued expenses as of December 31, 2021, has been reclassified to the balance sheet caption current portion of liabilities for legal matters to conform to the current period presentation in the consolidated balance sheets.

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	Debt The following is a summary of the Company’s term loan indebtedness (in thousands): December 31, December 31, Term Loan due May 2025 $ 2,563,876 $ 2,590,876 Rondo Term Loan due January 2025 72,000 139,250 Other — 624 Total debt 2,635,876 2,730,750 Less: debt issuance costs (13,934) (20,083) Total debt, net of debt issuance costs 2,621,942 2,710,667 Less: current portion of long-term debt (29,961) (30,614) Total long-term debt, net $ 2,591,981 $ 2,680,053 Senior Secured Credit Facilities On May 4, 2018 the Company entered into a senior credit agreement that provided a term loan (“Term Loan”) with a principal amount of $2.7 billion and an asset backed revolving credit facility (“Revolving Credit Facility”) under which loans and letters of credit up to a principal amount of $500.0 million were available (principal amount of up to $25.0 million was available for letters of credit). On June 2, 2022, the Company entered into a revolving credit agreement (the “New Credit Agreement”) that amended the Revolving Credit Facility and reduced the principal amount of loans and letters of credit to $350.0 million (the “New Revolving Credit Facility”). The Term Loan, Revolving Credit Facility and the New Revolving Credit Facility are collectively referred to as the “Senior Secured Credit Facilities”. Refer to below section titled New Credit Agreement for further details regarding the New Revolving Credit Facility. The Term Loan is repayable in equal quarterly installments at a rate of 1.00% of the original principal amount annually, with the balance payable at maturity on May 4, 2025. The Term Loan bears a variable annual interest rate, which is a LIBOR-designated rate plus 3.5% at December 31, 2022. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company’s interest rate exposure associated with the variability in future cash flows from changes in the one-month LIBOR associated with its Term Loan. For further details, refer to Note 20. Financial Instruments. The Term Loan requires regular principal payments of $6.75 million quarterly in 2023, 2024, and 2025, with the balance of the Term Loan payable at maturity on May 4, 2025. Annually, the Company is also required to calculate the amount of excess cash flows, as defined in the Term Loan agreement. Based on the results of the excess cash flows calculation for the year ended December 31, 2020, the Company made a $14.4 million additional principal payment in March 2021. Based on the results of the excess cash flows calculation for the years ended December 31, 2022 and 2021, no additional principal payments were due. The proceeds from the Term Loan were used to finance, in part, the cost of the acquisition of Impax and to pay off Amneal’s debt and substantially all of Impax’s debt at the close of the acquisition of Impax. The proceeds of any loans made under the Senior Secured Credit Facilities can be used for capital expenditures, acquisitions, working capital needs and other general purposes, subject to covenants as described below. The Company incurred costs associated with the Term Loan due May 2025 of $38.1 million and the Revolving Credit Facility of $4.6 million, which were capitalized and are being amortized over the life of the applicable debt agreement to interest expense using the effective interest method. S ubject to the refinancing, there was a decrease in the borrowing capacity of certain lenders between the New Revolving Credit Facility and the Revolving Credit Facility. As a result, the Company recorded a $0.3 million charge for the year ended December 31, 2022 in loss on refinancing. Additionally, the Company incurred costs of $1.6 million associated with the New Credit Agreement, which were capitalized as deferred financing costs with the remaining unamortized costs associated with the Revolving Credit Facility, and will be amortized over the life of the New Credit Agreement. The Term Loan has been recorded in the balance sheet net of issuance costs. Costs associated with the New Revolving Credit Facility have been recorded in other assets. For each of the years ended December 31, 2022, 2021 and 2020, amortization of deferred financing costs related to the Term Loan, the New Revolving Credit Facility and the Revolving Credit Facility was $6.1 million, $6.4 million and $6.5 million, respectively. The Senior Secured Credit Facilities contain a number of covenants that, among other things, create liens on Amneal’s and its subsidiaries’ assets. The Senior Secured Credit Facilities contain certain negative covenants that, among other things and subject to certain exceptions, restrict Amneal’s and its subsidiaries’ ability to incur additional debt or guarantees, grant liens, make loans, acquisitions or other investments, dispose of assets, merge, dissolve, liquidate or consolidate, pay dividends or other payments on capital stock, make optional payments or modify certain debt instruments, modify certain organizational documents, enter into arrangements that restrict the ability to pay dividends or grant liens, or enter into or consummate transactions with affiliates. The Senior Secured Credit Facilities contain customary events of default, subject to certain exceptions. Upon the occurrence of certain events of default, the obligations under the Senior Secured Credit Facilities may be accelerated and the commitments may be terminated. At December 31, 2022, Amneal was in compliance with all covenants associated with the Senior Secured Credit Facilities. A discussion of the covenants associated with the New Credit Agreement is below. New Credit Agreement The New Credit Agreement (i) replaced the Revolving Credit Facility with the New Revolving Credit Facility, a $350.0 million senior secured revolving credit facility that matures on June 2, 2027, (ii) provides for up to $25.0 million of the New Revolving Credit Facility to be available for the purpose of issuing letters of credit, (iii) provides for up to $35.0 million of the New Revolving Credit Facility to be available for the purpose of issuing swingline loans, (iv) allows the Company to request an incremental increase in the revolving facility commitments by up to $150.0 million, and (v) terminated the revolving credit facility commitments of lenders under the Revolving Credit Facility. Interest is payable on the New Revolving Credit Facility at a rate equal to the alternate base rate (“ABR”) or the secured overnight financing rate (“SOFR”), plus an applicable margin, in each case, subject to an ABR floor of 1.00% or a SOFR floor of 0.00%, as applicable. The applicable margin for the New Revolving Credit Facility is initially 0.25% per annum for ABR loans and 1.25% per annum for SOFR loans. The applicable margin on borrowings under the New Revolving Credit Facility thereafter will adjust ranging from 0.25% to 0.50% per annum for ABR loans and from 1.25% to 1.50% per annum for SOFR loans determined by the average historical excess availability. The proceeds of any loans made under the New Revolving Credit Facility can be used for capital expenditures, acquisitions, working capital needs and other general purposes, subject to covenants as described below. The Company pays a commitment fee based on the average daily unused amount of the New Revolving Credit Facility at a rate of 0.25% per annum. As of December 31, 2022, the interest rate for borrowings under the New Revolving Credit Facility was approximately 5.9%. The New Credit Agreement contains certain negative covenants that, among other things and subject to certain exceptions, restrict the Company’s and certain subsidiaries’ ability to incur additional debt or guarantees, grant liens, make loans, acquisitions or other investments, dispose of assets, merge, dissolve, liquidate or consolidate, pay dividends or other payments on capital stock, make optional payments or modify certain debt instruments, modify certain organizational documents, enter into arrangements that restrict the ability to pay dividends or grant liens, or enter into or consummate transactions with affiliates. The New Revolving Credit Facility also includes a financial covenant whereby the Company must maintain a minimum fixed-charge coverage ratio if certain borrowing conditions are met. The New Revolving Credit Facility contains customary events of default, subject to certain exceptions. Upon the occurrence of certain events of default, the obligations under the New Revolving Credit Facility may be accelerated and the commitments may be terminated. As of December 31, 2022, the Company had $60.0 million in borrowings and $285.9 million of available capacity under the New Revolving Credit Facility Acquisition Financing - Revolving Credit and Term Loan Agreement On January 31, 2020, in connection with the Rondo Acquisitions, Rondo Intermediate Holdings, LLC (“Rondo Holdings”), a wholly-owned subsidiary of Rondo, entered into a revolving credit and term loan agreement (“Rondo Credit Facility”) that provided a term loan (“Rondo Term Loan”) with a principal amount of $180.0 million and a revolving credit facility (“Rondo Revolving Credit Facility”) which loans up to a principal amount of $30.0 million. The Rondo Term Loan is repayable in equal quarterly installments at a rate of 5.0% of the original principal amount annually, with the balance payable at maturity on January 31, 2025. The Rondo Credit Facility bears a variable annual interest rate, which originated as one-month LIBOR plus 3.0%. During September 2021, the Company prepaid $25.0 million of outstanding principal of the Rondo Term Loan, which permitted the variable rate to be repriced. At December 31, 2022, the variable annual interest rate is one-month LIBOR plus 2.5%. Additionally, the annual interest rate for borrowings under the Rondo Credit Facility may be reduced or increased by 0.25% based on step-downs and step-ups determined by the total net leverage ratio, as defined in that agreement. At December 31, 2022, the Company had no outstanding borrowings under the Rondo Revolving Credit Facility. A commitment fee based on the average daily unused amount of the Rondo Credit Facility is assessed at a rate based on total net leverage ratio, between 0.25% and 0.50% per annum. At December 31, 2022, the Rondo Credit Facility commitment fee rate was 0.25% per annum. Costs associated with the Rondo Term Loan of $3.5 million and the Rondo Credit Facility of $0.6 million have been capitalized and are being amortized over the life of the applicable debt instrument to interest expense using the effective interest method. The Rondo Term Loan has been recorded in the balance sheet net of issuance costs. Costs associated with the Rondo Revolving Credit Facility have been recorded in other assets. For the year ended December 31, 2022, amortization of deferred financing costs associated with the Rondo Credit Facility was less than $1.0 million. The Rondo Credit Facility contains a number of covenants that, among other things, create liens on the equity securities and assets of Rondo Holdings, Rondo, AvKARE, LLC and R&S. The Rondo Credit Facility contains certain negative, affirmative and financial covenants that, among other things, restrict the ability to incur additional debt, grant liens, transact in mergers and acquisitions, make certain investments and payments or engage in certain transactions with affiliates. The Rondo Credit Facility also contains customary events of default. Upon the occurrence of certain events of default, the obligations under the Rondo Credit Facility may be accelerated and/or the interest rate may be increased. At December 31, 2022, Rondo was in compliance with all covenants. The Company is not party to the Rondo Credit Facility and is not a guarantor of any debt incurred thereunder. The Rondo Term Loan requires principal payments of $9.0 million per year for the next two years and the balance payable at maturity on January 31, 2025. During the year ended December 31, 2022, the Company repaid $67.3 million of outstanding principal of the Rondo Term Loan. Additionally, the Company repaid the remaining $0.6 million in principal of other debt obligations in June 2022. Rondo Acquisitions Financing – Notes Payable-Related Party On January 31, 2020, the closing date of the Rondo Acquisitions, Rondo or its subsidiary, Rondo Top Holdings, LLC, issued the Sellers Notes with a stated aggregate principal amount of $44.2 million and the Short-Term Sellers Note with a stated principal amount of $1.0 million. The Sellers Notes are unsecured and accrue interest at a rate of 5% per annum, not compounded, until June 30, 2025. The Sellers Notes are subject to prepayment at the option of Rondo, as the obligor, without premium or penalty. Mandatory payment of the outstanding principal and interest is due on June 30, 2025 if certain financial targets are achieved, the borrowers’ cash flows are sufficient (as defined in the Sellers Notes) and repayment is not prohibited by senior debt. If repayment of all outstanding principal and accrued interest on the Sellers Notes is not made on June 30, 2025, the requirements for repayment are revisited on June 30 of each subsequent year until all principal and accrued interest are satisfied no later than January 31, 2030 or earlier, upon a change in control, as defined. The Short-Term Sellers Note was also unsecured, accrued interest at a rate of 1.6%, and was paid during February 2021. In accordance with ASC 805, Business Combinations, all consideration transferred was measured at its acquisition-date fair value. The Sellers Notes were stated at the fair value estimate of $35.0 million, which was estimated using the Monte-Carlo simulation approach under the option pricing framework. The Short-Term Sellers Note of $1.0 million was recorded at the stated principal amount of $1.0 million, which approximated fair value. The $9.2 million discount on the Sellers Notes will be amortized to interest expense using the effective interest method from January 31, 2020 to June 30, 2025 and the carrying value of the Sellers Notes will accrete to the stated principal amount of $44.2 million. During the year ended December 31, 2022, amortization of the discount related to the Sellers Notes was $1.7 million.

Other Long-Term Liabilities

Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2022
Other Liabilities [Abstract]
Other Long-Term Liabilities	Other Long-Term Liabilities Other long-term liabilities were comprised of the following (in thousands): December 31, 2022 December 31, 2021 Interest rate swap (1) $ — $ 11,473 Uncertain tax positions 563 3,177 Long-term portion of liabilities for legal matters 49,442 — Long-term compensation (2) 16,737 21,589 Contingent consideration 11,997 — Other long-term liabilities 8,729 2,664 Total other long-term liabilities $ 87,468 $ 38,903 (1) Refer to Note 19. Fair Value Measurements and Note 20. Financial Instruments for information about the Company’s interest rate swap. (2) Includes $7.6 million and $11.8 million of long-term deferred compensation plan liabilities (refer to Note 19. Fair Value Measurements

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	Leases The majority of the Company's operating and financing lease portfolio consists of corporate offices, manufacturing sites, warehouse space, R&D facilities, and land. The Company's leases have remaining lease terms of 1 year to 22 years (excluding international land easements with remaining terms of approximately 28-97 years). Rent expense for the years ended December 31, 2022, 2021 and 2020 was $22.6 million, $19.8 million, and $26.3 million, respectively. During the year ended December 31, 2020, the Company recorded $0.6 million for the impairment of the operating lease right-of-use asset associated with the Company’s Blue Bell, PA facility due to the closure of that site. There were no impairments of operating lease right-of-use assets for the years ended December 31, 2022 and December 31, 2021. The components of total lease costs were as follows (in thousands): Years Ended December 31, 2022 2021 2020 Operating lease cost (1) $ 17,800 $ 15,057 21,664 Finance lease cost: Amortization of right-of-use assets 4,808 4,713 4,487 Interest on lease liabilities 4,508 4,601 4,773 Total finance lease cost 9,316 9,314 9,260 Total lease cost $ 27,116 $ 24,371 $ 30,924 (1) Includes variable and short-term lease costs. Supplemental balance sheet information related to the Company's leases was as follows (in thousands): Operating leases December 31, 2022 December 31, 2021 Operating lease right-of-use assets $ 38,211 $ 39,899 Operating lease right-of-use assets - related party (1) 17,910 20,471 Total operating lease right-of-use assets $ 56,121 $ 60,370 Operating lease liabilities $ 32,126 $ 32,894 Operating lease liabilities - related party (1) 15,914 18,783 Current portion of operating lease liabilities 8,321 9,686 Current portion of operating lease liabilities - related party (1) 2,869 2,636 Total operating lease liabilities $ 59,230 $ 63,999 Financing leases Financing lease right of use assets $ 63,424 $ 64,475 Financing lease liabilities $ 60,769 $ 60,251 Current portion of financing lease liabilities 3,488 3,101 Total financing lease liabilities $ 64,257 $ 63,352 (1) Refer to Note 24. Related Party Transactions for information about related party leases. Supplemental cash flow information related to leases was as follows (in thousands): Years Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 4,539 $ 4,601 Operating cash flows from operating leases $ 16,217 $ 15,006 Financing cash flows from finance leases $ 3,484 $ 3,179 Non-cash activity: Right-of-use assets obtained in exchange for new operating lease liabilities $ 7,504 $ 12,006 Right-of-use assets obtained in exchange for new financing lease liabilities $ 4,606 $ 1,072 The table below reflects the weighted average remaining lease term and weighted average discount rate for the Company's operating and finance leases: December 31, 2022 December 31, 2021 Weighted average remaining lease term - operating leases 5 years 5 years Weighted average remaining lease term - finance leases 19 years 21 years Weighted average discount rate - operating leases 8.5% 6.9% Weighted average discount rate - finance leases 7.2% 7.1% Maturities of lease liabilities as of December 31, 2022 were as follow (in thousands): Operating Financing 2023 $ 15,843 $ 7,976 2024 16,558 6,913 2025 14,264 6,466 2026 10,393 5,989 2027 7,420 5,645 Thereafter 11,550 85,220 Total lease payments 76,028 118,209 Less: Imputed interest (16,798) (53,952) Total $ 59,230 $ 64,257 Maturities of lease liabilities as of December 31, 2021 were as follows (in thousands): Operating Financing 2022 $ 16,136 $ 7,492 2023 16,412 6,726 2024 15,215 5,572 2025 11,363 5,474 2026 7,400 5,474 Thereafter 9,712 89,862 Total lease payments 76,238 120,600 Less: Imputed interest (12,239) (57,248) Total $ 63,999 $ 63,352
Leases	Leases The majority of the Company's operating and financing lease portfolio consists of corporate offices, manufacturing sites, warehouse space, R&D facilities, and land. The Company's leases have remaining lease terms of 1 year to 22 years (excluding international land easements with remaining terms of approximately 28-97 years). Rent expense for the years ended December 31, 2022, 2021 and 2020 was $22.6 million, $19.8 million, and $26.3 million, respectively. During the year ended December 31, 2020, the Company recorded $0.6 million for the impairment of the operating lease right-of-use asset associated with the Company’s Blue Bell, PA facility due to the closure of that site. There were no impairments of operating lease right-of-use assets for the years ended December 31, 2022 and December 31, 2021. The components of total lease costs were as follows (in thousands): Years Ended December 31, 2022 2021 2020 Operating lease cost (1) $ 17,800 $ 15,057 21,664 Finance lease cost: Amortization of right-of-use assets 4,808 4,713 4,487 Interest on lease liabilities 4,508 4,601 4,773 Total finance lease cost 9,316 9,314 9,260 Total lease cost $ 27,116 $ 24,371 $ 30,924 (1) Includes variable and short-term lease costs. Supplemental balance sheet information related to the Company's leases was as follows (in thousands): Operating leases December 31, 2022 December 31, 2021 Operating lease right-of-use assets $ 38,211 $ 39,899 Operating lease right-of-use assets - related party (1) 17,910 20,471 Total operating lease right-of-use assets $ 56,121 $ 60,370 Operating lease liabilities $ 32,126 $ 32,894 Operating lease liabilities - related party (1) 15,914 18,783 Current portion of operating lease liabilities 8,321 9,686 Current portion of operating lease liabilities - related party (1) 2,869 2,636 Total operating lease liabilities $ 59,230 $ 63,999 Financing leases Financing lease right of use assets $ 63,424 $ 64,475 Financing lease liabilities $ 60,769 $ 60,251 Current portion of financing lease liabilities 3,488 3,101 Total financing lease liabilities $ 64,257 $ 63,352 (1) Refer to Note 24. Related Party Transactions for information about related party leases. Supplemental cash flow information related to leases was as follows (in thousands): Years Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 4,539 $ 4,601 Operating cash flows from operating leases $ 16,217 $ 15,006 Financing cash flows from finance leases $ 3,484 $ 3,179 Non-cash activity: Right-of-use assets obtained in exchange for new operating lease liabilities $ 7,504 $ 12,006 Right-of-use assets obtained in exchange for new financing lease liabilities $ 4,606 $ 1,072 The table below reflects the weighted average remaining lease term and weighted average discount rate for the Company's operating and finance leases: December 31, 2022 December 31, 2021 Weighted average remaining lease term - operating leases 5 years 5 years Weighted average remaining lease term - finance leases 19 years 21 years Weighted average discount rate - operating leases 8.5% 6.9% Weighted average discount rate - finance leases 7.2% 7.1% Maturities of lease liabilities as of December 31, 2022 were as follow (in thousands): Operating Financing 2023 $ 15,843 $ 7,976 2024 16,558 6,913 2025 14,264 6,466 2026 10,393 5,989 2027 7,420 5,645 Thereafter 11,550 85,220 Total lease payments 76,028 118,209 Less: Imputed interest (16,798) (53,952) Total $ 59,230 $ 64,257 Maturities of lease liabilities as of December 31, 2021 were as follows (in thousands): Operating Financing 2022 $ 16,136 $ 7,492 2023 16,412 6,726 2024 15,215 5,572 2025 11,363 5,474 2026 7,400 5,474 Thereafter 9,712 89,862 Total lease payments 76,238 120,600 Less: Imputed interest (12,239) (57,248) Total $ 63,999 $ 63,352

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis (in thousands): Fair Value Measurement Based on December 31, 2022 Total Quoted Significant Significant Assets Interest Rate Swap (1) $ 85,586 $ — $ 85,586 $ — Liabilities Deferred compensation plan liabilities (2) $ 9,674 $ — $ 9,674 $ — Contingent consideration liability (3) $ 15,427 $ — $ — $ 15,427 December 31, 2021 Liabilities Interest Rate Swap (1) $ 11,473 $ — $ 11,473 $ — Deferred compensation plan liabilities (2) $ 13,883 $ — $ 13,883 $ — Contingent consideration liability (3) $ 5,900 $ — $ — $ 5,900 (1) The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 20. Financial Instruments for information about the Company’s interest rate swap. (2) As of December 31, 2022, deferred compensation plan liabilities of $2.1 million and $7.6 million were recorded in current and non-current liabilities, respectively. As of December 31, 2021, deferred compensation plan liabilities of $2.1 million and $11.8 million were recorded in current and non-current liabilities, respectively. These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants. (3) The fair value measurement of contingent consideration liability has been classified as a Level 3 recurring liability as its valuation requires judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair value could be higher or lower than what the Company determined. As of December 31, 2022, the contingent consideration liability associated with the Saol Acquisition included $0.1 million recorded in accounts payable and accrued expenses and $12.0 million recorded in other-longer term liabilities. As of December 31, 2022 and 2021, the contingent consideration liability associated with the KSP Acquisition was valued at approximately $3.3 million and $5.9 million , respectively, and recorded within related party payables - long term. Refer to Note 3. Acquisitions for additional information related to contingent consideration associated with the KSP Acquisition and the Saol Acquisition. There were no transfers between levels in the fair value hierarchy during the year ended December 31, 2022. Contingent consideration On April 2, 2021, the Company completed the KSP Acquisition, which provided for contingent milestone payments of up to an aggregate of $8.0 million (undiscounted) upon the achievement of certain regulatory milestones, as well as contingent royalty payments that are tiered depending on the net sales amount of aggregate annual net sales for certain future pharmaceutical products. On February 9, 2022, the Company completed the Saol Acquisition, which provides for contingent royalty payments that are tiered depending on the aggregate annual net sales for certain pharmaceutical products, beginning in 2023. The following table provides a reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): Year Ended Year Ended Balance, beginning of period $ 5,900 $ — Addition due to the Saol Acquisition 8,796 — Addition due to the KSP Acquisition — 5,700 Net change in fair value during period 731 200 Balance, end of period $ 15,427 $ 5,900 The fair value measurement of the contingent consideration liabilities was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, timing of achieving specified regulatory milestones and the estimated amount of future sales of the acquired products. The contingent consideration liability is estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to fair value of the contingent consideration liabilities can result from changes to one or a number of the aforementioned inputs. If different assumptions were used for various inputs, the estimated fair value could be higher or lower than what the Company determined. The following table summarizes the significant unobservable inputs used in the fair value measurement of our contingent consideration liabilities as of December 31, 2022 and 2021: Contingent Consideration Liability Fair Value as of December 31, 2022 (in thousands) Unobservable input Range Weighted Average (1) Regulatory Milestones (KSP Acquisition) $ 390 Discount rate 7.2 % 8.5 % 7.3 % Probability of payment 1.8 % 20.0 % 18.6 % Projected year of payment 2024 2026 2024 Royalties (KSP Acquisition) $ 2,900 Discount rate 12.5 % 12.5 % 12.5 % Probability of payment 1.8 % 20.0 % 18.6 % Projected year of payment 2024 2033 2028 Royalties (Saol Acquisition) $ 12,137 Discount rate 17.8 % 17.8 % 17.8 % Projected year of payment 2023 2033 2027 Contingent Consideration Liability Fair Value as of December 31, 2021 (in thousands) Unobservable input Range Weighted Average (1) Regulatory Milestones (KSP Acquisition) $ 500 Discount rate 2.2 % - 4.4% 2.4% Probability of payment 1.8 % - 20.0% 16.7% Projected year of payment 2023 - 2027 2023 Royalties (KSP Acquisition) $ 5,400 Discount rate 11.5 % - 11.5% 11.5% Probability of payment 1.8 % - 20.0% 18.0% Projected year of payment 2023 - 2032 2029 (1) Unobservable inputs were weighted by the relative fair value of each product candidate acquired. Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying amounts of cash, accounts receivable and accounts payable approximate their fair values due to the short-term maturity of these instruments. The Term Loan is in the Level 2 category within the fair value level hierarchy. The fair value was determined using market data for valuation. The fair value of the Term Loan at December 31, 2022 and 2021 was approximately $2.3 billion and $2.6 billion, respectively. The Rondo Term Loan is in the Level 2 category within the fair value level hierarchy. The fair value of the Rondo Term Loan at December 31, 2022 and 2021 was approximately $70.9 million and $138.9 million, respectively. The Sellers Notes are in the Level 2 category within the fair value level hierarchy. At December 31, 2022 and 2021 the fair value of the Sellers Notes were $39.1 million and $37.9 million, respectively. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis There were no non-recurring fair value measurements during the years ended December 31, 2022 and 2021.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments The Company uses an interest rate swap to manage its exposure to market risks for changes in interest rates. Interest Rate Risk Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company is exposed to interest rate risk on its debt obligations. The Company's debt obligations consist of variable-rate and fixed-rate debt instruments (for further details, refer to Note 16. Debt ). The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has entered into an interest rate swap on the Term Loan. Interest Rate Derivative – Cash Flow Hedge The interest rate swap involves the periodic exchange of payments without the exchange of underlying principal or notional amounts. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month LIBOR associated with its Term Loan. As of December 31, 2022 , the total gain, net of income taxes, related to the Company’s cash flow hedge was $85.6 million, of which $42.3 million was recognized in accumulated other comprehensive income and $43.3 million was recognized in non-controlling interests. As of December 31, 2021, t he total loss, net of income taxes, related to the Company’s cash flow hedge was $11.5 million, of which $6.0 million was recognized in accumulated other comprehensive loss and $5.5 million was recognized in non-controlling interests. A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands): December 31, 2022 December 31, 2021 Derivatives Designated as Hedging Instruments Balance Sheet Fair Value Balance Sheet Fair Value Variable-to-fixed interest rate swap Other Assets $ 85,586 Other long-term liabilities $ 11,473

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Commercial Manufacturing, Collaboration, License, and Distribution Agreements The Company continues to seek to enhance its product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing. Accordingly, the Company, in certain instances, may be contractually obligated to make potential future development, regulatory, and commercial milestone, royalty and/or profit sharing payments in conjunction with collaborative agreements or acquisitions that the Company has entered into with third parties. The Company has also licensed certain technologies or intellectual property from various third parties. The Company is generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. The agreements generally permit the Company to terminate the agreement with no significant continuing obligation. The Company could be required to make significant payments pursuant to these arrangements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. Refer to Note 5. Alliance and Collaboration for additional information. Certain of these arrangements are with related parties. Refer to Note 24. Related Party Transactions for additional information. Contingencies Legal Proceedings The Company's legal proceedings are complex, constantly evolving, and subject to uncertainty. As such, the Company cannot predict the outcome or impact of its significant legal proceedings which are set forth below. Additionally, the Company manufactures and derives a portion of its revenue from the sale of pharmaceutical products in the opioid class of drugs and may therefore face claims arising from the regulation and/or consumption of such products. While the Company believes it has meritorious claims and/or defenses to the matters described below (and intends to vigorously prosecute and defend them), the nature and cost of litigation is unpredictable, and an unfavorable outcome of such proceedings could include damages, fines, penalties and injunctive or administrative remedies. For any proceedings where losses are probable and reasonably capable of estimation, the Company accrues a potential loss. When the Company has a probable loss for which a reasonable estimate of the liability is a range of losses and no amount within that range is a better estimate than any other amount, the Company records the loss at the low end of the range. While these accruals have been deemed reasonable by the Company’s management, the assessment process relies heavily on estimates and assumptions that may ultimately prove inaccurate or incomplete. Additionally, unforeseen circumstances or events may lead the Company to subsequently change its estimates and assumptions. Unless otherwise indicated below, the Company is unable at this time to estimate the possible loss or the range of loss, if any, associated with such legal proceedings and claims. Any such claims, proceedings, investigations or litigation, regardless of the merits, might result in substantial costs to defend or settle, borrowings under our debt agreements, restrictions on product use or sales, or otherwise harm our business. The ultimate resolution of any or all claims, legal proceedings or investigations are inherently uncertain and difficult to predict, could differ materially from our estimates and could have a material adverse effect on the Company's results of operations and/or cash flows in any given accounting period, or on the Company's overall financial condition. The Company currently intends to vigorously prosecute and/or defend these proceedings as appropriate. From time to time, however, the Company may settle or otherwise resolve these matters on terms and conditions that it believes to be in its best interest . An insurance recovery, if any, is recorded in the period in which it is probable the recovery will be realized. Charges (insurance recoveries) related to legal matters, net were comprised of the following (in thousands): Year Ended December 31, 2022 2021 2020 Opana ER® antitrust litigation $ 262,837 $ — $ — Civil prescription opioid litigation 17,993 — — Securities class action - Cambridge Retirement System v. Amneal (15,500) 25,000 — Galeas v. Amneal 1,200 — — Other 3,400 — 5,860 Total $ 269,930 $ 25,000 $ 5,860 Liabilities for legal matters were comprised of the following (in thousands): Year Ended December 31, Matter 2022 2021 Opana ER® antitrust litigation (1) $ 83,944 $ — Opana ER® antitrust litigation - accrued interest 1,423 — Civil prescription opioid litigation 17,993 — Securities class action - Fleming v. Impax (2) — 33,000 Securities class action - Cambridge Retirement System v. Amneal (3) — 25,000 Galeas v. Amneal 1,200 — Other 2,923 — Current portion of liabilities for legal matters $ 107,483 $ 58,000 Opana ER® antitrust litigation (1) $ 50,000 $ — Imputed interest (1,405) — Accrued interest 847 — Long-term portion of liabilities for legal matters (included in other long-term liabilities) $ 49,442 $ — (1) During 2022, the Company paid $131.1 million of the $265.0 million settlement to certain plaintiffs pursuant to the Opana ER® antitrust litigation settlement agreements (see below under Opana ER® Antitrust Litigation for additional information). (2) Upon final approval by the court, the securities class action Fleming v. Impax was settled for $33.0 million during 2022 using a security deposit funded by insurance in 2021 (refer to Note 11. Prepaid Expenses and Other Current Assets ). See below for additional information. (3) Upon final approval by the Court, the securities class action Cambridge Retirement System v. Amneal was settled during 2022 for $25.0 million with cash paid by the Company of $9.5 million and insurance recoveries of $15.5 million. See below for additional information. As of December 31, 2022, the remaining payments associated with the Opana ER® antitrust litigation settlement agreements are as follows: Amount Due January 2023 $ 83,944 January 2024 50,000 $ 133,944 3% interest is payable on the amounts due in January 2023 and January 2024. The Company includes the interest accrual on these amounts as a component of the current portion of liabilities for legal matters. Additional interest of 2.7% was imputed on the $50.0 million long-term liability due in January 2024, resulting in an initial discount of $2.2 million, which is being amortized to interest expense over the life of the liability using the effective interest method. Refer to the respective discussions below for additional information on the significant matters in the tables above. Medicaid Reimbursement and Price Reporting Matters The Company is required to provide pricing information to state agencies, including agencies that administer federal Medicaid programs. Certain state agencies have alleged that manufacturers have reported improper pricing information, which allegedly caused them to overpay reimbursement costs. Other agencies have alleged that manufacturers have failed to timely file required reports concerning pricing information. Liabilities are periodically established by the Company for any potential claims or settlements of overpayment. The Company intends to vigorously defend against any such claims. The ultimate settlement of any potential liability for such claims may be higher or lower than estimated. Patent Litigation There is substantial litigation in the pharmaceutical, biological, and biotechnology industries with respect to the manufacture, use, and sale of new products which are the subject of conflicting patent and intellectual property claims. One or more patents often cover the brand name products for which the Company is developing generic versions and the Company typically has patent rights covering the Company’s branded products. Under federal law, when a drug developer files an Abbreviated New Drug Application (“ANDA”) for a generic drug seeking approval before expiration of a patent which has been listed with the FDA as covering the brand name product, the developer must certify its product will not infringe the listed patent(s) and/or the listed patent is invalid or unenforceable (commonly referred to as a “Paragraph IV” certification). Notices of such certification must be provided to the patent holder, who may file a suit for patent infringement within 45 days of the patent holder’s receipt of such notice. If the patent holder files suit within the 45-day period, the FDA can review and tentatively approve the ANDA, but generally is prevented from granting final marketing approval of the product until a final judgment in the action has been rendered in favor of the generic drug developer, or 30 months from the date the notice was received, whichever is sooner. The Company’s Generics segment is typically subject to patent infringement litigation brought by branded pharmaceutical manufacturers in connection with the Company’s Paragraph IV certifications seeking an order delaying the approval of the Company’s ANDA until expiration of the patent(s) at issue in the litigation. The uncertainties inherent in patent litigation make the outcome of such litigation difficult to predict. For the Company’s Generics segment, the potential consequences in the event of an unfavorable outcome in such litigation include delaying launch of its generic products until patent expiration. If the Company were to launch its generic product prior to successful resolution of a patent litigation, the Company could be liable for potential damages measured by the profits lost by the branded product manufacturer rather than the profits earned by the Company if it is found to infringe a valid, enforceable patent, or enhanced treble damages in cases of willful infringement. For the Company’s Specialty segment, an unfavorable outcome may significantly accelerate generic competition ahead of expiration of the patents covering the Company’s branded products. All such litigation typically involves significant expense. The Company is generally responsible for all of the patent litigation fees and costs associated with current and future products not covered by its alliance and collaboration agreements. The Company has agreed to share legal expenses with respect to third-party and Company products under the terms of certain of the alliance and collaboration agreements. The Company records the costs of patent litigation as expense in the period when incurred for products it has developed, as well as for products which are the subject of an alliance or collaboration agreement with a third-party. Patent Defense Matter Biogen International GmbH, et al. v. Amneal Pharmaceuticals LLC, et al. (Dimethyl Fumarate) In June 2017, Biogen International GmbH (“Biogen”) filed suit against Amneal and various other generic manufacturers in the United States District Court for the District of Delaware (“D. Del.”) alleging patent infringement based on the filing of ANDAs by Amneal and others for generic alternatives to Biogen’s Tecfidera® (dimethyl fumarate) capsules product (Biogen International GmbH, et al. v. Amneal Pharmaceuticals LLC, et al., No. 1:17-cv-00823-MN). Biogen also filed suit in June 2017 against Mylan Pharmaceuticals Inc. (“Mylan”) in the United States District Court for the Northern District of West Virginia (“N.D. W. Va.”) relating to Mylan’s own ANDA for Tecfidera®. On June 18, 2020, the N.D. W. Va. court issued an order finding the sole Biogen patent at issue invalid. Biogen appealed the order (the “Mylan Appeal”) to the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”). On September 22, 2020, the D. Del. court entered judgment in favor of the defendants (including Amneal), adopting the finding of invalidity made by the N.D. W. Va. court. Biogen appealed the D. Del. Order (“the Amneal Consolidated Appeal”). Amneal, like Mylan and several other generic manufacturers, launched its generic dimethyl fumarate capsule products “at-risk,” pending the outcome of Biogen’s appeal of the N.D. W. Va. order. On November 30, 2021, the Federal Circuit affirmed the N.D. W. Va. court’s order that Biogen’s patent is invalid: on March 23, 2022, issued a mandate in the Mylan Appeal as to the invalidity of the patent; and on June 16, 2022, Biogen filed a cert petition with the Supreme Court of the United States (the “U.S. Supreme Court”) which was denied on October 3, 2022. On October 31, 2022, the Federal Circuit dismissed Biogen’s consolidated appeals. Other Litigation Related to the Company’s Business Opana ER® FTC Matters On February 25, 2014, Impax received a Civil Investigative Demand (“CID”) from the Federal Trade Commission (“FTC”) concerning its investigation into the drug Opana® ER and its generic equivalents. On March 30, 2016, the FTC filed a complaint against Impax, Endo Pharmaceuticals Inc. (“Endo”), and others in the United States District Court for the Eastern District of Pennsylvania, alleging that Impax and Endo violated antitrust laws when they entered into a June 2010 settlement agreement that resolved patent litigation in connection with the submission of Impax’s ANDA for generic original Opana® ER. In October 2016, the Court granted Impax’s motion to sever, formally terminating the suit against Impax. In January 2017, the FTC filed a Part 3 Administrative Complaint against Impax with similar allegations regarding the 2010 settlement. Following trial, in May 2018, the Administrative Law Judge ruled in favor of Impax and dismissed the Complaint in its entirety. FTC Complaint Counsel appealed the decision to the full Commission, and in March 2019, the FTC issued an Opinion & Order reversing the Administrative Law Judge’s decision. The Opinion & Order did not provide for any monetary damages but enjoined Impax from entering into future agreements containing certain terms. Impax filed a Petition for Review of the FTC’s Opinion & Order with the United States Court of Appeals for the Fifth Circuit, and on April 13, 2021, the Fifth Circuit issued a decision denying Impax’s Petition for Review, effectively affirming the FTC’s Opinion & Order. On September 10, 2021, Impax filed a petition for writ of certiorari in the Supreme Court, which was denied in December 2021. On July 12, 2019, the Company received a CID from the FTC concerning an August 2017 settlement agreement between Impax and Endo, which resolved a subsequent patent infringement and breach of contract dispute between the parties regarding the above-referenced June 2010 settlement agreement related to Opana® ER. The Company cooperated with the FTC regarding the CID. On January 25, 2021, the FTC filed a complaint against Endo, Impax and Amneal in the United States District Court for the District of Columbia, alleging that the 2017 settlement violated antitrust laws. In April 2021, the Company filed a motion to dismiss the FTC’s complaint, and that motion is currently pending. The Company believes it has strong defenses to the FTC’s allegations and intends to vigorously defend the action, however, no assurance can be given as to the timing or outcome of the litigation. Opana ER® Antitrust Litigation From June 2014 to April 2015, a number of complaints styled as class actions on behalf of direct purchasers and indirect purchasers (or end-payors) and several separate individual complaints on behalf of certain direct purchasers (the “opt-out plaintiffs”) of Opana ER® were filed against Endo and Impax. In December 2014, the United States Judicial Panel on Multidistrict Litigation (the “JPML”) transferred the actions to the United States District Court for the Northern District of Illinois (“N.D. Ill.”) for coordinated pretrial proceedings, as In Re: Opana ER Antitrust Litigation (MDL No. 2580) (“MDL”). In each case, the complaints allege that Endo engaged in an anticompetitive scheme by, among other things, entering into an anticompetitive settlement agreement with Impax to delay generic competition of Opana ER® and in violation of state and federal antitrust laws. Plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. In June 2022, Impax entered into a preliminary settlement agreement with the class of direct purchasers that, if all conditions are satisfied, would result in the resolution of substantially all the direct purchasers’ and individual complainants’ underlying claims and lawsuits in the MDL. At the same time, Impax entered into a settlement agreement with individual complainants that resolved all of their claims and lawsuits in the MDL. Subsequently, Impax entered into a separate preliminary settlement agreement with the class of indirect purchasers that, if all conditions are satisfied, would result in the resolution of substantially all the indirect purchasers’ underlying claims and lawsuits in the MDL. The direct purchaser plaintiffs, indirect purchaser plaintiffs, and individual complainants are referred to herein collectively as “the Plaintiffs.” On November 3, 2022, the N.D. Ill. approved the direct purchasers’ settlement. On December 15, 2022, the N.D. Ill. approved the indirect purchasers’ settlement. Pursuant to the settlement agreements, the Company has agreed to pay a total of $265.0 million between 2022 and mid-January 2024 to resolve substantially all the Plaintiffs’ claims. 3% interest is due on $150.0 million payable between December 2022 and mid-January 2024. The settlement agreements are not an admission of liability or fault by Impax, the Company or its subsidiaries. Upon court approval of the final settlement agreements as discussed above, substantially all the claims and lawsuits in the litigation were resolved. During the year ended December 31, 2022, the Company recorded a pre-tax charge of $262.8 million associated with the settlement agreements. Imputed interest of $2.2 million will be recognized to interest expense during the payment period. Sergeants Benevolent Association Health & Welfare Fund v. Actavis, PLC, et. al. In August 2015, a complaint styled as a class action was filed against Forest Laboratories (a subsidiary of Actavis plc) and numerous generic drug manufacturers, including Amneal, in the United States District Court for the Southern District of New York involving patent litigation settlement agreements between Forest Laboratories and the generic drug manufacturers concerning generic versions of Forest’s Namenda® IR product. The complaint (as amended on February 12, 2016) asserts federal and state antitrust claims on behalf of indirect purchasers, who allege in relevant part that during the class period they indirectly purchased Namenda® IR or its generic equivalents in various states at higher prices than they would have absent the defendants’ allegedly unlawful anticompetitive conduct. Plaintiff seeks, among other things, unspecified monetary damages, and equitable relief, including disgorgement and restitution. On September 13, 2016, the Court stayed the indirect purchaser plaintiff’s claims pending factual development or resolution of claims brought in a separate, related complaint by direct purchasers (in which the Company is not a defendant). On September 10, 2018, the Court lifted the stay and referred the case to the assigned Magistrate Judge for supervision of supplemental, non-duplicative discovery in advance of mediation to be scheduled in 2019. The parties thereafter participated in supplemental discovery, as well as supplemental motion-to-dismiss briefing. On December 26, 2018, the Court granted in part and denied in part motions to dismiss the indirect purchaser plaintiff’s claims. On January 7, 2019, Amneal, its relevant co-defendants, and the indirect purchaser plaintiff informed the Magistrate Judge that they had agreed to mediation, which occurred in April 2019. In June 2019, the Company reached a settlement with the plaintiff, subject to Court approval. On September 10, 2019, the Court entered an order preliminarily approving the settlement and indefinitely staying the case as to the settling defendants (including the Company), until the disposition of the claims against the non-settling defendants. The remaining defendants subsequently also settled with the plaintiff. The plaintiff filed proposed materials seeking final approval of all settlements, including with the Company, and to finally resolve the case. The Court has scheduled a fairness hearing on the proposed settlement, which is set to take place on March 23, 2023. The amount of the settlement was not material to the Company’s consolidated financial statements. United States Department of Justice Investigations On November 6, 2014, Impax disclosed that one of its sales representatives received a grand jury subpoena from the Antitrust Division of the United States Department of Justice (the “DOJ”). On March 13, 2015, Impax received a grand jury subpoena from the DOJ requesting the production of information and documents regarding the sales, marketing, and pricing of four generic prescription medications. Impax has cooperated in the investigation and produced documents and information in response to the subpoenas from 2014 to 2016. However, no assurance can be given as to the timing or outcome of the investigation. On April 30, 2018, Impax received a CID from the Civil Division of the DOJ (the “Civil Division”). The CID requests the production of information and documents regarding the pricing and sale of Impax’s pharmaceuticals and interactions with other generic pharmaceutical manufacturers regarding whether generic pharmaceutical manufacturers engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted to the Federal government. Impax has cooperated with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation. In Re Generic Pharmaceuticals Pricing Antitrust Litigation Since March 2016, multiple putative antitrust class action complaints have been filed on behalf of direct purchasers, indirect purchasers (or end-payors), and indirect resellers, as well as individual complaints on behalf of certain direct and indirect purchasers, and municipalities (the “opt-out plaintiffs”) against manufacturers of generic drugs, including Impax and the Company. The complaints allege a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for various generic drugs in violation of federal and state antitrust and consumer protection laws. Plaintiffs seek unspecified monetary damages and equitable relief, including disgorgement and restitution. The lawsuits have been consolidated in an MDL in the United States District Court for the Eastern District of Pennsylvania ( In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2724, (E.D. Pa . )). On May 10, 2019, Attorneys General of 43 States and the Commonwealth of Puerto Rico filed a complaint in the United States District Court for the District of Connecticut against various manufacturers and individuals, including the Company, alleging a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for multiple generic drugs. On November 1, 2019, the State Attorneys General filed an Amended Complaint on behalf of nine additional states and territories. On June 10, 2020, Attorneys General of 46 States, the Commonwealth of Puerto Rico, the Commonwealth of the Northern Mariana Islands, the Territory of Guam, the U.S. Virgin Islands, and the District of Columbia filed a new complaint against various manufacturers and individuals, including the Company, alleging a conspiracy to fix prices, rig bids, and allocate markets or customers for additional generic drugs. Plaintiff States seek unspecified monetary damages and penalties and equitable relief, including disgorgement and restitution. On September 9, 2021, the State Attorneys General filed an Amended Complaint on behalf of California in addition to the original Plaintiff States. Both the May 10, 2019 and June 10, 2019 lawsuits have been incorporated into MDL No. 2724, and the June 10, 2020 lawsuit has been selected for bellwether status. On March 30, 2022, the State of Alabama voluntarily dismissed all its claims in the two actions against all defendants, including the Company, without prejudice. On February 21, 2023, the Territory of Guam voluntarily dismissed all its claims in the two actions against all defendants, including the Company, with prejudice. On February 27, 2023, the Court addressed defendants’ motions to dismiss the June 10, 2020 bellwether action, holding that the states may not pursue certain federal remedies, and otherwise denying Amneal’s joint and individual motion to dismiss. The court did not analyze the substance of the states’ state law claims, reserving those issues for a separate ruling. Fact and document discovery in MDL No. 2724 are proceeding. The court has entered a Pretrial Order setting a schedule for the bellwether cases, which includes a June 1, 2023 deadline for bellwether fact discovery and a March 13, 2023 deadline for the filing of summary judgement motions. No trial date has been set. On June 3, 2020, the Company and Impax were also named in a putative class action complaint filed in the Federal Court of Canada in Toronto, Ontario against numerous generic pharmaceutical manufacturers, on behalf of a putative class of individuals who purchased generic drugs in the private sector from 2012 to the present (Kathryn Eaton v. Teva Canada Limited, et. al., No. T-607-20). The complaint alleges price fixing, among other claims. On August 23, 2022, plaintiff filed a second amended complaint. The case has otherwise not progressed to date. Civil Prescription Opioid Litigation The Company and certain of its affiliates have been named as defendants in various matters filed in state and federal courts relating to the sale of prescription opioid pain relievers. Plaintiffs in these actions include state Attorneys General, county and municipal governments, hospitals, Native American tribes, pension funds, third-party payors and individuals. Plaintiffs seek unspecified monetary damages and other forms of relief based on various causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleged violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), state and federal controlled substances laws and other statutes. All cases involving the Company also name other manufacturers, distributors and retail pharmacies as defendants, and there are numerous other cases involving allegations relating to prescription opioid pain relievers against other manufacturers, distributors and retail pharmacies in which the Company and its affiliates are not named. Nearly all cases pending in federal district courts have been consolidated for pre-trial proceedings in an MDL in the United States District Court for the Northern District of Ohio (In re: National Prescription Opiate Litigation, Case No. 17-mdl-2804). There are approximately 914 cases in the MDL in which the Company or its affiliates have been named as defendants. The Company is also named in approximately 77 state court cases pending in ten states. The Company has filed motions to dismiss in many of these cases. No firm trial dates have been set except in Alabama (July 24, 2023) and Texas (May 20, 2024 (Dallas County) and September 30, 2024 (Bexar County). The Company was not involved in the September 2022 trial in New Mexico previously reported because of the tentative settlement the Company reached with the New Mexico Attorney General in May 2022 to resolve the New Mexico Attorney General’s claims against the Company. The Company anticipates a final determination approving the settlement in 2023. On August 3, 2022, the Company and certain of its affiliates were named as defendants in a Complaint filed in Tennessee state court, along with numerous other manufacturers, distributors, retailers, and healthcare providers, in which it is alleged the defendants are liable in civil damages to six minors who allegedly were born with neonatal abstinence syndrome (“NAS”) allegedly as a result of their biological mothers’ alleged use of diverted prescription opioid medications. The plaintiffs’ claim against each defendant in that case requires plaintiffs to prove by clear and convincing evidence that the defendant intentionally participated in Tennessee in that state’s illegal drug market as defined in the Tennessee Drug Dealer Liability Act. The case is currently stayed, but the Company intends to file a motion to dismiss the complaint when the case resumes. The Company also was named in two NAS cases in West Virginia state court which have been consolidated with other West Virginia state court NAS cases before the West Virginia Mass Litigation Panel (“WV MLP”). On November 1, 2022, the Company entered into a preliminary settlement agreement to resolve all pending litigation brought by West Virginia political subdivisions. The Company filed a motion to dismiss the complaints on February 3, 2023. Based on the preliminary settlement agreements with the states of New Mexico and West Virginia and an assessment of the information currently available, the Company recorded an $18.0 million charge for the year ended December 31, 2022, related to the majority of the MDL and state court cases. For the remaining cases, primarily brought by hospitals, pension funds, third-party payors and individuals, the Company has not recorded a liability as of December 31, 2022 because it concluded that a loss was not probable and estimable. New York Attorney General Subpoena On January 13, 2023, the Company received an investigatory subpoena from the Attorney General of the State of New York. The subpoena seeks documents broadly relating to the Company’s opioid business. The Company intends to comply with the subpoena. Securities Class Actions On April 17, 2017, New York Hotel Trades Council & Hotel Association of New York City, Inc. Pension Fund filed an amended putative class action complaint in the United States District Court for the Northern District of California against Impax and four former Impax officers alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 ( Fleming v. Impax Laboratories Inc ., et al., No. 4:16-cv-6557-HSG). Plaintiff alleges that Impax (1) concealed collusion with competitors to fix the price of the generic drug digoxin; (2) concealed anticipated erosion in the price of generic drug diclofenac; and (3) overstated the value of the generic drug budesonide. In August 2019, the Court granted Impax’s motion to dismiss Plaintiff’s second amended complaint in its entirety. Plaintiff appealed to the United States Court of Appeals for the Ninth Circuit, and on January 11, 2021, the Ninth Circuit issued an unpublished opinion affirming in part and reversing in part the District Court’s decision. Defendants subsequently filed a motion for rehearing with the Ninth Circuit, and Plaintiff filed a motion to intervene seeking to add Sheet Metal Workers’ Pension Fund of Southern California, Arizona and Nevada (“Sheet Metal Workers”) as an additional named Plaintiff. The Ninth Circuit denied the motions, and on April 1, 2021, the case was remanded to the District Court. On April 19, 2021, the Company filed a motion to dismiss the remaining claims and an opposition to Sheet Metal Workers’ renewed motion to intervene. In June 2021, the parties reached a tentative agreement to settle all claims in the case for $33 million, subject to certain terms and conditions and subject to court approval. The district court entered an order granting preliminary approval of the settlement on November 22, 2021 and held a fairness hearing on March 31, 2022. On July 15, 2022, the district court entered an order granting final approval of the settlement. On July 21, 2022, a stipulated final judgment was entered, effectively terminating this matter before the district court. The settlement was fully covered by insurance and was paid from an escrow account. Refer to Note 11. Prepaid Expenses and Other Current Assets for amounts deposited into a settlement escrow account as of December 31, 2021. On December 18, 2019, Cambridge Retirement S

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity Voting Rights Holders of Class A Common Stock and Class B Common Stock are entitled to one vote for each share of stock held, except as required by law. Holders of Class A Common Stock and Class B Common Stock vote together as a single class on each matter submitted to a stockholder vote. Holders of Class A Common Stock and Class B Common Stock are not entitled to vote on any amendment to the Company’s Charter that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote on such terms pursuant to the Company's Charter or law. Dividend Rights The holders of Class A Common Stock are entitled to receive dividends, if any, payable in cash, property, or securities of the Company, as may be declared by the Company's board of directors, out of funds legally available for the payment of dividends, subject to any preferential or other rights of the holders of any outstanding shares of preferred stock. The holders of Class B Common Stock will not be entitled to receive any dividends. Participation Rights Under the Company's Charter, the holders of Class A Common Stock and Class B Common Stock have no participation rights. However, the Company's Second Amended and Restated Stockholders Agreement dated as of December 31, 2017 (the “Stockholders Agreement”) provides that if the Company proposes to issue any securities, other than in certain issuances, the Members will have the right to purchase a pro rata share of such securities, based on the number of shares of common stock owned by the Members before such issuance. Issuance and Restrictions on Company Common Stock Pursuant to the Third Amended and Restated Limited Liability Company Agreement of Amneal dated May 4, 2018 (the “Limited Liability Company Agreement”), Amneal will issue to the Company an additional Amneal common unit for each additional share of Class A Common Stock issued by the Company. Additionally, pursuant to the Charter, shares of Class B Common Stock will be issued to the Members and their permitted transferees only to the extent necessary in certain circumstances to maintain a one-to-one ratio between the number of Amneal Common Units and the number of shares of Class B Common Stock held by such members. Shares of Class B Common Stock are transferable only for no consideration to the Company for automatic retirement or in accordance with the Stockholders Agreement and the Limited Liability Company Agreement. Liquidation Rights On the liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Class A Common Stock are entitled to share equally in all assets of the Company available for distribution among the stockholders of the Company after payment to all creditors and subject to any preferential or other rights of the holders of any outstanding shares of preferred stock. The holders of Class B common stock are not entitled to share in such net assets. Redemption The Limited Liability Company Agreement provides that holders of Amneal Common Units may, from time to time, require the Company to redeem all or a portion of their interests for newly issued shares of Class A Common Stock on a one-for-one basis. Upon receipt of a redemption request, the Company may, instead, elect to effect an exchange of Amneal Common Units directly with the holder. Additionally, the Company may elect to settle any such redemption or exchange in shares of Class A Common stock or in cash. In the event of a cash settlement, the Company would issue new shares of Class A Common Stock and use the proceeds from the sale of these newly issued shares of Class A Common Stock to fund the cash settlement, which, in effect, limits the amount of the cash payments to the redeeming member. In connection with any redemption, the Company will receive a corresponding number of Amneal Common Units, increasing the Company’s total ownership interest in Amneal. Additionally, an equivalent number of shares of Class B Common Stock will be surrendered and canceled. Preferred Stock Under the Company’s certificate of incorporation, the Company’s Board of Directors has the authority to issue preferred stock and set its rights and preferences. As of December 31, 2022, no preferred stock had been issued. Non-Controlling Interests As discussed in Note 2. Summary of Significant Accounting Policies , the Company consolidates the financial statements of Amneal and its subsidiaries and records non-controlling interests for the portion of Amneal’s economic interests that is not held by the Company. Non-controlling interests are adjusted for capital transactions that impact the non-publicly held economic interests in Amneal. Under the terms of Amneal’s limited liability company agreement, as amended, Amneal is obligated to make tax distributions to its members. For the years ended December 31, 2022, 2021, and 2020, tax distributions of $10.6 million, $53.5 million, and $2.8 million, respectively, were recorded as reductions of non-controlling interests. There was no liability for tax distributions payable to Members as of December 31, 2022 and 2021. During September 2020, the Company made a $3.3 million payment to the non-controlling interest holders in one of Amneal's non-public subsidiaries, Gemini Laboratories, LLC, to distribute earnings of $0.8 million and acquire their ownership interests in the non-public subsidiary for $2.5 million. As discussed in Note 3. Acquisitions , the Company acquired a 98% interest in KSP on April 2, 2021. The sellers of KSP, a related party, hold the remaining interest. The Company will attribute 2% of the net income or loss of KSP to these non-controlling interests. Redeemable Non-Controlling Interests - AvKARE, LLC and R&S As discussed in Note 3 . Acquisitions , the Company acquired a 65.1% interest in Rondo on January 31, 2020. The sellers of AvKARE, LLC and R&S hold the remaining 34.9% interest (“Rondo Class B Units”). Beginning on January 1, 2026, the holders of the Rondo Class B Units have the right (“Put Right”) to require the Company to acquire the Rondo Class B Units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization (EBITDA) if certain financial targets and other conditions are met. Additionally, beginning on January 31, 2020, the Company has the right to acquire the Rondo Class B Units based on the same value and conditions as the Put Right. The Rondo Class B Units are also redeemable by the holders upon a change in control. Since the redemption of the Rondo Class B Units is outside of the Company's control, the units have been presented outside of stockholders’ equity as redeemable non-controlling interests. Upon closing of the Acquisitions on January 31, 2020, these redeemable non-controlling interests were recorded at an estimated fair value of $11.5 million. The fair value of the redeemable non-controlling interests was estimated using the Monte-Carlo simulation approach under the option pricing framework, which considers the redemption rights of both the Company and the holders of the Rondo Class B Units. The Company will attribute 34.9% of the net income of Rondo to the redeemable non-controlling interests. The Company will also accrete the redeemable non-controlling interests to redemption value upon an event that makes redemption certain. For the years ended December 31, 2022 and 2021, tax distributions of $6.9 million and $3.6 million, respectively, were recorded as reductions of redeemable non-controlling interests . As of December 31, 2022 and 2021, there were no amounts due for tax distributions related to these redeemable non-controlling interests. Redeemable Non-Controlling Interests - Puniska As discussed in Note 3 . Acquisitions , the Company acquired a 74% interest in Puniska on November 2, 2021. Amneal was required pursuant to the purchase agreement to acquire the remaining 26% of Puniska upon approval of the transaction by the government of India. Since approval of the government of India was outside of the Company’s control, upon closing of the Puniska Acquisition, the equity interests of Puniska that the Company did not own were presented outside of stockholders' equity as redeemable non-controlling interests. The Company attributed 26% of the net losses of Puniska to the redeemable non-controlling interests. Upon approval of the transaction by the government of India in March 2022, the Company paid the $1.7 million redemption value for the remaining 26% of the equity interests of Puniska. For the year ended December 31, 2022, t he Company recorded accretion of $0.9 million to increase the redeemable non-controlling interests to redemption value. Changes in Accumulated Other Comprehensive Loss by Component (in thousands): Foreign Unrealized Accumulated Balance December 31, 2020 $ (14,497) $ (26,821) $ (41,318) Other comprehensive income before reclassification (4,255) 20,972 16,717 Reallocation of ownership interests (93) (133) (226) Balance December 31, 2021 (18,845) (5,982) (24,827) Other comprehensive income before reclassification (13,394) 48,270 34,876 Reallocation of ownership interests (143) 33 (110) Balance December 31, 2022 $ (32,382) $ 42,321 $ 9,939

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan In May 2018, the Company adopted the Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan (“2018 Plan”) under which the Company may grant stock options, restricted stock units and other equity-based awards to employees and non-employee directors providing services to the Company and its subsidiaries. The stock option, RSU and MPRSU award grants are made in accordance with the Company’s 2018 Plan and are subject to forfeiture if the vesting conditions are not met. On May 5, 2020, the stockholders of the Company approved an amendment to the 2018 Plan which authorized an additional 14 million shares of Class A common stock available for issuance under the 2018 Plan. The aggregate number of shares of Class A common stock authorized for issuance pursuant to the Company's 2018 Plan is 37 million shares. As of December 31, 2022, the Company had 10,005,452 shares available for issuance under the 2018 Plan. The Company recognizes the grant date fair value of each option and share of restricted stock unit over its vesting period. Stock options and RSU awards are granted under the Company’s 2018 Plan and generally vest over a 4 year period and, in the case of stock options, have a term of 10 years. The following table summarizes all of the Company’s stock option activity for the years ended December 31, 2022, 2021, and 2020: Stock Options Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2019 6,177,126 $ 8.87 Options exercised (116,681) 2.75 Options forfeited (2,249,216) 16.09 Outstanding at December 31, 2020 3,811,229 $ 4.80 7.9 $ 5.6 Options exercised (342,350) 2.76 Options forfeited (417,379) 11.09 Outstanding at December 31, 2021 3,051,500 $ 4.17 7.0 $ 5.3 Options exercised (207,452) 2.75 Options forfeited (195,607) 2.77 Outstanding at December 31, 2022 2,648,441 $ 4.38 6.0 $ — Options exercisable at December 31, 2022 2,288,371 $ 4.64 6.0 $ — The intrinsic value of options exercised during the year ended December 31, 2022 was approximately $0.1 million. There were no options granted in the years ended December 31, 2022, 2021 and 2020. The following table summarizes all of the Company's restricted stock unit activity for the years ended December 31, 2022, 2021, and 2020: Restricted Stock Units Number of Weighted- Weighted- Aggregate Non-vested at December 31, 2019 2,637,358 $ 12.16 Granted 8,414,762 3.67 Vested (692,868) 12.33 Forfeited (1,226,700) 6.48 Non-vested at December 31, 2020 9,132,552 $ 5.09 1.7 $ 41.7 Granted 6,870,481 5.86 Vested (1,906,607) 5.97 Forfeited (912,826) 6.68 Non-vested at December 31, 2021 13,183,600 $ 5.25 1.4 $ 63.7 Granted 10,117,037 4.54 Vested (2,697,134) 5.95 Forfeited (2,674,890) 5.07 Non-vested at December 31, 2022 17,928,613 $ 4.77 1.3 $ 35.7 The table above includes 3,053,738 MPRSUs granted to executives during 2022. Vesting of these awards is contingent upon the Company’s achievement of stock price hurdles over the performance period starting March 1, 2022 and requires the employee’s continued employment or service through February 28, 2025. The MPRSUs cliff vest at the end of the 3 year period and have a maximum potential to vest at 200% (6,107,476 shares) based on the Company's stock price performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated fair value per share of the MPRSUs was $6.22 and was calculated using a Monte Carlo simulation model. 2,731,612 of these MPRSUs remain outstanding and unvested at December 31, 2022. The table above also includes 2,331,211 MPRSUs granted to executives during 2021. Vesting of these awards is contingent upon the Company’s achievement of stock price hurdles over the performance period starting March 1, 2021 and requires the employee’s continued employment or service through February 29, 2024. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (4,662,422 shares) based on the Company's stock price performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated fair value per share of the MPRSUs ranged from $5.31 and $8.58 and was calculated using a Monte Carlo simulation model. 2,010,449 of these MPRSUs remained outstanding and unvested at December 31, 2022. In addition, the table above includes 2,977,711 MPRSUs granted to executives during the first quarter of 2020. Vesting of these awards is contingent upon the Company’s achievement of stock price hurdles over the performance period starting March 1, 2020 and requires the employee’s continued employment or service through February 28, 2023. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (5,955,422 shares) based on the Company's stock price performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated fair value per share of the MPRSUs ranged from $2.13 and $3.63 and was calculated using a Monte Carlo simulation model. 2,431,462 of these MPRSUs remained outstanding and unvested at December 31, 2022. As of December 31, 2022, the Company had total unrecognized stock-based compensation expense of $50.4 million related to all of its stock-based awards, which is expected to be recognized over a weighted average period of 1.8 years. The amount of stock-based compensation expense recognized by the Company was as follows (in thousands): Year Ended December 31, 2022 2021 2020 Cost of goods sold $ 4,811 $ 4,688 $ 4,166 Selling, general and administrative 20,746 18,718 13,343 Research and development 6,290 5,006 3,241 Total $ 31,847 $ 28,412 $ 20,750

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions The Company has various business agreements with certain third-party companies in which there is some common ownership and/or management between those entities, on the one hand, and the Company, on the other hand. The Company has no direct ownership or management in any of such related party companies. The following table summarizes the Company’s related party transactions (in thousands): Year ended December 31, Related Party and Nature of Transaction Caption in Balance Sheet and Statement of Operations 2022 2021 2020 A Kashiv Biosciences LLC i. Parking space lease Cost of goods sold $ 100 $ 99 $ 99 ii. License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Filgrastim Selling, general and administrative 5,000 — — ii. License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for P egfilgrastim-pbbk Intangible asset 15,000 — — ii. License and commercialization agreement - Filgrastim and Pegfilgrastim -research and development milestone Research and development — — 1,000 ii. Inventory purchases under license and commercialization agreement - Filgrastim and Pegfilgrastim Inventory and cost of goods sold 260 — — iii. Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate Research and development 1,761 1,362 1,550 iv. Transition services associated with the KSP Acquisition Selling, general and administrative — 255 — v. Development and commercialization - consulting - various products Research and development 2 628 196 vi, Development supply agreement Research and development — — — vii. Development and commercialization agreements - Levothyroxine Sodium and Posaconazole Research and development — — 2,688 viii. K127 development and commercialization agreement* Research and development — 3,000 2,000 ix. Commercial product support for EluRyng and other products* Cost of goods sold and research and development — 1,239 6,130 x. Profit sharing - various products* Cost of goods sold — 2,680 11,189 xi. Development and commercialization agreements - various products* Research and development — 150 206 Total $ 22,123 $ 9,413 $ 25,058 B LAX Hotel, LLC Financing lease Inventory and cost of goods sold $ — $ 217 $ 2,608 Interest component of financing lease Interest expense — 362 4,395 Total $ — $ 579 $ 7,003 C Kanan, LLC - operating lease Inventory and cost of goods sold $ 2,104 $ 2,103 $ 2,093 D Sutaria Family Realty, LLC - operating lease Inventory and cost of goods sold $ 1,211 $ 1,179 $ 1,142 E PharmaSophia, LLC - research and development services income Research and development $ (45) $ (329) $ (521) E PharmaSophia, LLC - license and commercialization agreement Research and development $ 1,093 $ — $ — F Fosun International Limited - license and supply agreement Net revenue $ — $ (200) $ — G Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement Inventory and cost of goods sold $ 2,742 $ 11,380 $ 11,570 H Tracy Properties LLC - operating lease Selling, general and administrative $ 565 $ 532 $ 497 I AzaTech Pharma LLC - supply agreement Inventory and cost of goods sold $ 4,963 $ 5,156 $ 4,506 J AvPROP, LLC - operating lease Selling, general and administrative $ 178 $ 165 $ 142 K Tarsadia Investments, LLC - financial consulting services Selling, general and administrative $ — $ — $ — L Avtar Investments, LLC - consulting services Selling, general and administrative $ 216 $ 361 $ 982 M TPG Operations, LLC - consulting services Selling, general and administrative $ 19 $ 249 $ — N Alkermes Plc Inventory and cost of goods sold $ 235 $ 138 $ — O R&S Solutions LLC - logistics services Selling, general and administrative $ 85 $ 183 $ 80 P Zep Inc. Net revenue $ — $ — $ (637) Q Sellers of Gemini Laboratories, LLC - acquisition agreement Non-controlling interests $ — $ — $ 3,300 R Asana Biosciences, LLC Research and development $ (5) $ (4) $ — U Members - tax receivable agreement Other expense $ 631 $ — $ — *Agreement between Amneal and Kashiv was acquired with KSP and has become a transaction among Amneal’s consolidated subsidiaries subsequent to the transaction closing on April 2, 2021. The disclosure relates to the historical agreement as a related party transaction through April 2, 2021 (refer to Note 3. Acquisitions for additional information). The following table summarizes the amounts due to or from the Company for related party transactions (in thousands): December 31, 2022 December 31, 2021 E PharmaSophia, LLC - research and development agreement $ — $ 1,081 T Sellers of AvKARE LLC and R&S - state tax indemnification 486 68 A Kashiv - various agreements 12 14 G Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement — 16 R Asana BioSciences, LLC 2 — Related party receivables - short term $ 500 $ 1,179 A Kashiv - deferred consideration associated with the KSP Acquisition $ — $ 30,500 A Kashiv - various agreements 110 314 S Sellers of Puniska - consideration for acquisition — 14,225 G Apace Packaging, LLC - packaging agreement 756 560 I AzaTech Pharma LLC - supply agreement 863 1,783 L Avtar Investments LLC - consulting services 72 37 T Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 442 442 U Members - tax receivable agreement 201 — O R&S Solutions LLC - logistics services 7 — N Alkermes Plc 28 — H Tracy Properties LLC — — Related party payables - short term $ 2,479 $ 47,861 A Kashiv - contingent consideration $ 3,290 $ 5,900 T Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 5,929 3,719 U Members - tax receivable agreement 430 — Related party payables - long term $ 9,649 $ 9,619 Related Party Descriptions (A) Kashiv Biosciences LLC Kashiv is an independent contract development organization focused primarily on the development of 505(b)(2) NDA products. Amneal has various business agreements with Kashiv. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Kashiv. In addition, they serve on the Board of Managers of Kashiv. On January 11, 2021, the Company and Kashiv entered into a definitive agreement for Amneal to acquire a 98% interest in KSP, a subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs. The acquisition closed on April 2, 2021 and included contingent payments for achievement of certain regulatory milestones and potential royalty payments base on annual net sales for certain future pharmaceutical products. Certain of the contracts between Amneal and Kashiv were acquired in this transaction and have become transactions among Amneal’s consolidated subsidiaries subsequent to the transaction closing. Refer to Note 3. Acquisitions for further details on the KSP acquisition. Below is a summary of the related party arrangements held between the Company and Kashiv which were not impacted by the KSP Acquisition: i. The parties entered into a lease for parking spaces in Piscataway, NJ. The annual lease cost is $0.1 million per year. ii. In 2017 Kashiv and Amneal entered into an exclusive license and commercialization agreement (the “Kashiv Biosimilar Agreement”) to distribute and sell two biosimilar products, Filgrastim and Pegfilgrastim, in the U.S. Kashiv is responsible for development, regulatory filings, obtaining FDA approval, and manufacturing, and Amneal is responsible for marketing, selling, and pricing activities. The term of the agreement is 10 years from the respective product’s launch date. The Kashiv Biosimilar Agreement provided for potential future milestone payments to Kashiv of up to $183.0 million, as follows: (i) up to $22.5 million relating to regulatory approval and execution, (ii) up to $43.0 million for successful delivery of commercial launch inventory, (iii) up to $50.0 million depending on the number of competitors at launch for one product, and (iv) between $15.0 million and $67.5 million for the achievement of cumulative net sales for both products. In July 2022, the Company and Kashiv amended the Kashiv Biosimilar Agreement to, among other things, (i) eliminate milestones related to the manufacturing and delivery of the Kashiv products, (ii) revise the net sales milestones to provide for future milestone payments by the Company to Kashiv of up to $37.5 million for the achievement of cumulative combined net sales goals for both products, and (iii) adjust the supply price of product that Kashiv manufacturers and supplies to the Company, which will lower the cost per unit of both products. The remaining milestones are subject to reaching certain commercial sales volume objectives. In addition, the agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs. On May 27, 2022, the FDA approved the Company’s biologic license application, associated with the amended Kashiv Biosimilar Agreement, for Pegfilgrastim-pbbk. In connection with this regulatory approval and associated activity, the Company incurred a milestone of $15.0 million during the year ended December 31, 2022, payable to Kashiv. The milestone was capitalized as an intangible asset and will be amortized to cost of sales over an estimated useful life of 8.3 years. The Company paid Kashiv $15.0 million in August 2022 related to this milestone. The Company recognized a $5.0 million milestone in selling, general and administrative expense upon FDA approval of Filgrastim in February 2022. iii. Amneal and Kashiv entered into a product development agreement for the development and commercialization of two generic peptide products, Ganirelix Acetate and Cetrorelix Acetate. Under the agreement, the intellectual property and ANDA for these products are owned by Amneal, and Kashiv will receive a profit share for all sales of the products made by Amneal. In connection with the agreement, Amneal made an upfront payment of $1.1 million in August 2020. The agreement also provides for potential future milestone payments to Kashiv of (i) up to $2.1 million relating to development milestones, and (ii) up to $0.3 million relating to regulatory filings. The milestones are subject to certain performance conditions which may or may not be achieved, including FDA filings. In addition, Amneal agreed to pay $2.6 million of development fees to Kashiv as the development work is completed. iv. As discussed in Note 3. Acquisitions, the purchase price for the KSP Acquisition included a contractually stated amount of deferred consideration of $30.5 million. As of December 31, 2021, deferred consideration of $30.5 million w as recorded in related party payable-short term. Amneal paid all of the deferred consideration in 2022. Additionally, as of December 31, 2022 and 2021 , a contingent consideration liability of $3.3 million and $5.9 million, respectively, associated with the KSP Acquisition was recorded in related party payable-long term. For the year ended December 31, 2021, the Company recorded $0.3 million of expenses for transition services associated with the KSP Acquisition provided by Kashiv. v. Amneal has various consulting arrangements with Kashiv to collaborate on the development and commercialization of certain generic pharmaceutical products. vi. In December 2022, Amneal and Kashiv entered into a development supply agreement specific to four generic product candidates. Amneal will be responsible to manufacture batch products, as well as to perform certain developmental activities on behalf of Kashiv. Kashiv, as owner of the IP, will be responsible for regulatory filings, obtaining FDA approval, marketing, selling, and pricing activities. Pursuant to the terms of the development supply agreement, Amneal is eligible to earn up to $2.4 million related to the aforementioned services. During the year ended December 31, 2022, the Company did not recorded any revenue related to this agreement. vii. Pursuant to a product development agreement, Amneal and Kashiv agreed to collaborate on the development and commercialization of Levothyroxine Sodium. Under the agreement, the intellectual property and ANDA for this product is owned by Amneal, and Kashiv received a profit share for all sales of the product made by Amneal. Amneal is precluded from selling the product made by Kashiv during the term of the license and supply agreement with Jerome Stevens Pharmaceuticals (refer to Note 5. Alliances and Collaboration ). Under the terms of the amended agreement with Kashiv, Amneal paid $2.0 million in July 2019 and may be required to pay up to an additional $18.0 million upon certain regulatory milestones being met. Amneal and Kashiv entered into a product development agreement for the development and commercialization of Posaconazole. Under this agreement, the intellectual property and ANDA for this product is owned by Amneal and Kashiv is to receive a profit share for all sales of the product made by Amneal. In connection with the agreement, Amneal paid an upfront amount of $0.3 million in May 2020 for execution of the agreement which was expensed in research and development. The agreement also provides for potential future milestone payments to Kashiv of (i) up $0.8 million relating to development milestones, (ii) up to $0.3 million relating to regulatory approval, and (iii) up to $1.0 million for the achievement of cumulative net sales. The milestones were subject to certain performance conditions which may or may not be achieved, including FDA filing, FDA approval and commercial sales volume objectives. The following disclosures relate to agreements between Amneal and Kashiv that were acquired as part of the KSP Acquisition. These agreements became a transaction among Amneal’s consolidated subsidiaries subsequent to the closing of the KSP Acquisition on April 2, 2021. These below transactions were considered related party transactions through April 2, 2021 (refer to Note 3. Acquisitions for additional information). viii. Amneal and Kashiv entered into a licensing agreement for the development and commercialization of Kashiv’s orphan drug K127 (pyridostigmine) for the treatment of Myasthenia Gravis. Under the terms of the agreement, Kashiv was responsible for all development and clinical work required to secure Food and Drug Administration approval and Amneal was responsible for filing the NDA and commercializing the product. The Company made an upfront payment of approximately $1.5 million to Kashiv in December 2019, and Kashiv was eligible to receive development and regulatory milestones totaling approximately $16.5 million. Kashiv was also eligible to receive tiered royalties from the low double-digits to mid-teens on net sales of K127. ix. On February 20, 2020, the Company and Kashiv entered into a master services agreement covering certain services that Kashiv provided the Company for commercial product support related to EluRyng and other products, including Ranitidine and Nitrofurantoin. x. Amneal had various development, commercialization and consulting arrangements with Kashiv to collaborate on the development and commercialization of certain generic pharmaceutical products. Kashiv received a percentage of net profits with respect to Amneal’s sales of these products. xi. Amneal had various development, commercialization and consulting arrangements with Kashiv to collaborate on the development and commercialization of certain generic pharmaceutical products. This activity related to the total reimbursable expenses associated with these arrangements. (B) LAX Hotel, LLC The Company had a financing lease with LAX Hotel, LLC for two buildings located in Long Island, New York, which are used as an integrated manufacturing and office facility. The Company leased these buildings from LAX Hotel, LLC from 2012 until January 2021. LAX Hotel, LLC had been controlled by a member of the Amneal Group, who also serves as observer on the Company's Board of Directors. As a result, this lease had been historically accounted for as a related party financing lease. During January 2021, LAX Hotel, LLC sold its interests in the leased buildings to an unrelated third-party. Therefore, this lease is no longer a related party transaction, and the corresponding financing lease right-of-use asset and liability were reclassified in the consolidated balance sheet as of December 31, 2021 to reflect this change. For annual payments required under the terms of non-cancelable lease agreements over the next five years and thereafter, refer to Note 12. Leases . (C) Kanan, LLC Kanan, LLC (“Kanan”) is a real estate company that owns Amneal’s manufacturing facilities located at 65 Readington Road, Branchburg, New Jersey, 131 Chambers Brook Road, Branchburg, New Jersey and 1 New England Avenue, Piscataway, New Jersey. Certain executive officers of the Company beneficially own, through certain revocable trusts, equity securities of Kanan. In addition, they serve on the Board of Managers of Kanan. Amneal leases these facilities from Kanan under two separate triple-net lease agreements that expire in 2027 and 2031, respectively, at an annual rental cost of approximately $2.0 million combined, subject to CPI rent escalation adjustments as provided in the lease agreements. (D) Sutaria Family Realty, LLC Industrial Real Estate Holdings NY, LLC (“IRE”) is a real estate management entity, which was the sub-landlord of Amneal’s leased manufacturing facility located at 75 Adams Avenue, Hauppauge, New York. IRE is controlled by a member of the Amneal Group who also serves as an observer on our Board of Directors. Effective June 1, 2020, the lease was assigned to the Company with the consent of the landlord, Sutaria Family Realty, LLC, which is also a related party because a member of Company management is a beneficial owner. Concurrently with the assignment of the lease, the Company exercised a renewal option for $0.1 million to extend the lease by 5 years until March 31, 2026. Monthly rent payments are $0.1 million and increase by 3% annually. (E) PharmaSophia, LLC PharmaSophia, LLC (“PharmaSophia”) is a joint venture formed by Nava Pharma, LLC (“Nava”) and Oakwood Laboratories, LLC for the purpose of developing certain products. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Nava. Nava beneficially owns 50% of the outstanding equity securities of PharmaSophia. In addition, these executive officers also serve on the Board of Managers of PharmaSophia. PharmaSophia and Nava are parties to an R&D agreement pursuant to which Nava provides R&D services to PharmaSophia (the “Nava Agreement”). Nava subcontracted this obligation to Amneal under a subcontract R&D services agreement pursuant to which Amneal provides R&D services to Nava in connection with the products being developed by PharmaSophia. In October 2022, PharmaSophia and Amneal entered into an exclusive license and commercialization agreement (the “PharmaSophia Agreement”) to develop, manufacture, and sell one injectable product. Under the terms of the agreement, Amneal committed to spend up to $6.0 million to further develop the product, including all related expenses up to submission of the ANDA, which will be owned by Amneal. Also under the terms of the PharmaSophia Agreement, PharmaSophia settled a liability of $1.1 million payable to Amneal under the terms of the Nava Agreement by reducing the amount of Amneal’s committed spending under the terms of the PharmaSophia Agreement to $4.9 million. Amneal recorded $1.1 million of research and development expense for the year ended December 31, 2022 as a result of the settlement. PharmaSophia will receive a 50% profit share for all sales of product made by Amneal under the PharmaSophia Agreement. (F) Fosun International Limited Fosun International Limited (“Fosun”) is a Chinese international conglomerate and investment company that is a shareholder of the Company. On June 6, 2019, the Company entered into a license and supply agreement with a subsidiary of Fosun, which is a Chinese pharmaceutical company. Under the terms of the agreement, the Company will hold the imported drug license required for pharmaceutical products manufactured outside of China and will supply Fosun with finished, packaged products for Fosun to then sell in the China market. Fosun will be responsible for obtaining regulatory approval in China and for shipping the product from Amneal’s facility to Fosun’s customers in China. In consideration for access to the Company's U.S. regulatory filings to support its China regulatory filings and for the supply of product, Fosun paid the Company a $1.0 million non-refundable fee, net of tax, in July 2019 and will be required to pay the Company $0.3 million for each of eight products upon the first commercial sale of each in China in addition to a supply price and a profit share. On August 12, 2021, the Company entered into an active pharmaceutical ingredient (“API”) co-development agreement with a subsidiary of Fosun. Under the terms of the agreement, the Company provided Fosun a license to manufacture and sell two pharmaceutical products outside of the United States. Fosun will be responsible for obtaining regulatory approval outside the United States. Fosun paid the Company a $0.2 million non-refundable fee which was recognized in 2021 as revenue and will be required to pay the Company $0.1 million for each of the two products upon the first commercial sale of each in China in addition to a profit share. (G) Apace KY, LLC d/b/a Apace Packaging LLC Apace KY, LLC d/b/a Apace Packaging LLC (“Apace”) provides packaging solutions pursuant to an exclusive packaging agreement. Apace markets its services which include bottling and blistering for the pharmaceutical industry. A member of Company management beneficially owns outstanding equity securities of Apace. (H) Tracy Properties LLC R&S leases operating facilities, office and warehouse space from Tracy Properties LLC (“Tracy”). A member of Company management beneficially owns outstanding equity securities of Tracy. (I) AzaTech Pharma, LLC R&S purchases inventory from AzaTech Pharma LLC (“AzaTech”) for resale. A member of Company management beneficially owns outstanding equity securities of AzaTech. (J) AvPROP, LLC AvKARE LLC leases its operating facilities from AvPROP, LLC (“AvPROP”). A member of Company management beneficially owns outstanding equity securities of AvPROP. (K) Tarsadia Investments, LLC Tarsadia Investments, LLC (“Tarsadia”) is a private investment firm that provides financial services and is a significant shareholder of the Company. A member of Amneal Group, and an observer to the Board, is the Chairman and Founder of Tarsadia. Another member of the Amneal Group, and a member of the Board, is a Managing Director of Tarsadia. Tarsadia offers capital and strategic support for companies with substantial growth potential primarily in the healthcare, financial services, real estate, and clean technology sectors. The Company entered into an agreement in which Tarsadia will provide financial consulting services. The services are not expected to have a material impact to the Company’s financial statements. (L) Avtar Investments, LLC Avtar Investments, LLC (“Avtar”) is a private investment firm. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Avtar. During April 2020, the Company entered into an agreement in which Avtar will provide consulting services. (M) TPG Operations, LLC TPG Operations LLC (“TPG”) is a private investment firm that provides financial services and is a significant stockholder of the Company. An observer of our Board is a managing director of TPG. TPG offers capital and strategic support for companies with substantial growth potential primarily in the healthcare, financial services, real estate, and clean technology sectors. In March 2020, the Company entered into an agreement in which TPG provided financial consulting services for a period of 7 months. The agreement was subsequently extended until March 2022. (N) Alkermes Plc Rondo Partners LLC purchases inventory from Alkermes Plc for resale. A member of the Board also sits on the board of directors for Alkermes Plc. (O) R&S Solutions LLC R&S Solutions LLC provides logistic services to the Company. A member of Company management beneficially owns outstanding equity securities of R&S Solutions LLC. (P) Zep Inc. Zep Inc. (“Zep”) is a producer and distributor of maintenance and cleaning solutions for retail, food and beverage, industrial and institutional, and vehicle care customers. An executive officer of the Company serves as a director of Zep. During May 2020, AvKARE entered into an agreement to supply cleaning products to Zep. (Q) Gemini Laboratories, LLC During September 2020, the Company made a $3.3 million payment to the non-controlling interest holders in one of Amneal's non-public subsidiaries, Gemini Laboratories, LLC, to distribute earnings of $0.8 million and acquire their ownership interests in the non-public subsidiary for $2.5 million. (R) Asana Biosciences, LLC Asana Biosciences, LLC (“Asana”) is an early stage drug discovery and R&D company focusing on several therapeutic areas, including oncology, pain and inflammation. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Asana. In addition, they serve on the Board of Managers of Asana. From time to time, Amneal provides R&D services to Asana under a development and manufacturing agreement and storage services under a storage agreement. (S) Puniska Acquisition The purchase price for the Puniska Acquisition included $14.2 million due to the sellers, which was outstanding at December 31, 2021 (paid by Amneal in 2022), for the satisfaction of a preexisting payable upon approval of the transaction by the government of India. Further, the Company paid $1.7 million for the remaining 26% equity interest of Puniska (included in redeemable non-controlling interests in the Company’s consolidated balance sheet as of December 31, 2021 ) upon approval of the Puniska Acquisition by the government of India in 2022. Refer to Note. 3 Acquisitions for related party transactions associated with the Puniska Acquisition. (T) Sellers of AvKARE LLC and R&S Tax Indemnification – Rondo Acquisitions In accordance with the Rondo Equity Purchase Agreement, the Company will be indemnified by the sellers of AvKARE, LLC and R&S for $0.1 million of state taxes paid on behalf of the sellers for a tax period prior to the closing of the Rondo Acquisition. As a result, the Company recorded $0.1 million of related party receivables - short term as of December 31, 2021. Notes Payable – Related Party Certain holders of the Rondo Class B Units are also holders of the Sellers Notes and were holders of the Short-Term Sellers Note, which Amneal repaid in 2021. For additional information, refer to Note 16. Debt . Refer to Note. 3 Acquisitions and Note 22. Stockholders’ Equity for related party transactions associated with the Rondo Acquisitions . Tax Distributions Under the terms of the limited liability company agreement between the Company and the holders of the Rondo Class B Units, Rondo is obligated to make tax distributions to those holders, subject to certain limitations as defined in the Rondo Credit Facility. For further details, refer to Note 22. Stockholders' Equity . (U) Tax Receivable Agreement In connection with the acquisition of Impax, the Company entered into a tax receivable agreement for which it is generally required to pay the other holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal Common Units for shares of Class A Common Stock and (ii) tax benefits attributable to payments made under the TRA. Refer to Note 7. Income Taxes for additional information. (V) Tax Distributions to Members Under the terms of the Limited Liability Company Agreement, Amneal is obligated to make tax distributions to its members, which are also holders of non-controlling interests in the Company. For further details, refer to Note 22. Stockholders' Equity and Note. 7 Income Taxes for further details.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit PlansThe Company has voluntary defined contribution plans covering eligible employees in the United States which provide for a Company match. For the years ended December 31, 2022, 2021 and 2020, the Company made matching contributions of $9.5 million, $8.9 million and $7.7 million, respectively. The Company also has a deferred compensation plan for certain former executives and employees of Impax, some of whom are currently employed by the Company. In January 2019, the Company announced that it will no longer accept contributions from employees or make matching contributions for the deferred compensation plan. Deferred compensation liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived by reference to hypothetical investments selected by the participants and is included in accounts payable and accrued expenses and other long-term liabilities. Refer to Note 19. Fair Value Measurements for additional information.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Information	Segment Information The Company has three reportable segments: Generics, Specialty, and AvKARE. Generics The Company’s Generics segment includes a retail and institutional portfolio of over 250 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals. Specialty The Company’s Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease, and endocrine disorders. AvKARE The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a wholesale distributor of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, and medical and surgical products. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. Chief Operating Decision Makers The Company’s chief operating decision makers evaluate the financial performance of the Company’s segments based upon segment operating income (loss). Items below operating income (loss) are not reported by segment, since they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision makers. The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, R&D expenses, and other operating expenses to the extent specifically identified by segment (in thousands): Year Ended December 31, 2022 Generics (1) Specialty AvKARE (1) Corporate Total Net revenue (2) $ 1,432,073 $ 374,121 $ 406,110 $ — $ 2,212,304 Cost of goods sold 890,245 177,107 349,133 — 1,416,485 Cost of goods sold impairment charges 5,786 5,325 — — 11,111 Gross profit 536,042 191,689 56,977 — 784,708 Selling, general and administrative 109,781 90,031 53,659 146,229 399,700 Research and development 167,509 28,179 — — 195,688 In-process research and development impairment charges 12,970 — — — 12,970 Intellectual property legal development expenses 4,251 107 — — 4,358 Acquisition, transaction-related and integration expenses 25 49 — 635 709 Restructuring and other charges 821 — — 600 1,421 Change in fair value of contingent consideration — 731 — — 731 (Insurance recoveries) charges for property losses and associated expenses, net (1,911) — — — (1,911) Charges related to legal matters, net 22,400 — — 247,530 269,930 Other operating income (3,960) — — — (3,960) Operating income (loss) $ 224,156 $ 72,592 $ 3,318 $ (394,994) $ (94,928) Year Ended December 31, 2021 Generics (1) Specialty AvKARE (1) Corporate Total Net revenue (2) $ 1,366,338 $ 378,319 $ 349,012 $ — $ 2,093,669 Cost of goods sold 825,568 193,562 282,874 — 1,302,004 Cost of goods sold impairment charges 22,692 — — — 22,692 Gross profit 518,078 184,757 66,138 — 768,973 Selling, general and administrative 64,500 84,481 57,918 158,605 365,504 Research and development 158,365 43,482 — — 201,847 In-process research and development impairment charges 710 — — — 710 Intellectual property legal development expenses 7,562 154 — — 7,716 Acquisition, transaction-related and integration expenses — 16 1,422 6,617 8,055 Restructuring and other charges 80 — — 1,777 1,857 Change in fair value of contingent consideration — 200 — — 200 (Insurance recoveries) charges for property losses and associated expenses, net 5,368 — — — 5,368 Charges related to legal matters, net — — — 25,000 25,000 Operating income (loss) $ 281,493 $ 56,424 $ 6,798 $ (191,999) $ 152,716 Year Ended December 31, 2020 Generics (1) Specialty AvKARE (1) Corporate Total Net revenue (2) $ 1,343,210 $ 355,567 $ 293,746 $ — $ 1,992,523 Cost of goods sold 894,422 192,910 242,219 — 1,329,551 Cost of goods sold impairment charges 34,579 — — — 34,579 Gross profit 414,209 162,657 51,527 — 628,393 Selling, general and administrative 56,134 75,917 58,544 136,132 326,727 Research and development 150,068 29,862 — — 179,930 In-process research and development impairment charges 2,680 — — — 2,680 Intellectual property legal development expenses 10,647 8 — — 10,655 Acquisition, transaction-related and integration expenses 328 85 641 7,934 8,988 Restructuring and other charges (614) — — 3,012 2,398 Charges related to legal matters, net 5,610 250 — — 5,860 Operating income (loss) $ 189,356 $ 56,535 $ (7,658) $ (147,078) $ 91,155 (1) Operating results for the sale of Amneal products by AvKARE were included in Generics effective with the closing of the Rondo Acquisitions on January 31, 2020. (2) Net revenue from external customers is attributed to countries based on the location of the product shipment. For the years ended December 31, 2022, 2021, and 2020, net revenue from external customers attributed to foreign countries was immaterial. Long-Lived Assets Long-lived assets, which are comprised of property, plant and equipment, net and operating and financing lease right-of-use assets, are attributed based on physical location. Long-lived assets by country were as follows (in thousands): December 31, 2022 December 31, 2021 United States $ 354,504 $ 388,818 India 180,325 189,885 Ireland 54,531 60,300 $ 589,360 $ 639,003

(Insurance Recoveries) Charges

(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net	12 Months Ended
	Dec. 31, 2022
Unusual or Infrequent Items, or Both [Abstract]
(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net	(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net On September 1, 2021, Tropical Storm Ida brought extreme rainfall and flash flooding to New Jersey that caused damage to two of the Company’s facilities. The Company concluded that all inventory on-hand at the time of the flooding was damaged and unsellable and that a majority of the equipment was damaged beyond repair. In addition, the Company incurred significant costs to repair both facilities. Accordingly, the Company recorded $10.4 million of charges for property losses and associated expenses for the year ended December 31, 2021. The Company has insurance policies for property damage, inventory losses and business interruption. Insurance recoveries are recorded in the periods when it is probable they will be realized. During the year ended December 31, 2022 and 2021, insurance recoveries of $1.9 million and $5.0 million, respectively, associated with property damage and equipment losses were received and recorded as a reduction of property losses and associated expenses. (Insurance recoveries) charges for property losses and associated expenses was comprised of the following (in thousands): Years Ended December 31, 2022 2021 Impairment of equipment $ — $ 4,202 Impairment of inventory — 950 Repairs and maintenance expenses — 3,716 Salaries and benefits — 1,500 Total property losses and associated expenses — 10,368 Less: Insurance recoveries received (1,911) (5,000) (Insurance recoveries) charges for property losses and associated expenses, net $ (1,911) $ 5,368

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event Under the terms of the O pana ER® antitrust litigation settlement agreements (refer to Note 21. Commitments and Contingencies ), the Company paid $83.9 million which was primarily funded by $80.0 million of borrowings under the New Revolving Credit Facility in January 2023.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Accounting Principles	Accounting Principles The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated.
Principles of Consolidation	Principles of ConsolidationAlthough the Company has a minority economic interest in Amneal, it is Amneal’s sole managing member, having the sole voting power to make all of Amneal’s business decisions and controls its management. Therefore, the Company consolidates the financial statements of Amneal and its subsidiaries. The Company records non-controlling interests for the portion of Amneal’s economic interests that it does not hold.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition When assessing its revenue recognition, the Company performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the performance obligation. The Company recognizes revenue when it transfers control of its products to customers, in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those products. From time to time, the Company may enter into arrangements where it licenses certain products to a third-party distributor. Licensing arrangement performance obligations generally include intellectual property (“IP”) rights and research and development (“R&D”) and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company’s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company’s IP. Revenue from sales-based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied.
Stock-Based Compensation	Stock-Based Compensation The Company’s stock-based compensation consists of stock options, restricted stock units (“RSUs”) and market performance-based restricted stock units (“MPRSUs”) awarded to employees and non-employee directors. Stock options are measured at their fair value on the grant date or date of modification, as applicable. RSUs, including MPRSUs, are measured at the stock price on the grant date or date of modification, as applicable. The Company recognizes compensation expense on a straight-line basis over the requisite service and/or performance period, as applicable. Forfeitures of awards are accounted for as a reduction in stock-based compensation expense in the period such awards are forfeited. The Company's policy is to issue new shares upon option exercises and the vesting of RSUs and MPRSUs.
Contingent consideration	Contingent considerationBusiness acquisitions may include future payments that are contingent upon the occurrence of certain pharmaceutical regulatory milestones or net sales of pharmaceutical products. For acquisitions that are accounted for as a business combination, the obligations for such contingent consideration payments are recorded at fair value on the acquisition date. For contingent milestone payments, the Company uses a probability-weighted income approach utilizing an appropriate discount rate. For contingent tiered royalties on net sales, the Company uses a Monte Carlo simulation model. Contingent consideration liabilities are revalued to fair value at the end of each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in fair value of contingent consideration in the consolidated statements of operations.
Foreign Currencies	Foreign CurrenciesThe Company has operations in the U.S., India, Ireland, and other foreign jurisdictions.  Generally, the Company’s foreign operating subsidiaries’ functional currency is the local currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Translation adjustments are included in accumulated other comprehensive income (loss) and non-controlling interests in the consolidated balance sheets and are included in comprehensive (loss) income. Transaction gains and losses are included in net (loss) income in the Company’s consolidated statements of operations as a component of foreign exchange (loss) gain, net. Such foreign currency transaction gains and losses include fluctuations related to long term intercompany loans that are payable in the foreseeable future. Translation gains and losses on intercompany balances of a long-term investment nature are included in foreign currency translation adjustments in accumulated other comprehensive income (loss) and non-controlling interests, and comprehensive (loss) income.
Business Combinations	Business Combinations Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, the acquiring entity in a business combination records the assets acquired and liabilities assumed at the date of acquisition at their fair values. Any excess of the purchase price over the fair value of net assets and other identifiable intangible assets acquired is recorded as goodwill. Acquisition-related costs, primarily professional fees, are expensed as incurred.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash on deposit and highly liquid investments with original maturities of three months or less. A portion of the Company’s cash flows are derived outside the U.S. As a result, the Company is subject to market risk associated with changes in foreign exchange rates. The Company maintains cash balances at both U.S.-based and international-based commercial banks. At various times during the year, cash balances in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation.
Restricted Cash	Restricted Cash At December 31, 2022 and 2021, respectively, the Company had restricted cash balances of $9.3 million and $8.9 million, respectively, in its bank accounts primarily related to the purchase of certain land and equipment in India.
Accounts Receivable and Allowance for Credit Losses	Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary. The Company does not require collateral to secure amounts owed to it by its customers. Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects the best estimate of expected credit losses of the accounts receivable portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. The Company determines its allowance methodology by pooling receivable balances at the customer level. The Company consider various factors, including its previous loss history, individual credit risk associated to each customer, and the current and future condition of the general economy. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent that any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of such customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, account balances are charged off against the allowance when management believes it is probable the receivable will not be recovered. The Company does not have any off-balance-sheet credit exposure related to customers.
Chargebacks Received From Manufacturers	Chargebacks Received from ManufacturersWhen a sale occurs on a contracted item, the difference between the cost the Company pays to the manufacturer of that item and the contract price that the end customer has with the manufacturer is rebated to the Company by the manufacturer as a chargeback. Chargebacks are recorded as a reduction to cost of sales and either a reduction in the amount due to the manufacturer (if there is a right of offset) or as a receivable from the manufacturer.
Inventories	Inventories Inventories consist of finished goods held for sale, raw materials, and work in process. Inventories are stated at net realizable value, with cost determined using the first-in, first-out method. Adjustments for excess and obsolete inventories are established based upon historical experience and management’s assessment of current product demand. These assessments include inventory obsolescence based on its expiration date, damaged or rejected product, and slow-moving products.
Property, Plant and Equipment	Upon retirement or disposal, the cost of the asset disposed and the accumulated depreciation are removed from the accounts, and any gain or loss is reflected as part of operating income (loss) in the period of disposal. Expenditures that significantly increase value or extend useful lives of property, plant, and equipment are capitalized, whereas those for normal maintenance and repairs are expensed. The Company capitalizes interest on borrowings during the construction period of major capital projects as part of the related asset and amortizes the capitalized interest into earnings over the related asset’s remaining useful life.
Leases	Leases All significant lease arrangements are recognized as right-of-use (“ROU”) assets and lease liabilities at lease commencement. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of the future lease payments using the Company's incremental borrowing rate. Operating lease expense is recognized on a straight-line basis over the lease term. At each balance sheet date, operating and financing lease liabilities continue to represent the present value of the future payments. Financing lease ROU assets are expensed using the straight-line method, unless another basis is more representative of the pattern of economic benefit, to lease expense. Interest on financing lease liabilities is recognized in interest expense. Leases with an initial term of 12 months or less (short-term leases) are not recognized in the balance sheet and the related lease payments are recognized as incurred over the lease term. The Company separates lease and non-lease components. A portion of the Company's real estate leases are subject to periodic changes in the Consumer Price Index ("CPI"). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.
In-Process Research and Development	In-Process Research and Development The fair value of in-process research and development (“IPR&D”) acquired in a business combination is determined based on the present value of each research project’s projected cash flows using an income approach. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and the life of each research project’s underlying marketability. In determining the fair value of each research project, expected cash flows are adjusted for certain risks of completion, including technical and regulatory risk. The value attributable to IPR&D projects at the time of acquisition is capitalized as an indefinite-lived intangible asset and tested for impairment until the project is completed or abandoned. Upon completion of the project, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized over the estimated useful life of the asset based on the pattern in which the economic benefits are expected to be consumed or otherwise used up or, if that pattern is not readily determinable, on a straight-line basis. If the project is abandoned, the indefinite-lived intangible asset is charged to expense. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company's outlook and market performance of the Company's industry and recent and forecasted financial performance.
Goodwill and Amortization of Intangible Assets with Finite Lives	Goodwill Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. The Company reviews goodwill for possible impairment annually during the fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable. In order to test goodwill for impairment, an entity is permitted to first assess qualitative factors to determine whether a quantitative assessment of goodwill is necessary. The qualitative factors considered by the Company may include, but are not limited to, general economic conditions, the Company’s outlook, market performance of the Company’s industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. If a quantitative assessment is required, the Company determines the fair value of its reporting unit using a combination of the income and market approaches. If the net book value of the reporting unit exceeds its fair value, the Company recognizes a goodwill impairment charge for the reporting unit equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value. See Note 13. Goodwill and Other Intangible Assets , for further discussion of the Company's quantitative assessment of goodwill. Assumptions and estimates used in the evaluation of impairment may affect the carrying value of long-lived assets, which could result in impairment charges in future periods. Such assumptions include projections of future cash flows and the current fair value of the asset. Amortization of Intangible Assets with Finite Lives Intangible assets, other than indefinite-lived intangible assets, are amortized over the estimated useful life of the asset based on the pattern in which the economic benefits are expected to be consumed or otherwise used up or, if that pattern is not readily determinable, on a straight-line basis. The useful life is the period over which the assets are expected to contribute directly or indirectly to future cash flows. Intangible assets are not written-off in the period of acquisition unless they become impaired during that period.
Impairment of Long-Lived Assets (Including Intangible Assets with Finite Lives)	Impairment of Long-Lived Assets (Including Intangible Assets with Finite Lives)The Company reviews its long-lived assets, including intangible assets with finite lives, for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company evaluates assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value which is generally an expected present value cash flow technique. Management’s policy in determining whether an impairment indicator exists comprises measurable operating performance criteria as well as other qualitative measures.
Financial Instruments	Financial Instruments The Company minimizes its risks from interest fluctuations through its normal operating and financing activities and, when deemed appropriate through the use of derivative financial instruments. Derivative financial instruments are used to manage risk and are not used for trading or other speculative purposes. The Company does not use leveraged derivative financial instruments. Derivative financial instruments that qualify for hedge accounting must be designated and effective as a hedge of the identified risk exposure at the inception of the contract. Accordingly, changes in fair value of the derivative contract must be highly correlated with changes in fair value of the underlying hedged item at inception of the hedge and over the life of the hedge contract. All derivatives are recorded on the balance sheet as assets or liabilities and measured at fair value. For derivatives designated as cash flow hedges, the effective portion of the changes in fair value of the derivatives are recorded in accumulated other comprehensive loss, net of income taxes and subsequently amortized as an adjustment to interest expense over the period during which the hedged forecasted transaction affects earnings, which is when the Company recognizes interest expense on the hedged cash flows. Cash flows of such derivative financial instruments are classified consistent with the underlying hedged item. Highly effective hedging relationships that use interest rate swaps as the hedging instrument and that meet criteria under ASC 815, Derivatives and Hedging , may qualify for the “short-cut method” of assessing effectiveness. The short-cut method allows the Company to make the assumption of no ineffectiveness, which means that the change in fair value of the hedged item can be assumed to be equal to the change in fair value of the derivative. Unless critical terms change, no further evaluation of effectiveness is performed for these hedging relationships unless a critical term is changed. For a hedging relationship that does not qualify for the short-cut method, the Company measures its effectiveness using the “hypothetical derivative method”, in which the change in fair value of the hedged item must be measured separately from the change in fair value of the derivative. At inception and quarterly thereafter, the Company formally assesses whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. The Company compares the change in the fair value of the actual interest rate derivative to the change in the fair value of a hypothetical interest rate derivative with critical terms that match the hedged interest rate payments. After the initial quantitative assessment, this analysis is performed on a qualitative basis and, if it is determined that the hedging relationship was and continues to be highly effective, no further analysis is required. All components of each derivative financial instrument's gain or loss are included in the assessment of hedge effectiveness. If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive income (loss) net of income taxes, unless it is probable that the forecasted transaction will not occur. If it is probable that the forecasted transaction will not occur by the originally specified time period, the Company discontinues hedge accounting, and any deferred gains or losses reported in accumulated other comprehensive income (loss) are classified into earnings immediately. The Company is subject to credit risk as a result of nonperformance by counterparties to the derivative agreements. Upon inception and quarterly thereafter, the Company makes judgments on each counterparty’s creditworthiness for nonperformance by counterparties.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes , which requires the recognition of tax benefits or expenses on temporary differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company’s consolidated balance sheets as deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. ASC 740-10 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected to be taken in a tax return that affect amounts reported in the financial statements. The Company has reviewed and will continue to review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company’s assessment of the conclusions reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain tax positions, if applicable, as a component of income tax expense.
Comprehensive (Loss) Income	Comprehensive (Loss) Income Comprehensive (loss) income includes net (loss) income and all changes in stockholders’ equity (except those arising from transactions with stockholders) including foreign currency translation adjustments resulting from the consolidation of foreign subsidiaries’ financial statements and unrealized gains (losses) on cash flows hedges, net of income taxes.
Research and Development and Intellectual Property Legal Development Expenses	Research and Development R&D activities are expensed as incurred. R&D expenses primarily consist of direct and allocated expenses incurred with the process of formulation, clinical research, and validation associated with new product development. Upfront and milestone payments made to third parties in connection with R&D collaborations are expensed as incurred up to the point of regulatory approval or when there is no alternative future use. Intellectual Property Legal Development Expenses The Company expenses external intellectual property legal development expenses as incurred. These costs relate to legal challenges of innovator’s patents for invalidity or non-infringement, which are customary in the generic pharmaceutical industry, and are incurred predominately during development of a product and prior to regulatory approval. Associated costs include, but are not limited to, formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend the intellectual property supporting the Company's regulatory filings.
Advertising Costs	Advertising CostsAdvertising costs are expensed as incurred.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832) , Disclosures by Business Entities About Government Assistance (“ASU 2021-10”), which requires entities to provide disclosures on material government assistance transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. ASU 2021-10 is effective for the Company’s annual disclosures as of and for the year ended December 31, 2022, with early adoption permissible. The Company elected to adopt this guidance during the second quarter of 2022 in connection with the recognition of cash incentives related to the India Production Linked Incentive Scheme for the Pharmaceutical Sector (“PLI Scheme”). Refer to Note 6. Government Grants , for additional information. Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. These amendments were effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848) , to expand and clarify the scope of Topic 848 to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU 2020-04. In December 2022, the FASB issued ASU 2022-06, Reference Rate reform (Topic 848): Deferral of the Sunset Date of Topic 848 , which deferred the sunset date of Topic 848, Reference Rate Reform to December 31, 2024. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”) , which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers
Reclassification	Reclassification The prior period balance related to liabilities for legal proceedings of $58.0 million, formerly included in accounts payable and accrued expenses as of December 31, 2021, has been reclassified to the balance sheet caption current portion of liabilities for legal matters to conform to the current period presentation in the consolidated balance sheets.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Property, Plant, and Equipment Estimated Useful Lives	Depreciation expense is computed primarily using the straight-line method over the estimated useful lives of the assets, which are as follows: Asset Classification Estimated Useful Life Buildings 30 years Computer equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of asset's useful life or remaining life of lease Machinery and equipment 5 - 10 years Vehicles 5 years Property, plant, and equipment, net was comprised of the following (in thousands): December 31, December 31, Land $ 10,706 $ 11,540 Buildings 225,630 230,994 Leasehold improvements 124,668 123,508 Machinery and equipment 411,572 414,098 Furniture and fixtures 13,823 12,745 Vehicles 1,699 1,485 Computer equipment 58,344 56,087 Construction-in-progress 69,344 58,263 Total property, plant, and equipment 915,786 908,720 Less: Accumulated depreciation (445,971) (394,562) Property, plant, and equipment, net $ 469,815 $ 514,158 Depreciation recognized by the Company was as follows (in thousands): Years Ended December 31, 2022 2021 2020 Depreciation $ 68,112 $ 60,705 $ 60,420

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2022
Business Acquisition [Line Items]
Schedule of Asset Acquisition	The Saol Acquisition was accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer. The purchase price was calculated as follows (in thousands): Cash $ 84,714 Contingent consideration (royalties) (1) 8,796 Fair value of consideration transferred $ 93,510 (1) The estimated fair value of contingent consideration on the acquisition date wa s $8.8 million and was based on significant Level 3 inputs that were not observable in the market. Key assumptions included the discount rate, projected year of payments and expected net product sales. Refer to Note 19. Fair Value Measurements , for additional information on the methodology and determination of this liability. The following is a summary of the purchase price allocation for the Saol Acquisition (in thousands): Final F air Values as of February 9, 2022 Inventory $ 2,162 Prepaid expenses and other current assets 98 Goodwill 7,553 Intangible assets 83,815 Total assets acquired 93,628 Accounts payable and accrued expenses 118 Fair value of consideration transferred $ 93,510
Schedule of Business Acquisition Pro Forma Data	The unaudited pro forma combined results of operations for the years ended December 31, 2021 and 2020 (assuming the closing of the Rondo Acquisitions occurred on January 1, 2019 and the closing of the KSP Acquisition occurred on January 1, 2020) are as follows (in thousands): Year Ended December 31, 2021 2020 Net revenue $ 2,093,861 $ 2,023,609 Net income $ 22,523 $ 54,083 Net income attributable to Amneal Pharmaceuticals, Inc. $ 11,802 $ 80,643
Saol Baclofen Franchise Acquisition
Business Acquisition [Line Items]
Schedule of Acquired Marketed Product Rights Intangible Assets	The acquired intangible assets are being amortized over their estimated useful lives as follows (in thousands): Final Fair Value Weighted-Average Marketed product rights $ 83,815 11.5
Puniska Healthcare Pvt Ltd
Business Acquisition [Line Items]
Schedule of Purchase Price	The Puniska Acquisition, excluding the land acquired in December 2021, was accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer. The purchase price was calculated as follows (in thousands): Cash (1) $ 72,880 Payable to sellers (2) 14,162 Fair value of consideration transferred $ 87,042 (1) Cash includes the payment made upon execution of the agreement.
Schedule of Purchase Price Allocation	The following is a summary of the purchase price allocation for the Puniska Acquisition (in thousands): Final Fair Values as of Cash $ 165 Trade accounts receivable, net 232 Inventories 1,092 Prepaid expenses and other current assets 4,473 Property, plant and equipment 53,423 Goodwill 30,091 Operating lease-right-of-use assets 234 Other assets 1,303 Total assets acquired 91,013 Accounts payable and accrued expenses 1,732 Operating lease liabilities 234 Other long-term liabilities 263 Total liabilities assumed 2,229 Redeemable non-controlling interests 1,742 Fair value of consideration transferred $ 87,042
Kashiv Specialty Pharmaceuticals, LLC
Business Acquisition [Line Items]
Schedule of Acquired Marketed Product Rights Intangible Assets	The acquired marketed product rights intangible assets are being amortized over their estimated useful lives as follows (in thousands): Fair Value Weighted-Average Marketed product rights $ 29,400 5.9
Schedule of Purchase Price	The purchase price was calculated as follows (in thousands): Cash, including working capital payments $ 74,440 Deferred consideration (1) 30,099 Contingent consideration (regulatory milestones) (2) 500 Contingent consideration (royalties) (2) 5,200 Settlement of Amneal trade accounts payable due to KSP (3) (7,117) Fair value of consideration transferred $ 103,122 (1) The deferred consideration is stated at the fair value estimate of $30.1 million, which is the $30.5 million contractually stated amount less a $0.4 million discount. The deferred consideration consists of $30.0 million which was paid on January 11, 2022 and $0.5 million, which was paid during three months ended September 30, 2022. As the deferred consideration is non-interest bearing, the Company, using guideline companies and market borrowings with comparable risk profiles, discounted the deferred consideration at 1.7% over the period from April 2, 2021 to the maturity dates, for a fair value of $30.1 million on the date of acquisition. This discount was amortized to interest expense over the life of the deferred consideration utilizing the effective interest rate method. (2) Kashiv is eligible to receive up to an additional $8.0 million in contingent payments upon the achievement of certain regulatory milestones and potential royalty payments from high single-digits to mid double-digits, depending on the amount of aggregate annual net sales for certain future pharmaceutical products. The estimated fair value of contingent consideration on the acquisition date was $5.7 million and was based on significant Level 3 inputs that were not observable in the market. Key assumptions included the discount rate, probability of achievement of milestones, projected year of payments and expected net product sales. Refer to Note 19. Fair Value Measurements , for additional information on the methodology and determination of this liability. (3) Represents trade accounts payable due to KSP that were effectively settled upon closing of the KSP Acquisition.
Schedule of Purchase Price Allocation	The following is a summary of the purchase price allocation for the KSP Acquisition (in thousands): Final Fair Values as of Cash $ 112 Restricted cash 500 Prepaid expenses and other current assets 381 Property, plant and equipment 5,375 Goodwill 43,530 Intangible assets 56,400 Operating lease right-of-use assets 9,367 Total assets acquired 115,665 Accounts payable and accrued expenses 1,239 Operating lease liability 9,177 Related party payable 127 Total liabilities assumed 10,543 Non-controlling interests 2,000 Fair value of consideration transferred $ 103,122

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The following table summarizes the percentages of net revenues from each of the Company's customers that individually accounted for 10% or more of its net revenues: For the year ended December 31, 2022 2021 2020 Customer A 21 % 21 % 23 % Customer B 18 % 20 % 17 % Customer C 22 % 24 % 23 % Customer D 10 % 10 % 11 %
Schedule of Disaggregated Revenue	The Company's significant therapeutic classes for each of its reportable segments, as determined based on net revenue for each of the years ended December 31, 2022, 2021 and 2020 are set forth below (in thousands): Year ended December 31, 2022 2021 2020 Generics Anti-Infective $ 23,193 $ 30,501 $ 40,381 Hormonal/Allergy 444,909 427,077 355,581 Antiviral (1) 40,601 4,832 25,724 Central Nervous System 393,281 381,110 422,405 Cardiovascular System 118,183 141,866 114,226 Gastroenterology 70,796 76,497 78,165 Oncology 64,285 103,327 61,113 Metabolic Disease/Endocrine 41,128 38,462 45,004 Respiratory 41,085 35,965 37,389 Dermatology 66,553 55,474 58,168 Other therapeutic classes 118,573 69,928 102,721 License agreement (2) 8,018 — — International and other 1,468 1,299 2,333 Total Generics net revenue 1,432,073 1,366,338 1,343,210 Specialty Hormonal/Allergy 91,465 68,397 54,631 Central Nervous System 255,656 277,196 285,737 Other therapeutic classes 27,000 32,726 15,199 Total Specialty net revenue 374,121 378,319 355,567 AvKARE (3) Distribution 260,560 192,921 161,673 Government Label 98,234 118,379 104,054 Institutional 27,742 25,176 18,546 Other 19,574 12,536 9,473 Total AvKARE net revenue 406,110 349,012 293,746 Total net revenue $ 2,212,304 $ 2,093,669 $ 1,992,523 (1) Antiviral net revenue for the year ended December 31, 2021 decreased from the prior year primarily due to a decline in Oseltamivir (generic Tamiflu®) sales from lower demand and increased returns activity above historical levels as a result of decreased influenza activity during the onset of the COVID-19 pandemic. (2) Refer to Note 5. Alliance and Collaboration for information on revenue recognized under a license agreement. (3) The AvKARE segment consists of the businesses acquired in the Rondo Acquisitions on January 31, 2020. Net revenue for the year ended December 31, 2020 represents eleven months of activity.
Schedule of Major Categories of Sales-Related Deductions	A rollforward of the major categories of sales-related deductions for the years ended December 31, 2022, 2021 and 2020 is as follows (in thousands): Contract Charge- Cash Accrued Accrued Balance at December 31, 2019 $ 829,807 $ 34,308 $ 150,361 $ 114,960 Impact of the Rondo Acquisitions 12,444 944 11,606 10 Provision related to sales recorded in the period 3,930,682 118,525 110,556 133,748 Credits/payments issued during the period (4,144,129) (131,087) (97,539) (117,630) Balance at December 31, 2020 628,804 22,690 174,984 131,088 Provision related to sales recorded in the period 3,164,331 107,810 105,127 137,452 Credits/payments issued during the period (3,289,233) (106,858) (118,133) (182,803) Balance at December 31, 2021 503,902 23,642 161,978 85,737 Provision related to sales recorded in the period 3,416,149 112,609 84,306 129,203 Credits/payments issued during the period (3,346,459) (108,797) (101,224) (128,910) Balance at December 31, 2022 $ 573,592 $ 27,454 $ 145,060 $ 86,030 The following table summarizes the changes in the Company’s valuation allowance on deferred tax assets (in thousands): Years Ended December 31, 2022 2021 2020 Balance at the beginning of the period $ 416,588 $ 422,812 $ 470,193 Increase (decrease) due to net operating losses and temporary differences 25,589 (10,828) (54,971) Increase due to stock-based compensation 224 5,513 — Decrease recorded against goodwill (1,590) — — Increase (decrease) recorded against additional paid-in capital 2,720 2,842 (1,631) (Decrease) increase recorded against other comprehensive income (8,636) (3,751) 9,221 Balance at the end of the period $ 434,895 $ 416,588 $ 422,812

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of (Loss) Income Before Income Taxes	The components of the Company's (loss) income before income taxes were as follows (in thousands): Years Ended December 31, 2022 2021 2020 United States $ (260,616) $ (10,540) $ (99,966) International 12,489 41,906 64,186 Total (loss) income before income taxes $ (248,127) $ 31,366 $ (35,780)
Schedule of Provision for (Benefit From) Income Tax Expense	The provision for (benefit from) income taxes was comprised of the following (in thousands): Years Ended December 31, 2022 2021 2020 Current: Domestic $ (1,073) $ 1,311 $ (113,754) Foreign 7,735 9,885 9,396 Total current income tax $ 6,662 $ 11,196 $ (104,358)
Schedule of Effective Income Tax Rate	The Company’s effective tax rates were as follows: Years Ended December 31, 2022 2021 2020 Federal income tax at the statutory rate 21.0 % 21.0 % 21.0 % State income tax, net of federal benefit (0.8) 4.2 (2.0) Income not subject to tax (10.7) 6.4 (29.8) Foreign rate differential (3.4) 17.3 (7.1) Permanent book/tax differences (0.3) 4.8 — CARES Act — — 139.9 Valuation allowance (10.3) (13.5) 163.2 Other 1.8 (4.5) 6.5 Effective income tax rate (2.7) % 35.7 % 291.7 %
Schedule of Major Categories of Sales-Related Deductions	A rollforward of the major categories of sales-related deductions for the years ended December 31, 2022, 2021 and 2020 is as follows (in thousands): Contract Charge- Cash Accrued Accrued Balance at December 31, 2019 $ 829,807 $ 34,308 $ 150,361 $ 114,960 Impact of the Rondo Acquisitions 12,444 944 11,606 10 Provision related to sales recorded in the period 3,930,682 118,525 110,556 133,748 Credits/payments issued during the period (4,144,129) (131,087) (97,539) (117,630) Balance at December 31, 2020 628,804 22,690 174,984 131,088 Provision related to sales recorded in the period 3,164,331 107,810 105,127 137,452 Credits/payments issued during the period (3,289,233) (106,858) (118,133) (182,803) Balance at December 31, 2021 503,902 23,642 161,978 85,737 Provision related to sales recorded in the period 3,416,149 112,609 84,306 129,203 Credits/payments issued during the period (3,346,459) (108,797) (101,224) (128,910) Balance at December 31, 2022 $ 573,592 $ 27,454 $ 145,060 $ 86,030 The following table summarizes the changes in the Company’s valuation allowance on deferred tax assets (in thousands): Years Ended December 31, 2022 2021 2020 Balance at the beginning of the period $ 416,588 $ 422,812 $ 470,193 Increase (decrease) due to net operating losses and temporary differences 25,589 (10,828) (54,971) Increase due to stock-based compensation 224 5,513 — Decrease recorded against goodwill (1,590) — — Increase (decrease) recorded against additional paid-in capital 2,720 2,842 (1,631) (Decrease) increase recorded against other comprehensive income (8,636) (3,751) 9,221 Balance at the end of the period $ 434,895 $ 416,588 $ 422,812
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to deferred taxes were as follows (in thousands): December 31, December 31, Deferred tax assets: Partnership interest in Amneal $ 203,336 $ 200,872 Projected imputed interest on TRA 25,255 25,615 Net operating loss carryforward 82,338 73,861 IRC Section 163(j) interest carryforward 54,996 46,407 Capitalized costs 2,505 1,300 Accrued expenses 431 498 Stock-based compensation 5,737 5,513 Intangible assets 23,967 28,380 Tax credits and other 36,330 34,142 Total deferred tax assets 434,895 416,588 Valuation allowance (434,895) (416,588) Net deferred tax assets $ — $ —
Schedule of Changes in Unrecognized Tax Benefits	A rollforward of unrecognized tax benefits for the years ended December 31, 2022, 2021 and 2020 is as follows (in thousands): Years Ended December 31, 2022 2021 2020 Unrecognized tax benefits at the beginning of the period $ 5,489 $ 5,368 $ 6,176 Gross change for current period positions 110 131 125 Gross change for prior period positions (1,983) (10) 443 Decrease due to settlements and payments — — (1,376) Unrecognized tax benefits at the end of the period $ 3,616 $ 5,489 $ 5,368

(Loss) Earnings per Share (Tabl

(Loss) Earnings per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of (Loss) Earnings per Share, Basic and Diluted	The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted (loss) earnings per share of Class A common stock (in thousands, except per share amounts): Years Ended December 31, 2022 2021 2020 Numerator: Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (129,986) $ 10,624 $ 91,059 Denominator: Weighted-average shares outstanding - basic 150,944 148,922 147,443 Effect of dilutive securities Stock options — 767 348 Restricted stock units — 2,132 1,122 Weighted-average shares outstanding - diluted 150,944 151,821 148,913 Net (loss) earnings per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: Basic $ (0.86) $ 0.07 $ 0.62 Diluted $ (0.86) $ 0.07 $ 0.61
Schedule of Antidilutive Securities Excluded from Computation of (Loss) Earnings per Share	The following table presents potentially dilutive securities excluded from the computations of diluted (loss) earnings per share of Class A common stock (in thousands). Years Ended December 31, 2022 2021 2020 Stock options 2,648 (1) 347 (3) 671 (3) Restricted stock units 10,755 (1) — — Performance stock units 7,174 (1) 5,055 (4) 2,973 (4) Shares of Class B common stock 152,117 (2) 152,117 (2) 152,117 (2) (1) Excluded from the computation of diluted loss per share of Class A common stock for the years ended December 31, 2022 because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company for the year ended December 31, 2022. (2) Shares of Class B common stock are considered potentially dilutive shares of Class A common stock. Shares of Class B common stock have been excluded from the computations of diluted (loss) earnings per share of Class A common stock for each of the years ended December 31, 2022, 2021 and 2020 because the effect of their inclusion would have been anti-dilutive under the if-converted method. (3) Excluded from the computation of diluted earnings per share of Class A common stock for the years ended December 31, 2021 and 2020 because the exercise price of the stock options exceeded the average market price of the Class A common stock during the period (out-of-the-money). (4) Excluded from the computation of diluted earnings per share of Class A common stock for the years ended December 31, 2021 and 2020 because the performance vesting conditions were not met.

Trade Accounts Receivable, Net

Trade Accounts Receivable, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Schedule of Trade Accounts Receivable, Net	Trade accounts receivable, net is comprised of the following (in thousands): December 31, December 31, Gross accounts receivable $ 1,344,959 $ 1,191,792 Allowance for credit losses (2,122) (1,665) Contract charge-backs and sales volume allowances (1) (573,592) (503,902) Cash discount allowances (27,454) (23,642) Subtotal (603,168) (529,209) Trade accounts receivable, net $ 741,791 $ 662,583 (1) Refer to Note 4. Revenue Recognition for additional information.
Schedules of Percent of Gross Trade Receivables	Trade accounts receivables from customers representing 10% or more of the Company’s total trade accounts receivable were as follows: December 31, 2022 December 31, 2021 Customer A 41 % 37 % Customer B 25 % 24 % Customer C 21 % 25 %

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Components of Inventories	Inventories are comprised of the following (in thousands): December 31, December 31, Raw materials $ 224,607 $ 214,508 Work in process 58,522 47,802 Finished goods 247,606 227,079 Total inventories $ 530,735 $ 489,389

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets are comprised of the following (in thousands): December 31, December 31, Deposits and advances $ 1,821 $ 1,174 Prepaid insurance 8,090 7,962 Prepaid regulatory fees 5,298 3,710 Escrow deposits for legal settlements (1) — 33,000 Income and other tax receivables 12,881 8,850 Prepaid taxes 16,593 16,085 Other current receivables (2) 33,133 9,770 Other prepaid assets 17,144 17,309 Chargebacks receivable (3) 8,605 12,358 Total prepaid expenses and other current assets $ 103,565 $ 110,218 (1) Escrow deposits for legal settlements included preliminary settlement escrow deposits by the Company’s insurers of $33.0 million as of December 31, 2021, associated with insured securities class action lawsuits. Refer to Note 21. Commitments and Contingencies for additional details regarding these matters. This escrow deposit was used to satisfy the securities class action Fleming v. Impax in 2022. (2) Other current receivables as of December 31, 2022 include a $21.4 million receivable for an upfront payment associated with the Orion Agreement which was collected in January 2023. Refer to Note 5. Alliance and Collaboration for additional information. (3) When a sale occurs on a contract item, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback (rebate) receivable and a reduction to cost of goods sold in the same period as the related sale.

Property, Plant, and Equipmen_2

Property, Plant, and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net Estimated Useful Lives	Depreciation expense is computed primarily using the straight-line method over the estimated useful lives of the assets, which are as follows: Asset Classification Estimated Useful Life Buildings 30 years Computer equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of asset's useful life or remaining life of lease Machinery and equipment 5 - 10 years Vehicles 5 years Property, plant, and equipment, net was comprised of the following (in thousands): December 31, December 31, Land $ 10,706 $ 11,540 Buildings 225,630 230,994 Leasehold improvements 124,668 123,508 Machinery and equipment 411,572 414,098 Furniture and fixtures 13,823 12,745 Vehicles 1,699 1,485 Computer equipment 58,344 56,087 Construction-in-progress 69,344 58,263 Total property, plant, and equipment 915,786 908,720 Less: Accumulated depreciation (445,971) (394,562) Property, plant, and equipment, net $ 469,815 $ 514,158 Depreciation recognized by the Company was as follows (in thousands): Years Ended December 31, 2022 2021 2020 Depreciation $ 68,112 $ 60,705 $ 60,420

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in goodwill were as follows (in thousands): Years Ended December 31, 2022 2021 Balance, beginning of period $ 593,017 $ 522,814 Goodwill acquired during the period 7,553 70,584 Adjustment during the period for the Puniska Acquisition 3,075 — Currency translation (4,792) (381) Balance, end of period $ 598,853 $ 593,017
Schedule of Finite-Lived Intangible Assets	Intangible assets were comprised of the following (in thousands): December 31, 2022 December 31, 2021 Weighted- Cost Accumulated Net Cost Accumulated Amortization Net Amortizing intangible assets: Product rights 7.5 $ 1,222,762 $ (573,281) $ 649,481 $ 1,122,612 $ (436,902) $ 685,710 Other intangible assets 4.1 133,800 (77,943) 55,857 133,800 (58,013) 75,787 Total 1,356,562 (651,224) 705,338 1,256,412 (494,915) 761,497 In-process research and development 390,755 — 390,755 405,425 — 405,425 Total intangible assets $ 1,747,317 $ (651,224) $ 1,096,093 $ 1,661,837 $ (494,915) $ 1,166,922
Finite-lived Intangible Assets Amortization Expense	Amortization expense related to intangible assets recognized was as follows (in thousands): Years Ended December 31, 2022 2021 2020 Amortization $ 172,063 $ 172,701 $ 174,967
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The following table presents future amortization expense for the next five years and thereafter, excluding $390.8 million of IPR&D intangible assets (in thousands). Future 2023 $ 163,473 2024 161,169 2025 122,478 2026 71,743 2027 50,180 Thereafter 136,295 Total $ 705,338

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Other Assets [Abstract]
Schedule of Other Assets	Other assets are comprised of the following (in thousands): December 31, December 31, Interest rate swap (1) $ 85,586 $ — Security deposits 3,523 3,895 Long-term prepaid expenses 3,711 5,896 Deferred revolving credit facility costs 2,206 1,603 Other long-term assets 8,191 9,220 Total $ 103,217 $ 20,614 (1) Refer to Note 19. Fair Value Measurements and Note 20. Financial Instruments

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses were comprised of the following (in thousands): December 31, December 31, 2021 (2) Accounts payable $ 165,980 $ 131,084 Accrued returns allowance (1) 145,060 161,978 Accrued compensation 54,038 62,098 Accrued Medicaid and commercial rebates (1) 86,030 85,737 Accrued royalties 19,309 20,893 Commercial chargebacks and rebates 10,226 10,226 Accrued professional fees 11,386 9,926 Taxes payable 359 2,523 Accrued other 45,811 40,880 Total accounts payable and accrued expenses $ 538,199 $ 525,345 (1) Refer to Note 4. Revenue Recognition for additional information. (2) The prior period balance related to liabilities for legal proceedings of $58.0 million (refer to Note 21. Commitments and Contingencies ), formerly included in accounts payable and accrued expenses as of December 31, 2021, has been reclassified to the balance sheet caption current portion of liabilities for legal matters to conform to the current period presentation in the consolidated balance sheets.

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The following is a summary of the Company’s term loan indebtedness (in thousands): December 31, December 31, Term Loan due May 2025 $ 2,563,876 $ 2,590,876 Rondo Term Loan due January 2025 72,000 139,250 Other — 624 Total debt 2,635,876 2,730,750 Less: debt issuance costs (13,934) (20,083) Total debt, net of debt issuance costs 2,621,942 2,710,667 Less: current portion of long-term debt (29,961) (30,614) Total long-term debt, net $ 2,591,981 $ 2,680,053

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Other Liabilities [Abstract]
Schedule of Other Long-Term Liabilities	Other long-term liabilities were comprised of the following (in thousands): December 31, 2022 December 31, 2021 Interest rate swap (1) $ — $ 11,473 Uncertain tax positions 563 3,177 Long-term portion of liabilities for legal matters 49,442 — Long-term compensation (2) 16,737 21,589 Contingent consideration 11,997 — Other long-term liabilities 8,729 2,664 Total other long-term liabilities $ 87,468 $ 38,903 (1) Refer to Note 19. Fair Value Measurements and Note 20. Financial Instruments for information about the Company’s interest rate swap. (2) Includes $7.6 million and $11.8 million of long-term deferred compensation plan liabilities (refer to Note 19. Fair Value Measurements

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Schedule of Components of Lease Costs / Supplemental Cash Flow Information	The components of total lease costs were as follows (in thousands): Years Ended December 31, 2022 2021 2020 Operating lease cost (1) $ 17,800 $ 15,057 21,664 Finance lease cost: Amortization of right-of-use assets 4,808 4,713 4,487 Interest on lease liabilities 4,508 4,601 4,773 Total finance lease cost 9,316 9,314 9,260 Total lease cost $ 27,116 $ 24,371 $ 30,924 (1) Includes variable and short-term lease costs. Supplemental cash flow information related to leases was as follows (in thousands): Years Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 4,539 $ 4,601 Operating cash flows from operating leases $ 16,217 $ 15,006 Financing cash flows from finance leases $ 3,484 $ 3,179 Non-cash activity: Right-of-use assets obtained in exchange for new operating lease liabilities $ 7,504 $ 12,006 Right-of-use assets obtained in exchange for new financing lease liabilities $ 4,606 $ 1,072
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to the Company's leases was as follows (in thousands): Operating leases December 31, 2022 December 31, 2021 Operating lease right-of-use assets $ 38,211 $ 39,899 Operating lease right-of-use assets - related party (1) 17,910 20,471 Total operating lease right-of-use assets $ 56,121 $ 60,370 Operating lease liabilities $ 32,126 $ 32,894 Operating lease liabilities - related party (1) 15,914 18,783 Current portion of operating lease liabilities 8,321 9,686 Current portion of operating lease liabilities - related party (1) 2,869 2,636 Total operating lease liabilities $ 59,230 $ 63,999 Financing leases Financing lease right of use assets $ 63,424 $ 64,475 Financing lease liabilities $ 60,769 $ 60,251 Current portion of financing lease liabilities 3,488 3,101 Total financing lease liabilities $ 64,257 $ 63,352 (1) Refer to Note 24. Related Party Transactions for information about related party leases.
Schedule of Lease Term and Discount Rate Information	The table below reflects the weighted average remaining lease term and weighted average discount rate for the Company's operating and finance leases: December 31, 2022 December 31, 2021 Weighted average remaining lease term - operating leases 5 years 5 years Weighted average remaining lease term - finance leases 19 years 21 years Weighted average discount rate - operating leases 8.5% 6.9% Weighted average discount rate - finance leases 7.2% 7.1%
Schedule of Operating Lease Maturities	Maturities of lease liabilities as of December 31, 2022 were as follow (in thousands): Operating Financing 2023 $ 15,843 $ 7,976 2024 16,558 6,913 2025 14,264 6,466 2026 10,393 5,989 2027 7,420 5,645 Thereafter 11,550 85,220 Total lease payments 76,028 118,209 Less: Imputed interest (16,798) (53,952) Total $ 59,230 $ 64,257 Maturities of lease liabilities as of December 31, 2021 were as follows (in thousands): Operating Financing 2022 $ 16,136 $ 7,492 2023 16,412 6,726 2024 15,215 5,572 2025 11,363 5,474 2026 7,400 5,474 Thereafter 9,712 89,862 Total lease payments 76,238 120,600 Less: Imputed interest (12,239) (57,248) Total $ 63,999 $ 63,352
Schedule of Finance Lease Maturities	Maturities of lease liabilities as of December 31, 2022 were as follow (in thousands): Operating Financing 2023 $ 15,843 $ 7,976 2024 16,558 6,913 2025 14,264 6,466 2026 10,393 5,989 2027 7,420 5,645 Thereafter 11,550 85,220 Total lease payments 76,028 118,209 Less: Imputed interest (16,798) (53,952) Total $ 59,230 $ 64,257 Maturities of lease liabilities as of December 31, 2021 were as follows (in thousands): Operating Financing 2022 $ 16,136 $ 7,492 2023 16,412 6,726 2024 15,215 5,572 2025 11,363 5,474 2026 7,400 5,474 Thereafter 9,712 89,862 Total lease payments 76,238 120,600 Less: Imputed interest (12,239) (57,248) Total $ 63,999 $ 63,352

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis (in thousands): Fair Value Measurement Based on December 31, 2022 Total Quoted Significant Significant Assets Interest Rate Swap (1) $ 85,586 $ — $ 85,586 $ — Liabilities Deferred compensation plan liabilities (2) $ 9,674 $ — $ 9,674 $ — Contingent consideration liability (3) $ 15,427 $ — $ — $ 15,427 December 31, 2021 Liabilities Interest Rate Swap (1) $ 11,473 $ — $ 11,473 $ — Deferred compensation plan liabilities (2) $ 13,883 $ — $ 13,883 $ — Contingent consideration liability (3) $ 5,900 $ — $ — $ 5,900 (1) The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 20. Financial Instruments for information about the Company’s interest rate swap. (2) As of December 31, 2022, deferred compensation plan liabilities of $2.1 million and $7.6 million were recorded in current and non-current liabilities, respectively. As of December 31, 2021, deferred compensation plan liabilities of $2.1 million and $11.8 million were recorded in current and non-current liabilities, respectively. These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants. (3) The fair value measurement of contingent consideration liability has been classified as a Level 3 recurring liability as its valuation requires judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair value could be higher or lower than what the Company determined. As of December 31, 2022, the contingent consideration liability associated with the Saol Acquisition included $0.1 million recorded in accounts payable and accrued expenses and $12.0 million recorded in other-longer term liabilities. As of December 31, 2022 and 2021, the contingent consideration liability associated with the KSP Acquisition was valued at approximately $3.3 million and $5.9 million , respectively, and recorded within related party payables - long term. Refer to Note 3. Acquisitions for additional information related to contingent consideration associated with the KSP Acquisition and the Saol Acquisition.
Reconciliation of Contingent Consideration Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)	The following table provides a reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): Year Ended Year Ended Balance, beginning of period $ 5,900 $ — Addition due to the Saol Acquisition 8,796 — Addition due to the KSP Acquisition — 5,700 Net change in fair value during period 731 200 Balance, end of period $ 15,427 $ 5,900
Significant Inputs Used in Fair Value Measurements	The following table summarizes the significant unobservable inputs used in the fair value measurement of our contingent consideration liabilities as of December 31, 2022 and 2021: Contingent Consideration Liability Fair Value as of December 31, 2022 (in thousands) Unobservable input Range Weighted Average (1) Regulatory Milestones (KSP Acquisition) $ 390 Discount rate 7.2 % 8.5 % 7.3 % Probability of payment 1.8 % 20.0 % 18.6 % Projected year of payment 2024 2026 2024 Royalties (KSP Acquisition) $ 2,900 Discount rate 12.5 % 12.5 % 12.5 % Probability of payment 1.8 % 20.0 % 18.6 % Projected year of payment 2024 2033 2028 Royalties (Saol Acquisition) $ 12,137 Discount rate 17.8 % 17.8 % 17.8 % Projected year of payment 2023 2033 2027 Contingent Consideration Liability Fair Value as of December 31, 2021 (in thousands) Unobservable input Range Weighted Average (1) Regulatory Milestones (KSP Acquisition) $ 500 Discount rate 2.2 % - 4.4% 2.4% Probability of payment 1.8 % - 20.0% 16.7% Projected year of payment 2023 - 2027 2023 Royalties (KSP Acquisition) $ 5,400 Discount rate 11.5 % - 11.5% 11.5% Probability of payment 1.8 % - 20.0% 18.0% Projected year of payment 2023 - 2032 2029 (1) Unobservable inputs were weighted by the relative fair value of each product candidate acquired.

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets	A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands): December 31, 2022 December 31, 2021 Derivatives Designated as Hedging Instruments Balance Sheet Fair Value Balance Sheet Fair Value Variable-to-fixed interest rate swap Other Assets $ 85,586 Other long-term liabilities $ 11,473

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Charges and Liabilities Related to Legal Matters	Charges (insurance recoveries) related to legal matters, net were comprised of the following (in thousands): Year Ended December 31, 2022 2021 2020 Opana ER® antitrust litigation $ 262,837 $ — $ — Civil prescription opioid litigation 17,993 — — Securities class action - Cambridge Retirement System v. Amneal (15,500) 25,000 — Galeas v. Amneal 1,200 — — Other 3,400 — 5,860 Total $ 269,930 $ 25,000 $ 5,860 Liabilities for legal matters were comprised of the following (in thousands): Year Ended December 31, Matter 2022 2021 Opana ER® antitrust litigation (1) $ 83,944 $ — Opana ER® antitrust litigation - accrued interest 1,423 — Civil prescription opioid litigation 17,993 — Securities class action - Fleming v. Impax (2) — 33,000 Securities class action - Cambridge Retirement System v. Amneal (3) — 25,000 Galeas v. Amneal 1,200 — Other 2,923 — Current portion of liabilities for legal matters $ 107,483 $ 58,000 Opana ER® antitrust litigation (1) $ 50,000 $ — Imputed interest (1,405) — Accrued interest 847 — Long-term portion of liabilities for legal matters (included in other long-term liabilities) $ 49,442 $ — (1) During 2022, the Company paid $131.1 million of the $265.0 million settlement to certain plaintiffs pursuant to the Opana ER® antitrust litigation settlement agreements (see below under Opana ER® Antitrust Litigation for additional information). (2) Upon final approval by the court, the securities class action Fleming v. Impax was settled for $33.0 million during 2022 using a security deposit funded by insurance in 2021 (refer to Note 11. Prepaid Expenses and Other Current Assets ). See below for additional information. (3) Upon final approval by the Court, the securities class action Cambridge Retirement System v. Amneal was settled during 2022 for $25.0 million with cash paid by the Company of $9.5 million and insurance recoveries of $15.5 million. See below for additional information.
Schedule of Antitrust Litigation Settlement Agreements	As of December 31, 2022, the remaining payments associated with the Opana ER® antitrust litigation settlement agreements are as follows: Amount Due January 2023 $ 83,944 January 2024 50,000 $ 133,944

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss by Component	Changes in Accumulated Other Comprehensive Loss by Component (in thousands): Foreign Unrealized Accumulated Balance December 31, 2020 $ (14,497) $ (26,821) $ (41,318) Other comprehensive income before reclassification (4,255) 20,972 16,717 Reallocation of ownership interests (93) (133) (226) Balance December 31, 2021 (18,845) (5,982) (24,827) Other comprehensive income before reclassification (13,394) 48,270 34,876 Reallocation of ownership interests (143) 33 (110) Balance December 31, 2022 $ (32,382) $ 42,321 $ 9,939

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	The following table summarizes all of the Company’s stock option activity for the years ended December 31, 2022, 2021, and 2020: Stock Options Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2019 6,177,126 $ 8.87 Options exercised (116,681) 2.75 Options forfeited (2,249,216) 16.09 Outstanding at December 31, 2020 3,811,229 $ 4.80 7.9 $ 5.6 Options exercised (342,350) 2.76 Options forfeited (417,379) 11.09 Outstanding at December 31, 2021 3,051,500 $ 4.17 7.0 $ 5.3 Options exercised (207,452) 2.75 Options forfeited (195,607) 2.77 Outstanding at December 31, 2022 2,648,441 $ 4.38 6.0 $ — Options exercisable at December 31, 2022 2,288,371 $ 4.64 6.0 $ —
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes all of the Company's restricted stock unit activity for the years ended December 31, 2022, 2021, and 2020: Restricted Stock Units Number of Weighted- Weighted- Aggregate Non-vested at December 31, 2019 2,637,358 $ 12.16 Granted 8,414,762 3.67 Vested (692,868) 12.33 Forfeited (1,226,700) 6.48 Non-vested at December 31, 2020 9,132,552 $ 5.09 1.7 $ 41.7 Granted 6,870,481 5.86 Vested (1,906,607) 5.97 Forfeited (912,826) 6.68 Non-vested at December 31, 2021 13,183,600 $ 5.25 1.4 $ 63.7 Granted 10,117,037 4.54 Vested (2,697,134) 5.95 Forfeited (2,674,890) 5.07 Non-vested at December 31, 2022 17,928,613 $ 4.77 1.3 $ 35.7
Schedule of Employee Service Share-based Compensation	The amount of stock-based compensation expense recognized by the Company was as follows (in thousands): Year Ended December 31, 2022 2021 2020 Cost of goods sold $ 4,811 $ 4,688 $ 4,166 Selling, general and administrative 20,746 18,718 13,343 Research and development 6,290 5,006 3,241 Total $ 31,847 $ 28,412 $ 20,750

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The following table summarizes the Company’s related party transactions (in thousands): Year ended December 31, Related Party and Nature of Transaction Caption in Balance Sheet and Statement of Operations 2022 2021 2020 A Kashiv Biosciences LLC i. Parking space lease Cost of goods sold $ 100 $ 99 $ 99 ii. License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Filgrastim Selling, general and administrative 5,000 — — ii. License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for P egfilgrastim-pbbk Intangible asset 15,000 — — ii. License and commercialization agreement - Filgrastim and Pegfilgrastim -research and development milestone Research and development — — 1,000 ii. Inventory purchases under license and commercialization agreement - Filgrastim and Pegfilgrastim Inventory and cost of goods sold 260 — — iii. Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate Research and development 1,761 1,362 1,550 iv. Transition services associated with the KSP Acquisition Selling, general and administrative — 255 — v. Development and commercialization - consulting - various products Research and development 2 628 196 vi, Development supply agreement Research and development — — — vii. Development and commercialization agreements - Levothyroxine Sodium and Posaconazole Research and development — — 2,688 viii. K127 development and commercialization agreement* Research and development — 3,000 2,000 ix. Commercial product support for EluRyng and other products* Cost of goods sold and research and development — 1,239 6,130 x. Profit sharing - various products* Cost of goods sold — 2,680 11,189 xi. Development and commercialization agreements - various products* Research and development — 150 206 Total $ 22,123 $ 9,413 $ 25,058 B LAX Hotel, LLC Financing lease Inventory and cost of goods sold $ — $ 217 $ 2,608 Interest component of financing lease Interest expense — 362 4,395 Total $ — $ 579 $ 7,003 C Kanan, LLC - operating lease Inventory and cost of goods sold $ 2,104 $ 2,103 $ 2,093 D Sutaria Family Realty, LLC - operating lease Inventory and cost of goods sold $ 1,211 $ 1,179 $ 1,142 E PharmaSophia, LLC - research and development services income Research and development $ (45) $ (329) $ (521) E PharmaSophia, LLC - license and commercialization agreement Research and development $ 1,093 $ — $ — F Fosun International Limited - license and supply agreement Net revenue $ — $ (200) $ — G Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement Inventory and cost of goods sold $ 2,742 $ 11,380 $ 11,570 H Tracy Properties LLC - operating lease Selling, general and administrative $ 565 $ 532 $ 497 I AzaTech Pharma LLC - supply agreement Inventory and cost of goods sold $ 4,963 $ 5,156 $ 4,506 J AvPROP, LLC - operating lease Selling, general and administrative $ 178 $ 165 $ 142 K Tarsadia Investments, LLC - financial consulting services Selling, general and administrative $ — $ — $ — L Avtar Investments, LLC - consulting services Selling, general and administrative $ 216 $ 361 $ 982 M TPG Operations, LLC - consulting services Selling, general and administrative $ 19 $ 249 $ — N Alkermes Plc Inventory and cost of goods sold $ 235 $ 138 $ — O R&S Solutions LLC - logistics services Selling, general and administrative $ 85 $ 183 $ 80 P Zep Inc. Net revenue $ — $ — $ (637) Q Sellers of Gemini Laboratories, LLC - acquisition agreement Non-controlling interests $ — $ — $ 3,300 R Asana Biosciences, LLC Research and development $ (5) $ (4) $ — U Members - tax receivable agreement Other expense $ 631 $ — $ — *Agreement between Amneal and Kashiv was acquired with KSP and has become a transaction among Amneal’s consolidated subsidiaries subsequent to the transaction closing on April 2, 2021. The disclosure relates to the historical agreement as a related party transaction through April 2, 2021 (refer to Note 3. Acquisitions for additional information). The following table summarizes the amounts due to or from the Company for related party transactions (in thousands): December 31, 2022 December 31, 2021 E PharmaSophia, LLC - research and development agreement $ — $ 1,081 T Sellers of AvKARE LLC and R&S - state tax indemnification 486 68 A Kashiv - various agreements 12 14 G Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement — 16 R Asana BioSciences, LLC 2 — Related party receivables - short term $ 500 $ 1,179 A Kashiv - deferred consideration associated with the KSP Acquisition $ — $ 30,500 A Kashiv - various agreements 110 314 S Sellers of Puniska - consideration for acquisition — 14,225 G Apace Packaging, LLC - packaging agreement 756 560 I AzaTech Pharma LLC - supply agreement 863 1,783 L Avtar Investments LLC - consulting services 72 37 T Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 442 442 U Members - tax receivable agreement 201 — O R&S Solutions LLC - logistics services 7 — N Alkermes Plc 28 — H Tracy Properties LLC — — Related party payables - short term $ 2,479 $ 47,861 A Kashiv - contingent consideration $ 3,290 $ 5,900 T Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 5,929 3,719 U Members - tax receivable agreement 430 — Related party payables - long term $ 9,649 $ 9,619

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, R&D expenses, and other operating expenses to the extent specifically identified by segment (in thousands): Year Ended December 31, 2022 Generics (1) Specialty AvKARE (1) Corporate Total Net revenue (2) $ 1,432,073 $ 374,121 $ 406,110 $ — $ 2,212,304 Cost of goods sold 890,245 177,107 349,133 — 1,416,485 Cost of goods sold impairment charges 5,786 5,325 — — 11,111 Gross profit 536,042 191,689 56,977 — 784,708 Selling, general and administrative 109,781 90,031 53,659 146,229 399,700 Research and development 167,509 28,179 — — 195,688 In-process research and development impairment charges 12,970 — — — 12,970 Intellectual property legal development expenses 4,251 107 — — 4,358 Acquisition, transaction-related and integration expenses 25 49 — 635 709 Restructuring and other charges 821 — — 600 1,421 Change in fair value of contingent consideration — 731 — — 731 (Insurance recoveries) charges for property losses and associated expenses, net (1,911) — — — (1,911) Charges related to legal matters, net 22,400 — — 247,530 269,930 Other operating income (3,960) — — — (3,960) Operating income (loss) $ 224,156 $ 72,592 $ 3,318 $ (394,994) $ (94,928) Year Ended December 31, 2021 Generics (1) Specialty AvKARE (1) Corporate Total Net revenue (2) $ 1,366,338 $ 378,319 $ 349,012 $ — $ 2,093,669 Cost of goods sold 825,568 193,562 282,874 — 1,302,004 Cost of goods sold impairment charges 22,692 — — — 22,692 Gross profit 518,078 184,757 66,138 — 768,973 Selling, general and administrative 64,500 84,481 57,918 158,605 365,504 Research and development 158,365 43,482 — — 201,847 In-process research and development impairment charges 710 — — — 710 Intellectual property legal development expenses 7,562 154 — — 7,716 Acquisition, transaction-related and integration expenses — 16 1,422 6,617 8,055 Restructuring and other charges 80 — — 1,777 1,857 Change in fair value of contingent consideration — 200 — — 200 (Insurance recoveries) charges for property losses and associated expenses, net 5,368 — — — 5,368 Charges related to legal matters, net — — — 25,000 25,000 Operating income (loss) $ 281,493 $ 56,424 $ 6,798 $ (191,999) $ 152,716 Year Ended December 31, 2020 Generics (1) Specialty AvKARE (1) Corporate Total Net revenue (2) $ 1,343,210 $ 355,567 $ 293,746 $ — $ 1,992,523 Cost of goods sold 894,422 192,910 242,219 — 1,329,551 Cost of goods sold impairment charges 34,579 — — — 34,579 Gross profit 414,209 162,657 51,527 — 628,393 Selling, general and administrative 56,134 75,917 58,544 136,132 326,727 Research and development 150,068 29,862 — — 179,930 In-process research and development impairment charges 2,680 — — — 2,680 Intellectual property legal development expenses 10,647 8 — — 10,655 Acquisition, transaction-related and integration expenses 328 85 641 7,934 8,988 Restructuring and other charges (614) — — 3,012 2,398 Charges related to legal matters, net 5,610 250 — — 5,860 Operating income (loss) $ 189,356 $ 56,535 $ (7,658) $ (147,078) $ 91,155 (1) Operating results for the sale of Amneal products by AvKARE were included in Generics effective with the closing of the Rondo Acquisitions on January 31, 2020. (2) Net revenue from external customers is attributed to countries based on the location of the product shipment. For the years ended December 31, 2022, 2021, and 2020, net revenue from external customers attributed to foreign countries was immaterial.
Schedule of Long-Lived Assets, by Geographical Areas	Long-lived assets, which are comprised of property, plant and equipment, net and operating and financing lease right-of-use assets, are attributed based on physical location. Long-lived assets by country were as follows (in thousands): December 31, 2022 December 31, 2021 United States $ 354,504 $ 388,818 India 180,325 189,885 Ireland 54,531 60,300 $ 589,360 $ 639,003

(Insurance Recoveries) Charge_2

(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Unusual or Infrequent Items, or Both [Abstract]
Schedule of Property Losses and Associated Expenses	(Insurance recoveries) charges for property losses and associated expenses was comprised of the following (in thousands): Years Ended December 31, 2022 2021 Impairment of equipment $ — $ 4,202 Impairment of inventory — 950 Repairs and maintenance expenses — 3,716 Salaries and benefits — 1,500 Total property losses and associated expenses — 10,368 Less: Insurance recoveries received (1,911) (5,000) (Insurance recoveries) charges for property losses and associated expenses, net $ (1,911) $ 5,368

Nature of Operations - Addition

Nature of Operations - Additional Information (Details) - Amneal Group	Dec. 31, 2022
Class of Stock [Line Items]
Ownership by parent (percent)	49.90%
Amneal Group
Class of Stock [Line Items]
Ownership percentage by noncontrolling owners (percent)	50.10%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Product Information [Line Items]
Restricted cash	$ 9,251	$ 8,949	$ 5,743
Cost of goods sold	1,416,485	1,302,004	1,329,551
Current portion of liabilities for legal matters	107,483	58,000
Selling, general and administrative
Product Information [Line Items]
Advertising costs	16,800	15,100	15,600
Shipping Costs
Product Information [Line Items]
Cost of goods sold	$ 18,700	$ 18,100	$ 17,400

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2022
Buildings
Property, Plant and Equipment [Line Items]
Estimated Useful Life	30 years
Computer equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated Useful Life	Shorter of asset's useful life or remaining life of lease
Machinery and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Machinery and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - USD ($)						1 Months Ended			2 Months Ended	9 Months Ended	11 Months Ended		12 Months Ended			21 Months Ended
	Feb. 09, 2022	Dec. 31, 2021	Nov. 02, 2021	Apr. 02, 2021	Jan. 31, 2020	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022	Jan. 11, 2021	Dec. 10, 2019
Business Acquisition [Line Items]
Goodwill		$ 593,017,000					$ 593,017,000		$ 593,017,000	$ 593,017,000	$ 598,853,000	$ 522,814,000	$ 598,853,000	$ 593,017,000	$ 522,814,000	$ 598,853,000
Net revenue													2,212,304,000	2,093,669,000	1,992,523,000
Operating (loss) income													(94,928,000)	152,716,000	91,155,000
Acquired non-controlling interest, non-public subsidiary								$ 3,300,000
Acquisition, transaction costs													700,000	8,100,000	9,000,000
Intangible assets		1,256,412,000					1,256,412,000		1,256,412,000	1,256,412,000	1,356,562,000		1,356,562,000	1,256,412,000		1,356,562,000
Amortization													172,063,000	172,701,000	174,967,000
Term Loan
Business Acquisition [Line Items]
Principal amount of debt					$ 180,000,000
Specialty
Business Acquisition [Line Items]
Goodwill		363,900,000					363,900,000		363,900,000	363,900,000	$ 366,300,000		366,300,000	363,900,000		$ 366,300,000
Net revenue													374,121,000	378,319,000	355,567,000
Marketed Product Rights
Business Acquisition [Line Items]
Intangible assets acquired	$ 83,815,000
Saol Baclofen Franchise Acquisition | Generic
Business Acquisition [Line Items]
Goodwill	5,200,000
Goodwill deductible for tax purposes	4,900,000
Saol Baclofen Franchise Acquisition | Specialty
Business Acquisition [Line Items]
Goodwill	2,400,000
Puniska Healthcare Pvt Ltd
Business Acquisition [Line Items]
Goodwill			$ 30,091,000
Definitive acquisition agreement amount			93,000,000
Consideration paid in cash on hand		$ 14,162,000	$ 72,880,000			$ 1,700,000							$ 1,700,000
Voting interest acquired (percent)			74%			26%					26%		26%			26%
Acquired non-controlling interest, non-public subsidiary							$ 4,300,000
Acquisition, transaction costs														1,000,000
Income (loss) of acquiree since date of acquisition									(1,800,000)
Total consideration, net of cash acquired									$ 87,042,000
Kashiv Specialty Pharmaceuticals, LLC
Business Acquisition [Line Items]
Goodwill				$ 43,530,000
Consideration paid in cash on hand				$ 100,100,000
Voting interest acquired (percent)				98%													98%
Acquisition, transaction costs														$ 3,100,000
Income (loss) of acquiree since date of acquisition										(21,300,000)
Total consideration, net of cash acquired				$ 104,500,000												$ 103,122,000
Working capital costs				4,400,000
Intangible assets				56,400,000
Amortization										$ 5,800,000
Kashiv Specialty Pharmaceuticals, LLC | Generic
Business Acquisition [Line Items]
Goodwill				40,800,000
Kashiv Specialty Pharmaceuticals, LLC | Specialty
Business Acquisition [Line Items]
Goodwill				2,700,000
Goodwill deductible for tax purposes				0
Kashiv Specialty Pharmaceuticals, LLC | Marketed Product Rights
Business Acquisition [Line Items]
Intangible assets acquired				29,400,000
Kashiv Specialty Pharmaceuticals, LLC | In-Process Research and Development
Business Acquisition [Line Items]
Intangible assets				$ 27,000,000
AvKARE and R&S Acquisitions
Business Acquisition [Line Items]
Net revenue												311,300,000
Operating (loss) income												4,400,000
Consideration paid in cash on hand					254,000,000
Voting interest acquired (percent)																		65.10%
Acquisition, transaction costs															$ 1,000,000
Total consideration, net of cash acquired					294,200,000
Working capital costs					2,000,000
Amortization												$ 31,900,000
AvKARE and R&S Acquisitions | Debt
Business Acquisition [Line Items]
Consideration paid in cash on hand					178,000,000
AvKARE and R&S Acquisitions | Cash on Hand
Business Acquisition [Line Items]
Consideration paid in cash on hand					76,000,000
AvKARE and R&S Acquisitions | Short Term Promissory Notes
Business Acquisition [Line Items]
Liabilities incurred					1,000,000
AvKARE and R&S Acquisitions | Long Term Promissory Notes
Business Acquisition [Line Items]
Liabilities incurred					44,200,000
Liabilities incurred, fair value					$ 35,000,000
Saol Baclofen Franchise Acquisition
Business Acquisition [Line Items]
Payment for asset acquisition	84,714,000
Asset acquisition, inventory acquired	$ 1,100,000
Asset acquisition, transaction cost													$ 100,000
Net revenue											$ 19,800,000
Operating (loss) income											$ (7,100,000)

Acquisitions - Payments to Acqu

Acquisitions - Payments to Acquire Business (Details) - USD ($) $ in Thousands			2 Months Ended	12 Months Ended		21 Months Ended
	Feb. 09, 2022	Apr. 02, 2021	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Sep. 30, 2022	Jan. 11, 2022	Dec. 31, 2020
Business Acquisition [Line Items]
Deferred consideration					$ 30,500
Puniska Healthcare Pvt Ltd
Business Acquisition [Line Items]
Fair value of consideration transferred			$ 87,042
Kashiv Specialty Pharmaceuticals, LLC
Business Acquisition [Line Items]
Fair value of consideration transferred		$ 104,500				$ 103,122
Cash, including working capital payments						74,440
Deferred consideration		30,100		$ 30,500		30,099
Contingent consideration (regulatory milestones)						500
Contingent consideration (royalties)						5,200
Settlement of Amneal trade accounts payable due to KSP						(7,117)
Deferred consideration		30,500					$ 500	$ 30,000
Deferred consideration discount		$ 400
Deferred consideration, discount rate (percent)		1.70%
Contingent consideration, maximum liability		$ 8,000
Contingent consideration		$ 5,700	$ 5,900	$ 15,427	$ 5,900	$ 15,427			$ 0
Saol Baclofen Franchise Acquisition
Business Acquisition [Line Items]
Cash	$ 84,714
Contingent consideration (royalties)	8,796
Fair value of consideration transferred	$ 93,510

Acquisitions - Purchase Price A

Acquisitions - Purchase Price Allocation for Acquisitions (Details) - USD ($) $ in Thousands	Feb. 09, 2022	Dec. 31, 2022	Dec. 31, 2021	Nov. 02, 2021	Apr. 02, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 598,853	$ 593,017			$ 522,814
Total assets acquired				$ 91,013
Total liabilities assumed				2,229
Puniska Healthcare Pvt Ltd
Business Acquisition [Line Items]
Cash				165
Trade accounts receivable, net				232
Inventories				1,092
Prepaid expenses and other current assets				4,473
Property, plant and equipment				53,423
Goodwill				30,091
Operating lease-right-of-use assets				234
Other assets				1,303
Accounts payable and accrued expenses				1,732
Operating lease liabilities				234
Other long-term liabilities				263
Redeemable non-controlling interests				1,742
Fair value of consideration transferred				$ 87,042
Kashiv Specialty Pharmaceuticals, LLC
Business Acquisition [Line Items]
Cash					$ 112
Restricted cash					500
Prepaid expenses and other current assets					381
Property, plant and equipment					5,375
Goodwill					43,530
Intangible assets					56,400
Operating lease-right-of-use assets					9,367
Total assets acquired					115,665
Accounts payable and accrued expenses					1,239
Operating lease liabilities					9,177
Related party payable					127
Total liabilities assumed					10,543
Redeemable non-controlling interests					2,000
Fair value of consideration transferred					$ 103,122
Saol Baclofen Franchise Acquisition
Asset Acquisition [Line Items]
Inventory	$ 2,162
Prepaid expenses and other current assets	98
Goodwill	7,553
Intangible assets	83,815
Total assets acquired	93,628
Accounts payable and accrued expenses	118
Fair value of consideration transferred	$ 93,510

Acquisitions - Acquired Markete

Acquisitions - Acquired Marketed Product Rights Intangible Assets (Details) - Marketed product rights - USD ($) $ in Thousands	Feb. 09, 2022	Apr. 02, 2021
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 83,815
Weighted-Average Useful Life (in years)	11 years 6 months
Kashiv Specialty Pharmaceuticals, LLC
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value		$ 29,400
Weighted-Average Useful Life (in years)		5 years 10 months 24 days

Acquisitions - Unaudited Pro Fo

Acquisitions - Unaudited Pro Forma Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Business Combination and Asset Acquisition [Abstract]
Net revenue	$ 2,093,861	$ 2,023,609
Net income	22,523	54,083
Net income attributable to Amneal Pharmaceuticals, Inc.	$ 11,802	$ 80,643

Revenue Recognition - Concentra

Revenue Recognition - Concentration of Revenue (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Customer A
Concentration Risk [Line Items]
Concentration risk (percent)	21%	21%	23%
Customer B
Concentration Risk [Line Items]
Concentration risk (percent)	18%	20%	17%
Customer C
Concentration Risk [Line Items]
Concentration risk (percent)	22%	24%	23%
Customer D
Concentration Risk [Line Items]
Concentration risk (percent)	10%	10%	11%

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Net revenue	$ 2,212,304	$ 2,093,669	$ 1,992,523
Generics
Disaggregation of Revenue [Line Items]
Net revenue	1,432,073	1,366,338	1,343,210
Specialty
Disaggregation of Revenue [Line Items]
Net revenue	374,121	378,319	355,567
AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	406,110	349,012	293,746
International and other | Generics
Disaggregation of Revenue [Line Items]
Net revenue	1,468	1,299	2,333
Anti-Infective | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	23,193	30,501	40,381
Hormonal/Allergy | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	444,909	427,077	355,581
Hormonal/Allergy | United States | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	91,465	68,397	54,631
Antiviral | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	40,601	4,832	25,724
Central Nervous System | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	393,281	381,110	422,405
Central Nervous System | United States | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	255,656	277,196	285,737
Cardiovascular System | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	118,183	141,866	114,226
Gastroenterology | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	70,796	76,497	78,165
Oncology | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	64,285	103,327	61,113
Metabolic Disease/Endocrine | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	41,128	38,462	45,004
Respiratory | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	41,085	35,965	37,389
Dermatology | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	66,553	55,474	58,168
Other therapeutic classes | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	118,573	69,928	102,721
Other therapeutic classes | United States | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	27,000	32,726	15,199
License Agreement | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	8,018	0	0
Distribution | United States | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	260,560	192,921	161,673
Government Label | United States | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	98,234	118,379	104,054
Institutional | United States | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	27,742	25,176	18,546
Other | United States | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	$ 19,574	$ 12,536	$ 9,473

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Contract Charge- backs and Sales Volume Allowances
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	$ 503,902	$ 628,804	$ 829,807
Impact of the Rondo Acquisitions			12,444
Provision related to sales recorded in the period	3,416,149	3,164,331	3,930,682
Credits/payments issued during the period	(3,346,459)	(3,289,233)	(4,144,129)
Balance, end of period	573,592	503,902	628,804
Cash Discount Allowances
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	23,642	22,690	34,308
Impact of the Rondo Acquisitions			944
Provision related to sales recorded in the period	112,609	107,810	118,525
Credits/payments issued during the period	(108,797)	(106,858)	(131,087)
Balance, end of period	27,454	23,642	22,690
Accrued Returns Allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	161,978	174,984	150,361
Impact of the Rondo Acquisitions			11,606
Provision related to sales recorded in the period	84,306	105,127	110,556
Credits/payments issued during the period	(101,224)	(118,133)	(97,539)
Balance, end of period	145,060	161,978	174,984
Accrued Medicaid and Commercial Rebates
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	85,737	131,088	114,960
Impact of the Rondo Acquisitions			10
Provision related to sales recorded in the period	129,203	137,452	133,748
Credits/payments issued during the period	(128,910)	(182,803)	(117,630)
Balance, end of period	$ 86,030	$ 85,737	$ 131,088

Alliance and Collaboration - Ad

Alliance and Collaboration - Additional Information (Details) € in Millions					1 Months Ended	12 Months Ended			54 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 28, 2022 EUR (€)	Aug. 16, 2018	May 07, 2018 USD ($)	Apr. 30, 2019 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Mar. 22, 2019 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development						$ 195,688,000	$ 201,847,000	$ 179,930,000
Expensed to costs of goods sold						1,416,485,000	1,302,004,000	1,329,551,000
Collaborative arrangement maximum milestone paid						26,500,000
License Agreement with Orion Corporation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term		8 years
Collaborative arrangement renew for successive term		2 years
Collaborative arrangement non-refundable milestone payment | €		€ 20
Collaborative arrangement upfront payment	$ 21,400,000
Collaborative arrangement aggregate sales-based milestone payment | €		€ 45
Collaborative arrangement maximum contingent payments amount	48,200,000
Research and development						0
Collaborative arrangement license revenue agreement						8,000,000
Collaborative arrangement remaining upfront amount						13,400,000
License Agreement with Orion Corporation | Prepaid Expenses and Other Current Assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement upfront payment receivable	21,400,000					21,400,000
License Agreement with Orion Corporation | Accounts Payable and Accrued Expenses
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred income	6,700,000					6,700,000
License Agreement with Orion Corporation | Other long-term liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred income	$ 6,700,000					6,700,000
JSP License And Commercialization Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term			10 years
Payment of up-front license contingent payment					$ 50,000,000
Accrued up-front license contingent payment											$ 50,000,000
JSP And Lannett Company Transition Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expensed to costs of goods sold						17,700,000
Biosimilar Licensing and Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development						$ 0	11,700,000	4,500,000
Collaborative arrangement maximum contingent payments amount				$ 78,300,000
Estimated useful life (in years)						7 years
Astra Zeneca
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement reduced royalty									$ 30,000,000	$ 30,000,000
Astra Zeneca | Royalty
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expensed to costs of goods sold						$ 1,400,000	$ 12,500,000	$ 17,200,000

Government Grants - Additional

Government Grants - Additional Information (Details) $ in Thousands, ₨ in Billions	1 Months Ended	12 Months Ended
	Nov. 30, 2021 INR (₨) company	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other operating income		$ 4,000
Prepaid expenses and other current assets		103,565	$ 110,218
Government of India
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of companies | company	55
Grants receivable	₨ 10	120,800
Government grant eligible term	6 years
Government of India | Prepaid Expenses and Other Current Assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepaid expenses and other current assets		$ 4,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	1 Months Ended		12 Months Ended
	Feb. 28, 2021	Jul. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Valuation allowance			$ 434,895,000	$ 416,588,000	$ 422,812,000	$ 470,193,000
Percentage of tax receivable agreement paid to other holders of Amneal common units			85%			85%
Reversal of accrued tax receivable agreement liability						$ 192,800,000
Liabilities under tax receivable agreement			$ 202,700,000
Tax receivable agreement liability			600,000
Tax receivable agreement expense			600,000
Net operating loss carryforwards							$ 345,000,000
Deferred tax assets, discrete income tax benefit					(110,000,000)
Income tax receivable, amount refunded	$ 2,000,000	$ 106,000,000
Net operating loss, CARES Act		110,000,000
Income tax receivable, interest		$ 4,000,000
Income tax (benefit) provision			$ 6,662,000	$ 11,196,000	$ (104,358,000)
Effective tax rate, percent			(2.70%)	35.70%	291.70%
Income tax returns subject to examination period			3 years
Provision for deferred income taxes			$ 0	$ 0	$ 0
Unrecognized tax benefits			3,616,000	5,489,000	5,368,000	$ 6,176,000
Unrecognized tax benefits that would impact the effective tax rate			3,500,000	5,400,000	5,000,000
Unrecognized tax benefits, net interest expense			(700,000)	100,000	(300,000)
Unrecognized tax benefits, accrued interest expense			100,000	800,000	800,000
Undistributed earnings of foreign subsidiaries			$ 111,000,000
Ministry of Finance, India
Operating Loss Carryforwards [Line Items]
Effective tax rate, percent			25.17%
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards			$ 253,800,000
Deferred tax assets, benefits (expenses), CARES Act					110,000,000
Federal | R&D Credit Carryforwards
Operating Loss Carryforwards [Line Items]
Credit carryforwards			13,300,000
Foreign
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards			$ 136,400,000
Foreign | Ministry of Finance, India
Operating Loss Carryforwards [Line Items]
Effective tax rate, percent			34.90%
Income tax returns subject to examination period			3 years
Minimum Alternate Tax (MAT), rate			21.50%
Income tax holiday, effect on earnings			$ 5,000,000	$ 3,000,000	$ 3,000,000
Foreign | Swiss Federal Tax Administration (FTA) , Switzerland
Operating Loss Carryforwards [Line Items]
Income tax returns subject to examination period			5 years
Foreign | Revenue Commissioners, Ireland
Operating Loss Carryforwards [Line Items]
Income tax returns subject to examination period			4 years
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards			$ 173,800,000
State | R&D Credit Carryforwards
Operating Loss Carryforwards [Line Items]
Credit carryforwards			$ 12,300,000

Income Taxes - Components of (L

Income Taxes - Components of (Loss) Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Total (loss) income before income taxes	$ (248,127)	$ 31,366	$ (35,780)
United States
Operating Loss Carryforwards [Line Items]
Total (loss) income before income taxes	(260,616)	(10,540)	(99,966)
International
Operating Loss Carryforwards [Line Items]
Total (loss) income before income taxes	$ 12,489	$ 41,906	$ 64,186

Income Taxes - Provision for (B

Income Taxes - Provision for (Benefit From) Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Domestic	$ (1,073)	$ 1,311	$ (113,754)
Foreign	7,735	9,885	9,396
Total current income tax	$ 6,662	$ 11,196	$ (104,358)

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal income tax at the statutory rate	21%	21%	21%
State income tax, net of federal benefit	(0.80%)	4.20%	(2.00%)
Income not subject to tax	(10.70%)	6.40%	(29.80%)
Foreign rate differential	(3.40%)	17.30%	(7.10%)
Permanent book/tax differences	(0.30%)	4.80%	0%
CARES Act	0%	0%	139.90%
Valuation allowance	(10.30%)	(13.50%)	163.20%
Other	1.80%	(4.50%)	6.50%
Effective income tax rate	(2.70%)	35.70%	291.70%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets, Changes in Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets, Valuation Allowance [Roll Forward]
Balance at the beginning of the period	$ 416,588	$ 422,812	$ 470,193
Increase (decrease) due to net operating losses and temporary differences	25,589	(10,828)	(54,971)
Increase due to stock-based compensation	224	5,513	0
Decrease recorded against goodwill	(1,590)	0	0
Increase (decrease) recorded against additional paid-in capital	2,720	2,842	(1,631)
(Decrease) increase recorded against other comprehensive income	(8,636)	(3,751)	9,221
Balance at the end of the period	$ 434,895	$ 416,588	$ 422,812

Income Taxes - Deferred Tax A_2

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Partnership interest in Amneal	$ 203,336	$ 200,872
Projected imputed interest on TRA	25,255	25,615
Net operating loss carryforward	82,338	73,861
IRC Section 163(j) interest carryforward	54,996	46,407
Capitalized costs	2,505	1,300
Accrued expenses	431	498
Stock-based compensation	5,737	5,513
Intangible assets	23,967	28,380
Tax credits and other	36,330	34,142
Total deferred tax assets	434,895	416,588
Valuation allowance	(434,895)	(416,588)	$ (422,812)	$ (470,193)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits at the beginning of the period	$ 5,489	$ 5,368	$ 6,176
Gross change for current period positions	110	131	125
Gross change for prior period positions	(1,983)	(10)
Gross change for prior period positions			443
Decrease due to settlements and payments	0	0	(1,376)
Unrecognized tax benefits at the end of the period	$ 3,616	$ 5,489	$ 5,368

(Loss) Earnings per Share - Com

(Loss) Earnings per Share - Computation of Basic and Diluted (Loss) Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.	$ (129,986)	$ 10,624	$ 91,059
Denominator:
Weighted-average shares outstanding - basic (in shares)	150,944	148,922	147,443
Effect of dilutive securities
Weighted-average shares outstanding - diluted (in shares)	150,944	151,821	148,913
Net (loss) earnings per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:
Basic (in dollars per share)	$ (0.86)	$ 0.07	$ 0.62
Diluted (in dollars per share)	$ (0.86)	$ 0.07	$ 0.61
Stock options
Effect of dilutive securities
Effect of dilutive securities (in shares)	0	767	348
Restricted stock units
Effect of dilutive securities
Effect of dilutive securities (in shares)	0	2,132	1,122

(Loss) Earnings per Share - Sec

(Loss) Earnings per Share - Securities Excluded from Diluted (Loss) Earnings per Share Computation (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shares of Class B common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	152,117	152,117	152,117
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	2,648	347	671
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	10,755	0	0
Performance stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	7,174	5,055	2,973

Trade Accounts Receivable, Ne_2

Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Receivables [Abstract]
Gross accounts receivable	$ 1,344,959	$ 1,191,792
Allowance for credit losses	(2,122)	(1,665)
Contract charge-backs and sales volume allowances	(573,592)	(503,902)
Cash discount allowances	(27,454)	(23,642)
Subtotal	(603,168)	(529,209)
Trade accounts receivable, net	$ 741,791	$ 662,583

Trade Accounts Receivable, Ne_3

Trade Accounts Receivable, Net - Concentration of Receivables (Details) - Customer Concentration Risk - Accounts Receivable	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Customer A
Concentration Risk [Line Items]
Concentration risk (percent)	41%	37%
Customer B
Concentration Risk [Line Items]
Concentration risk (percent)	25%	24%
Customer C
Concentration Risk [Line Items]
Concentration risk (percent)	21%	25%

Inventories - Components of Inv

Inventories - Components of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 224,607	$ 214,508
Work in process	58,522	47,802
Finished goods	247,606	227,079
Total inventories	$ 530,735	$ 489,389

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Gain Contingencies [Line Items]
Deposits and advances	$ 1,821	$ 1,174
Prepaid insurance	8,090	7,962
Prepaid regulatory fees	5,298	3,710
Escrow deposits for legal settlements	0	33,000
Income and other tax receivables	12,881	8,850
Prepaid taxes	16,593	16,085
Other current receivables	33,133	9,770
Other prepaid assets	17,144	17,309
Chargebacks receivable	8,605	12,358
Total prepaid expenses and other current assets	$ 103,565	110,218
Securities Class Action Lawsuits
Gain Contingencies [Line Items]
Escrow deposits for legal settlements		$ 33,000

Property, Plant, and Equipmen_3

Property, Plant, and Equipment, Net - Summary of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	$ 915,786	$ 908,720
Less: Accumulated depreciation	(445,971)	(394,562)
Property, plant, and equipment, net	469,815	514,158
Land
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	10,706	11,540
Buildings
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	225,630	230,994
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	124,668	123,508
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	411,572	414,098
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	13,823	12,745
Vehicles
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	1,699	1,485
Computer equipment
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	58,344	56,087
Construction-in-progress
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	$ 69,344	$ 58,263

Property, Plant, and Equipmen_4

Property, Plant, and Equipment, Net - Depreciation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 68,112	$ 60,705	$ 60,420

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Roll Forward]
Balance, beginning of period	$ 593,017	$ 522,814
Goodwill acquired during the period	7,553	70,584
Adjustment during the period for the Puniska Acquisition	3,075	0
Currency translation	(4,792)	(381)
Balance, end of period	$ 598,853	$ 593,017

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) product	Dec. 31, 2021 USD ($) product	Dec. 31, 2020 USD ($) product
Goodwill [Line Items]
Goodwill	$ 598,853,000	$ 593,017,000	$ 522,814,000
Goodwill impairment	0
Impairment charges	24,100,000	23,400,000	37,300,000
Intangible asset impairment charges, cost of goods sold	11,100,000	22,700,000	$ 34,600,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]			In-process research and development impairment charges, Cost of goods sold
Intangible asset impairment charges, in-process research and development	13,000,000	700,000	$ 2,700,000
Levothyroxine
Goodwill [Line Items]
Impairment charges		17,700,000
Intangible asset impairment charges, cost of goods sold		$ 22,700,000
Marketed Products
Goodwill [Line Items]
Intangible asset impairment charges, cost of goods sold	$ 11,100,000
Number of products experiencing impairment | product	3	7	6
Intangible assets impairment, number of products experiencing price erosion | product	1	5	4
Number of products contract terminated | product		2
In-Process Research and Development
Goodwill [Line Items]
Number of products experiencing impairment | product	2	1	4
Intangible assets impairment, number of products experiencing price erosion | product	1		3
Number of products contract terminated | product	1		1
Number of products not expected to be sold | product	1
Number of products experiencing increased competition at launch | product	1		1
Number of products no longer pursuing approval | product			4
Minimum | Long-term Revenue Growth Rate
Goodwill [Line Items]
Goodwill inputs, percentage	0%
Minimum | Discount rate
Goodwill [Line Items]
Goodwill inputs, percentage	11.50%
Maximum | Long-term Revenue Growth Rate
Goodwill [Line Items]
Goodwill inputs, percentage	1%
Maximum | Discount rate
Goodwill [Line Items]
Goodwill inputs, percentage	15.10%
Specialty
Goodwill [Line Items]
Goodwill	$ 366,300,000	$ 363,900,000
Percentage of fair value in excess of carrying amount	28%
Generics
Goodwill [Line Items]
Goodwill	$ 163,100,000	159,600,000
Percentage of fair value in excess of carrying amount	57%
Av Kare
Goodwill [Line Items]
Goodwill	$ 69,500,000	$ 69,500,000
Percentage of fair value in excess of carrying amount	148%

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Cost	$ 1,356,562	$ 1,256,412
Accumulated Amortization	(651,224)	(494,915)
Net	705,338	761,497
In-process research and development	390,755	405,425
Intangible assets, cost	1,747,317	1,661,837
Intangible assets, net	1,096,093	1,166,922
In-Process Research and Development
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ 0	0
Product rights
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Amortization Period (in years)	7 years 6 months
Cost	$ 1,222,762	1,122,612
Accumulated Amortization	(573,281)	(436,902)
Net	$ 649,481	685,710
Other intangible assets
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Amortization Period (in years)	4 years 1 month 6 days
Cost	$ 133,800	133,800
Accumulated Amortization	(77,943)	(58,013)
Net	$ 55,857	$ 75,787

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization	$ 172,063	$ 172,701	$ 174,967

Goodwill and Other Intangible_7

Goodwill and Other Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Future Amortization
2023	$ 163,473
2024	161,169
2025	122,478
2026	71,743
2027	50,180
Thereafter	136,295
Net	$ 705,338	$ 761,497

Other Assets - Schedule of Othe

Other Assets - Schedule of Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other Assets [Line Items]
Other assets	$ 103,217	$ 20,614
Interest rate swap
Other Assets [Line Items]
Other assets	85,586	0
Security deposits
Other Assets [Line Items]
Other assets	3,523	3,895
Long-term prepaid expenses
Other Assets [Line Items]
Other assets	3,711	5,896
Deferred revolving credit facility costs
Other Assets [Line Items]
Other assets	2,206	1,603
Other long-term assets
Other Assets [Line Items]
Other assets	$ 8,191	$ 9,220

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts payable	$ 165,980	$ 131,084
Accrued returns allowance	145,060	161,978
Accrued compensation	54,038	62,098
Accrued Medicaid and commercial rebates	86,030	85,737
Accrued royalties	19,309	20,893
Commercial chargebacks and rebates	10,226	10,226
Accrued professional fees	11,386	9,926
Taxes payable	359	2,523
Accrued other	45,811	40,880
Total accounts payable and accrued expenses	538,199	525,345
Current portion of liabilities for legal matters	$ 107,483	$ 58,000

Debt - Summary of Long-term Deb

Debt - Summary of Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt	$ 2,635,876	$ 2,730,750
Less: debt issuance costs	(13,934)	(20,083)
Total debt, net of debt issuance costs	2,621,942	2,710,667
Less: current portion of long-term debt	(29,961)	(30,614)
Total long-term debt, net	2,591,981	2,680,053
Other
Debt Instrument [Line Items]
Long-term debt	0	624
Term Loan due May 2025
Debt Instrument [Line Items]
Long-term debt	2,563,876	2,590,876
Rondo Term Loan due January 2025
Debt Instrument [Line Items]
Long-term debt	$ 72,000	$ 139,250

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)

1 Months Ended

12 Months Ended

Jan. 31, 2020

Dec. 31, 2022

Sep. 30, 2021

Mar. 31, 2021

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Jun. 30, 2022

Jun. 02, 2022

Feb. 28, 2021

Oct. 31, 2019

May 04, 2018

Debt Instrument [Line Items]

Long-term debt

$ 2,635,876,000

$ 2,635,876,000

$ 2,730,750,000

Interest Rate Lock Agreement

Debt Instrument [Line Items]

Notional amount

$ 1,300,000,000

Revolving Credit Facility

Debt Instrument [Line Items]

Outstanding borrowings on credit facility

60,000,000

60,000,000

Debt issuance costs, gross

$ 1,600,000

1,600,000

Write off of deferred debt issuance cost

$ 300,000

Commitment fee percentage on unused capacity

0.25%

Interest rate

590%

590%

Term Loan due May 2025

Debt Instrument [Line Items]

Long-term debt

$ 2,563,876,000

$ 2,563,876,000

2,590,876,000

Term Loan due May 2025 | Revolving Credit Facility

Debt Instrument [Line Items]

Change in fair value of contingent consideration

6,100,000

6,400,000

$ 6,500,000

Rondo Term Loan

Debt Instrument [Line Items]

Principal amount of debt

$ 180,000,000

Quarterly installment rate

5%

Debt issuance costs, gross

$ 3,500,000

Rondo Revolving Credit Facility

Debt Instrument [Line Items]

Maximum borrowing capacity

$ 30,000,000

Outstanding borrowings on credit facility

$ 0

$ 0

Rondo Credit Facility

Debt Instrument [Line Items]

Basis spread on variable rate

3%

2.50%

Debt issuance costs, gross

$ 600,000

Commitment fee percentage on unused capacity

0.25%

Commitment fee, as a percent

0.25%

Rondo Credit Facility | Minimum

Debt Instrument [Line Items]

Commitment fee percentage on unused capacity

0.25%

Rondo Credit Facility | Maximum

Debt Instrument [Line Items]

Change in fair value of contingent consideration

$ 1,000,000

Commitment fee percentage on unused capacity

0.50%

Senior Secured Credit Facility | Senior Credit Facility Term Loan Due May 2025

Debt Instrument [Line Items]

Principal amount of debt

$ 2,700,000,000

Quarterly installment rate

1%

Repayments of principal in next twelve months

$ 6,750,000

Repayments of principal in year two

6,750,000

Repayments of principal in year three

6,750,000

Additional principal repayment

$ 14,400,000

$ 0

$ 0

Debt issuance costs, gross

38,100,000

Senior Secured Credit Facility | Senior Credit Facility Term Loan Due May 2025 | LIBOR

Debt Instrument [Line Items]

Basis spread on variable rate

3.50%

Line of Credit | Revolving Credit Facility | ABR

Debt Instrument [Line Items]

Basis spread on variable rate

0.25%

Debt instrument, interest rate floor (percent)

1%

Line of Credit | Revolving Credit Facility | ABR | Minimum

Debt Instrument [Line Items]

Basis spread on variable rate

0.25%

Line of Credit | Revolving Credit Facility | ABR | Maximum

Debt Instrument [Line Items]

Basis spread on variable rate

0.50%

Line of Credit | Revolving Credit Facility | SOFR

Debt Instrument [Line Items]

Basis spread on variable rate

1.25%

Debt instrument, interest rate floor (percent)

0%

Line of Credit | Revolving Credit Facility | SOFR | Minimum

Debt Instrument [Line Items]

Basis spread on variable rate

1.25%

Line of Credit | Revolving Credit Facility | SOFR | Maximum

Debt Instrument [Line Items]

Basis spread on variable rate

1.50%

Line of Credit | Senior Secured Credit Facilities

Debt Instrument [Line Items]

Maximum borrowing capacity

500,000,000

Remaining borrowing capacity

$ 285,900,000

$ 285,900,000

Debt issuance costs, gross

4,600,000

Line of Credit | Senior Secured Credit Facilities | Letter of Credit

Debt Instrument [Line Items]

Maximum borrowing capacity

25,000,000

25,000,000

Remaining borrowing capacity

$ 25,000,000

Line of Credit | Senior Secured Credit Facilities | Revolving Credit Facility

Debt Instrument [Line Items]

Maximum borrowing capacity

350,000,000

350,000,000

$ 350,000,000

Line of credit facility, increase limit

150,000,000

150,000,000

Line of Credit | Senior Secured Credit Facilities | Bridge Loan

Debt Instrument [Line Items]

Maximum borrowing capacity

35,000,000

35,000,000

Rondo Term Loan

Debt Instrument [Line Items]

Repayments of principal in next twelve months

9,000,000

9,000,000

Repayments of principal in year two

$ 9,000,000

9,000,000

Prepayment of outstanding principal

$ 25,000,000

67,300,000

Long-term debt

$ 600,000

Long Term Promissory Notes | AvKARE and R&S Acquisitions

Debt Instrument [Line Items]

Change in fair value of contingent consideration

$ 1,700,000

Interest rate

5%

Liabilities incurred

$ 44,200,000

Liabilities incurred, fair value

35,000,000

Unamortized discount

9,200,000

Short Term Promissory Notes | AvKARE and R&S Acquisitions

Debt Instrument [Line Items]

Interest rate

1.60%

Liabilities incurred

1,000,000

Liabilities incurred, fair value

$ 1,000,000

Other Long-Term Liabilities - S

Other Long-Term Liabilities - Schedule of Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other Liabilities [Line Items]
Other long-term liabilities	$ 87,468	$ 38,903
Deferred compensation plan liabilities	9,674	13,883
Interest rate swap
Other Liabilities [Line Items]
Other long-term liabilities	0	11,473
Uncertain tax positions
Other Liabilities [Line Items]
Other long-term liabilities	563	3,177
Long-term portion of liabilities for legal matters
Other Liabilities [Line Items]
Other long-term liabilities	49,442	0
Long-term compensation
Other Liabilities [Line Items]
Other long-term liabilities	16,737	21,589
Deferred compensation plan liabilities	7,600	11,800
Long-term employee benefit	9,100	8,000
Contingent consideration
Other Liabilities [Line Items]
Other long-term liabilities	11,997	0
Other long-term liabilities
Other Liabilities [Line Items]
Other long-term liabilities	$ 8,729	$ 2,664

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Operating and finance lease, rent expense	$ 22,600,000	$ 19,800,000	$ 26,300,000
Operating lease right of use assets impairment loss	$ 0	$ 0	$ 600,000
Minimum
Lessee, Lease, Description [Line Items]
Operating and finance lease term	1 year
Minimum | International Land Easements
Lessee, Lease, Description [Line Items]
Operating and finance lease term	28 years
Maximum
Lessee, Lease, Description [Line Items]
Operating and finance lease term	22 years
Maximum | International Land Easements
Lessee, Lease, Description [Line Items]
Operating and finance lease term	97 years

Leases - Components of Total Le

Leases - Components of Total Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 17,800	$ 15,057	$ 21,664
Finance lease cost:
Amortization of right-of-use assets	4,808	4,713	4,487
Interest on lease liabilities	4,508	4,601	4,773
Total finance lease cost	9,316	9,314	9,260
Total lease cost	$ 27,116	$ 24,371	$ 30,924

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Operating leases
Operating lease right-of-use assets	$ 56,121	$ 60,370
Total operating lease liabilities	59,230	63,999
Financing leases
Total financing lease liabilities	64,257	63,352
Excluding Related Party
Operating leases
Operating lease right-of-use assets	38,211	39,899
Operating lease liabilities	32,126	32,894
Current portion of operating lease liabilities	8,321	9,686
Financing leases
Financing lease right of use assets	63,424	64,475
Financing lease liabilities	60,769	60,251
Current portion of financing lease liabilities	3,488	3,101
Related Party
Operating leases
Operating lease right-of-use assets	17,910	20,471
Operating lease liabilities	15,914	18,783
Current portion of operating lease liabilities	$ 2,869	$ 2,636

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from finance leases	$ 4,539	$ 4,601
Operating cash flows from operating leases	16,217	15,006
Financing cash flows from finance leases	3,484	3,179
Non-cash activity:
Right-of-use assets obtained in exchange for new operating lease liabilities	7,504	12,006
Right-of-use assets obtained in exchange for new financing lease liabilities	$ 4,606	$ 1,072

Leases - Term and Discount Rate

Leases - Term and Discount Rate Information (Details)	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted average remaining lease term - operating leases	5 years	5 years
Weighted average remaining lease term - finance leases	19 years	21 years
Weighted average discount rate - operating leases	8.50%	6.90%
Weighted average discount rate - finance leases	7.20%	7.10%

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Operating Leases
Year one	$ 15,843	$ 16,136
Year two	16,558	16,412
Year three	14,264	15,215
Year four	10,393	11,363
Year five	7,420	7,400
Thereafter	11,550	9,712
Total lease payments	76,028	76,238
Less: Imputed interest	(16,798)	(12,239)
Total	59,230	63,999
Financing Leases
Year one	7,976	7,492
Year two	6,913	6,726
Year three	6,466	5,572
Year four	5,989	5,474
Year five	5,645	5,474
Thereafter	85,220	89,862
Total lease payments	118,209	120,600
Less: Imputed interest	(53,952)	(57,248)
Total	$ 64,257	$ 63,352

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Interest rate swap	$ 85,586
Liabilities
Interest rate swap		$ 11,473
Deferred compensation plan liabilities	9,674	13,883
Contingent consideration liability	15,427	5,900
Kashiv Specialty Pharmaceuticals, LLC
Liabilities
Contingent consideration liability	3,300	5,900
Current Liabilities
Liabilities
Deferred compensation plan liabilities	2,100	2,100
Non-current Liabilities
Liabilities
Deferred compensation plan liabilities	7,600	11,800
Accounts Payable And Accrued Expenses | Saol Baclofen Franchise Acquisition
Liabilities
Contingent consideration liability	100
Other long-term liabilities | Saol Baclofen Franchise Acquisition
Liabilities
Contingent consideration liability	12,000
Quoted Prices in Active Markets (Level 1)
Assets
Interest rate swap	0
Liabilities
Interest rate swap		0
Deferred compensation plan liabilities	0	0
Contingent consideration liability	0	0
Significant Other Observable Inputs (Level 2)
Assets
Interest rate swap	85,586
Liabilities
Interest rate swap		11,473
Deferred compensation plan liabilities	9,674	13,883
Contingent consideration liability	0	0
Significant Unobservable Inputs (Level 3)
Assets
Interest rate swap	0
Liabilities
Interest rate swap		0
Deferred compensation plan liabilities	0	0
Contingent consideration liability	$ 15,427	$ 5,900

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Apr. 02, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt	$ 2,621,942	$ 2,710,667
Term Loan | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt fair value	2,300,000	2,600,000
Term Loan | Significant Other Observable Inputs (Level 2) | Rondo Partners LLC
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt fair value	70,900	138,900
Promissory Notes | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt	$ 39,100	$ 37,900
Kashiv Specialty Pharmaceuticals, LLC
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, maximum liability			$ 8,000

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of Contingent Consideration Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Net change in fair value during period	$ (731)	$ (200)	$ 0
Kashiv Specialty Pharmaceuticals, LLC
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	5,900	0
Addition due to the Acquisition	0	5,700
Net change in fair value during period	731	200
Balance, end of period	15,427	5,900	$ 0
Saol Baclofen Franchise Acquisition
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Addition due to the Acquisition	$ 8,796	$ 0

Fair Value Measurements - Signi

Fair Value Measurements - Significant Inputs Used in Fair Value Measurements (Details) $ in Thousands	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 15,427	$ 5,900
Regulatory Milestones (KSP Acquisition)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 390	$ 500
Regulatory Milestones (KSP Acquisition) | Minimum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.072	0.022
Regulatory Milestones (KSP Acquisition) | Minimum | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.018	0.018
Regulatory Milestones (KSP Acquisition) | Maximum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.085	0.044
Regulatory Milestones (KSP Acquisition) | Maximum | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.200	0.200
Regulatory Milestones (KSP Acquisition) | Weighted Average | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.073	0.024
Regulatory Milestones (KSP Acquisition) | Weighted Average | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.186	0.167
Royalties (KSP Acquisition)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 2,900	$ 5,400
Royalties (KSP Acquisition) | Minimum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.125	0.115
Royalties (KSP Acquisition) | Minimum | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.018	0.018
Royalties (KSP Acquisition) | Maximum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.125	0.115
Royalties (KSP Acquisition) | Maximum | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.200	0.200
Royalties (KSP Acquisition) | Weighted Average | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.125	0.115
Royalties (KSP Acquisition) | Weighted Average | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.186	0.180
Royalties (Saol Acquisition)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 12,137
Royalties (Saol Acquisition) | Minimum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.178
Royalties (Saol Acquisition) | Maximum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.178
Royalties (Saol Acquisition) | Weighted Average | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.178

Financial Instruments - Additio

Financial Instruments - Additional Information (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Oct. 31, 2019
Derivative [Line Items]
Net of income taxes, recognized in accumulated other comprehensive income (loss)	$ 85,600,000	$ (11,500,000)
Accumulated Other Comprehensive (Loss) Income
Derivative [Line Items]
Net of income taxes, recognized in accumulated other comprehensive income (loss)	42,300,000	(6,000,000)
Non- Controlling Interests
Derivative [Line Items]
Net of income taxes, recognized in accumulated other comprehensive income (loss)	$ 43,300,000	$ (5,500,000)
Interest Rate Lock Agreement
Derivative [Line Items]
Notional amount			$ 1,300,000,000

Financial Instruments - Summary

Financial Instruments - Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Derivative [Line Items]
Fair Value	$ 85,586
Derivatives Designated as Hedging Instruments | Variable-to-fixed interest rate swap | Other Assets
Derivative [Line Items]
Fair Value	$ 85,586	$ 11,473

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Charges Related to Legal Matters (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Loss Contingencies [Line Items]
Charges related to legal matters, net	$ 269,930	$ 25,000	$ 5,860
Opana ER® antitrust litigation
Loss Contingencies [Line Items]
Charges related to legal matters, net	262,837	0	0
Civil prescription opioid litigation
Loss Contingencies [Line Items]
Charges related to legal matters, net	17,993	0	0
Securities class action - Cambridge Retirement System v. Amneal
Loss Contingencies [Line Items]
Charges related to legal matters, net	(15,500)	25,000	0
Galeas v. Amneal
Loss Contingencies [Line Items]
Charges related to legal matters, net	1,200	0	0
Other
Loss Contingencies [Line Items]
Charges related to legal matters, net	$ 3,400	$ 0	$ 5,860

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Liabilities For Legal Matters (Details) - USD ($) $ in Thousands		12 Months Ended
	Mar. 28, 2022	Dec. 31, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters		$ 107,483	$ 58,000
Imputed interest		(1,405)	0
Accrued interest		847	0
Long-term portion of liabilities for legal matters (included in other long-term liabilities)		49,442	0
Insurance recoveries		1,900	5,000
Opana ER® antitrust litigation
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters		83,944	0
Opana ER® antitrust litigation		50,000	0
Amount Due		133,944
Opana ER® antitrust litigation | Amount Due On December 2022 | Minimum
Loss Contingencies [Line Items]
Amount Due		131,100
Opana ER® antitrust litigation | Amount Due On December 2022 | Maximum
Loss Contingencies [Line Items]
Amount Due		265,000
Opana ER® antitrust litigation - accrued interest
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters		1,423	0
Civil prescription opioid litigation
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters		17,993	0
Securities class action - Fleming v. Impax
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters		0	33,000
Litigation settlement amount		33,000
Securities class action - Cambridge Retirement System v. Amneal
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters		0	25,000
Litigation settlement amount	$ 25,000	25,000	25,000
Payment for legal settlements		9,500
Insurance recoveries		15,500
Galeas v. Amneal
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters		1,200	0
Litigation settlement amount		1,200
R&S Solutions LLC - logistics services
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters		$ 2,923	$ 0

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Antitrust Litigation Settlement Agreements (Details) - Opana ER® antitrust litigation $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Loss Contingencies [Line Items]
Amount Due	$ 133,944
January 2023
Loss Contingencies [Line Items]
Amount Due	83,944
January 2024
Loss Contingencies [Line Items]
Amount Due	$ 50,000

Commitments and Contingencies_4

Commitments and Contingencies - Additional Information (Details) $ in Thousands														12 Months Ended
	Feb. 21, 2023 defendant	Jan. 13, 2023 expert motion	Dec. 31, 2022 USD ($) case county state	Sep. 27, 2022 case	Mar. 30, 2022 defendant	Mar. 28, 2022 USD ($)	Mar. 22, 2022 lawsuit	Mar. 01, 2022 defendant	Feb. 08, 2022 defendant	Oct. 01, 2021 pharmacy defendant complaint	Dec. 31, 2020 claim	Mar. 13, 2015 medication	Nov. 06, 2014 representative	Dec. 31, 2022 USD ($) complaint claim case county state	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 22, 2022	Aug. 03, 2022 minor	May 18, 2022 objection	Mar. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jan. 31, 2021	Jun. 10, 2020 state	Nov. 01, 2019 state	May 10, 2019 state	Apr. 17, 2017 officer
Loss Contingencies [Line Items]
Long-term portion of liabilities for legal matters (included in other long-term liabilities)			$ 49,442											$ 49,442	$ 0
Litigation settlement, initial discount, amount			$ 2,200											2,200
Charges related to legal matters, net														262,800
Litigation settlement interest														$ 2,200
Number of pending claims, including third parties | case			914											914
Number of cases | case			77											77
Number of states with cases | state			10											10
Charges related to legal matters, net														$ (269,930)	(25,000)	$ (5,860)
Securities class action amount covered by insurance			$ 0											0	33,000
Charges (insurance recoveries) for property losses and associated expenses														1,900	5,000
Number of lawsuit filed | lawsuit							2
Subsequent Event
Loss Contingencies [Line Items]
Number of motions filed | motion		2
Kashiv BioSciences LLC
Loss Contingencies [Line Items]
Voting interest acquired (percent)																						98%
United States Department of Justice Investigations
Loss Contingencies [Line Items]
Number of sales representatives | representative													1
Number of generic prescription medications | medication												4
Generic Digoxin and Doxycycline Antitrust Litigation
Loss Contingencies [Line Items]
Number of states, filed civil lawsuit | state																							46		43
Loss contingency civil lawsuit filed number of additional states | state																								9
Number of defendants | defendant					2
Generic Digoxin and Doxycycline Antitrust Litigation | Subsequent Event
Loss Contingencies [Line Items]
Number of defendants | defendant	2
Fleming v. Impax Laboratories, Inc. et al.
Loss Contingencies [Line Items]
Number of former officers alleging violations | officer																										4
Securities class action amount covered by insurance																					$ 33,000
Litigation settlement amount														$ 33,000
Ranitidine
Loss Contingencies [Line Items]
Number of claims dismissed | claim											3			3
Number of personal injury short form complaints | complaint														313
Reciprocal jurisdictional discovery days																	90 days
Ranitidine Pennsylvania Lawsuit
Loss Contingencies [Line Items]
Number of complaints | complaint										2
Number of co-defendants | defendant								7	20	25
Number of pharmacies | pharmacy										1
Number of preliminary objections filed by the Company | objection																			1
Number of multi-plaintiff cases | case			6											6
Number of counties where cases were filed | county			3											3
Number of lawsuit filed | case			2	3
Ranitidine California Lawsuit
Loss Contingencies [Line Items]
Number of multi-plaintiff cases | case			7											7
Opana ER® antitrust litigation
Loss Contingencies [Line Items]
Loss contingency accrual			$ 265,000											$ 265,000
Charges related to legal matters, net														(262,837)	0	0
Neonatal Abstinence Syndrome
Loss Contingencies [Line Items]
Number of minors | minor																		6
Civil prescription opioid litigation
Loss Contingencies [Line Items]
Charges related to legal matters, net														(17,993)	0	0
Securities class action - Cambridge Retirement System v. Amneal
Loss Contingencies [Line Items]
Charges related to legal matters, net														15,500	(25,000)	0
Securities class action amount covered by insurance			$ 15,500											15,500
Litigation settlement amount						$ 25,000								25,000	25,000
Charges (insurance recoveries) for property losses and associated expenses														15,500
Payment for legal settlements														9,500
Galeas v. Amneal
Loss Contingencies [Line Items]
Loss contingency accrual																				$ 1,200
Charges related to legal matters, net														(1,200)	$ 0	$ 0
Litigation settlement amount														$ 1,200
Value Drug Company v. Takeda Pharmaceuticals U.S.A., Inc. | Subsequent Event
Loss Contingencies [Line Items]
Number of motions filed | motion		1
Number of experts included in motion to exclude | expert		5
Number of experts | expert		6
January 2023
Loss Contingencies [Line Items]
Interest rate			3%											3%
January 2024
Loss Contingencies [Line Items]
Interest rate			3%											3%
Additional interest rate			2.70%											2.70%
Long-term portion of liabilities for legal matters (included in other long-term liabilities)			$ 50,000											$ 50,000
Amount Due On December 2022 and Mid-January 2024
Loss Contingencies [Line Items]
Interest rate			3%											3%
Loss contingency accrual			$ 150,000											$ 150,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)					1 Months Ended			12 Months Ended
	Dec. 31, 2021 USD ($) shares	Nov. 02, 2021 USD ($)	Apr. 02, 2021 USD ($)	Jan. 31, 2020 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) shares	Sep. 30, 2020 USD ($) subsidiary	Dec. 31, 2022 USD ($) vote shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Jan. 11, 2021
Class of Stock [Line Items]
Preferred stock, shares issued (in shares) | shares	0					0		0	0
Tax distribution								$ 10,600,000	$ 53,500,000	$ 2,800,000
Included in related-party payables, tax distribution	$ 0					$ 0		0	0
Acquired non-controlling interest, non-public subsidiary							$ 3,300,000
Number of non-public subsidiaries, acquired non-controlling interest | subsidiary							1
Payments to acquire additional interest in subsidiaries							$ 800,000
Acquired non-controlling interest, non-public subsidiary							$ 2,500,000
Kashiv Specialty Pharmaceuticals, LLC
Class of Stock [Line Items]
Voting interest acquired (percent)			98%								98%
Consideration paid in cash on hand			$ 100,100,000
Kashiv Specialty Pharmaceuticals, LLC | Sellers of KSP
Class of Stock [Line Items]
Ownership percentage by noncontrolling owners (percent)			2%
AvKare and R&S
Class of Stock [Line Items]
Voting interest acquired (percent)				65.10%
Liabilities incurred, fair value				$ 11,500,000
Tax distribution recorded as a reduction to redeemable non-controlling interest								6,900,000	3,600,000
Amounts due to tax distributions related to redeemable non-controlling interests	0					0		$ 0	$ 0
AvKare and R&S | Rondo Partners LLC
Class of Stock [Line Items]
Ownership percentage by noncontrolling owners (percent)				34.90%
Puniska Healthcare Pvt Ltd
Class of Stock [Line Items]
Acquired non-controlling interest, non-public subsidiary						$ 4,300,000
Voting interest acquired (percent)		74%			26%			26%
Consideration paid in cash on hand	$ 14,162,000	$ 72,880,000			$ 1,700,000			$ 1,700,000
Increase in redeemable non-controlling interest to redemption value								$ 900,000
Class A Common Stock
Class of Stock [Line Items]
Number of votes per share | vote								1
Redemption ratio								1
Class B Common Stock
Class of Stock [Line Items]
Number of votes per share | vote								1
Conversion ratio								1

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	$ 366,973	$ 344,932
Other comprehensive income before reclassification	34,876	16,717
Reallocation of ownership interests	(110)	(226)
Stockholders' equity ending balance	183,979	366,973
Foreign currency translation adjustment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	(18,845)	(14,497)
Other comprehensive income before reclassification	(13,394)	(4,255)
Reallocation of ownership interests	(143)	(93)
Stockholders' equity ending balance	(32,382)	(18,845)
Unrealized gain (loss) on cash flow hedge, net of tax
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	(5,982)	(26,821)
Other comprehensive income before reclassification	48,270	20,972
Reallocation of ownership interests	33	(133)
Stockholders' equity ending balance	42,321	(5,982)
Accumulated other comprehensive (loss) income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	(24,827)	(41,318)
Stockholders' equity ending balance	$ 9,939	$ (24,827)

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended	12 Months Ended
	May 05, 2020	Mar. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	May 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, exercises in period, intrinsic value			$ 0.1
Options granted (in shares)			0	0	0
Compensation cost not yet recognized			$ 50.4
Compensation cost not yet recognized, period for recognition			1 year 9 months 18 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			4 years
Expiration period			10 years
MPRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			3 years
MPRSUs | Granted in 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted to executives (in shares)			3,053,738
Awards vesting, percentage			200%
Awards vesting, shares (in shares)			6,107,476
Estimated fair value per share (in dollars per share)			$ 6.22
Shares outstanding and unvested (in shares)			2,731,612
MPRSUs | Granted in 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted to executives (in shares)				2,331,211
Awards vesting, percentage			200%
Awards vesting, shares (in shares)			4,662,422
Shares outstanding and unvested (in shares)			2,010,449
MPRSUs | Granted in 2021 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair value per share (in dollars per share)			$ 5.31
MPRSUs | Granted in 2021 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair value per share (in dollars per share)			$ 8.58
MPRSUs | Granted First Quarter 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted to executives (in shares)		2,977,711
Awards vesting, percentage			200%
Awards vesting, shares (in shares)			5,955,422
Shares outstanding and unvested (in shares)			2,431,462
MPRSUs | Granted First Quarter 2020 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair value per share (in dollars per share)			$ 2.13
MPRSUs | Granted First Quarter 2020 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair value per share (in dollars per share)			$ 3.63
Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)	14,000,000
Number of shares authorized (in shares)						37,000,000
Number of shares available for grant (in shares)			10,005,452

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Number of Shares Under Option
Beginning balance (in shares)	3,051,500	3,811,229	6,177,126
Options exercised (in shares)	(207,452)	(342,350)	(116,681)
Options forfeited (in shares)	(195,607)	(417,379)	(2,249,216)
Ending balance (in shares)	2,648,441	3,051,500	3,811,229
Options exercisable ending balance (in shares)	2,288,371
Weighted- Average Exercise Price per Share
Beginning balance (in dollars per share)	$ 4.17	$ 4.80	$ 8.87
Options exercised (in dollars per share)	2.75	2.76	2.75
Options forfeited (in dollars per share)	2.77	11.09	16.09
Ending balance (in dollars per share)	4.38	$ 4.17	$ 4.80
Options exercisable ending balance (in dollars per share)	$ 4.64
Weighted- Average Remaining Contractual Life, Outstanding	6 years	7 years	7 years 10 months 24 days
Weighted- Average Remaining Contractual Life, Exercisable	6 years
Aggregate Intrinsic Value, Outstanding	$ 0	$ 5.3	$ 5.6
Aggregate Intrinsic Value, Exercisable	$ 0

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units (Details) - Restricted Stock Units - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Number of Restricted Stock Units
Non-vested beginning balance (in shares)	13,183,600	9,132,552	2,637,358
Granted (in shares)	10,117,037	6,870,481	8,414,762
Vested (in shares)	(2,697,134)	(1,906,607)	(692,868)
Forfeited (in shares)	(2,674,890)	(912,826)	(1,226,700)
Non-vested ending balance (in shares)	17,928,613	13,183,600	9,132,552
Weighted- Average Grant Date Fair Value
Non-vested beginning balance (in dollars per share)	$ 5.25	$ 5.09	$ 12.16
Granted (in dollars per share)	4.54	5.86	3.67
Vested (in dollars per share)	5.95	5.97	12.33
Forfeited (in dollars per share)	5.07	6.68	6.48
Non-vested ending balance (in dollars per share)	$ 4.77	$ 5.25	$ 5.09
Weighted- Average Remaining Years	1 year 3 months 18 days	1 year 4 months 24 days	1 year 8 months 12 days
Aggregate Intrinsic Value, Non-vested	$ 35.7	$ 63.7	$ 41.7

Stock-Based Compensation - Shar

Stock-Based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	$ 31,847	$ 28,412	$ 20,750
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	4,811	4,688	4,166
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	20,746	18,718	13,343
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	$ 6,290	$ 5,006	$ 3,241

Related Party Transactions - Re

Related Party Transactions - Related Party Agreements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Interest component of financing lease	$ 4,508	$ 4,601	$ 4,773
Related party receivables - short term	500	1,179
Related party payables - short term	2,479	47,861
Related party payables - long term	9,649	9,619
Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	22,123	9,413	25,058
Related party payables - short term	110	314
Inventory and Cost of Goods Sold - Kanan, LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	2,104	2,103	2,093
Inventory and Cost of Goods Sold - Sutaria Family Realty, LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	1,211	1,179	1,142
Research and Development - PharmaSophia LLC
Related Party Transaction [Line Items]
Income from related parties	(45)	(329)	(521)
Research and Development - PharmaSophia, LLC - License and Commercialization Agreement
Related Party Transaction [Line Items]
Income from related parties	1,093	0	0
Net Revenue - Fosun International Limited - License and Supply Agreement
Related Party Transaction [Line Items]
Income from related parties	0	(200)	0
Inventory and Cost of Goods Sold - Apace KY, LLC d/b/a Apace Packaging LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	2,742	11,380	11,570
Selling, General and Administrative - Tracy Properties LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	565	532	497
Inventory and Cost of Goods Sold - AzaTech Pharma LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	4,963	5,156	4,506
Selling, General and Administrative - AvPROP, LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	178	165	142
Selling, General and Administrative - Tarsadia Investments, LLC - Financial Consulting Services
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	0
Inventory and Cost of Goods Sold - Alkermes
Related Party Transaction [Line Items]
Amounts of transaction with related party	235	138	0
Selling, General and Administrative - R&S Solutions - Logistics Services
Related Party Transaction [Line Items]
Amounts of transaction with related party	85	183	80
Net Revenue - Zep Inc.
Related Party Transaction [Line Items]
Income from related parties	0	0	(637)
Sellers of Gemini Laboratories, LLC - acquisition agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	3,300
Asana Biosciences L L C - Research and Development
Related Party Transaction [Line Items]
Amounts of transaction with related party	(5)	(4)	0
Members - Tax Receivable Agreement - Other Expense
Related Party Transaction [Line Items]
Amounts of transaction with related party	631	0	0
Related Party | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Related party receivables - short term	12	14
Related party payables - short term	0	30,500
Related party payables - long term	3,290	5,900
Related Party | LAX Hotel, LLC
Related Party Transaction [Line Items]
Financing lease	0	217	2,608
Interest component of financing lease	0	362	4,395
Financing lease cost and interest expense	0	579	7,003
Related Party | Avtar Investments LLC
Related Party Transaction [Line Items]
Related party payables - short term	72	37
Related Party | Cost of Goods Sold - Parking Space Lease | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	100	99	99
Related Party | Selling, General and Administrative - Development and Commercialization Agreement | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	5,000	0	0
Related Party | Other Intangible Assets | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	15,000	0	0
Related Party | Research and Development - License and Commercialization Agreement - Filgrastim and Pegfilgrastim - Research and Development Milestone | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	1,000
Related Party | Inventory Purchases Under License and Commercialization Agreement - Filgrastim and Pegfilgrastim - Inventory and Cost of Goods Sold | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	260	0	0
Related Party | Research and Development - Development and Commercialization Agreement - Ganirelix Acetate and Centrorelix Acetate | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	1,761	1,362	1,550
Related Party | Selling, General and Administrative - Transition Services | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	255	0
Related Party | Development and commercialization - consulting - various products | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	2	628	196
Related Party | Research and Development - Development Supply Agreement | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	0
Related Party | Research and Development, Third-party product development | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	2,688
Related Party | Research and Development - K127 Development and Commercialization Agreement | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	3,000	2,000
Related Party | Cost of Goods Sold and Research and Development - Commercial Product Support | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	1,239	6,130
Related Party | Cost of Good Sold - Profit Sharing | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	2,680	11,189
Related Party | Research and Development - Development and Commercialization Agreements - Various products | Kashiv BioSciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	150	206
Related Party | Sales Milestone Expenses | Avtar Investments LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	216	361	982
TPG Operations, LLC - consulting services | Sales Milestone Expenses
Related Party Transaction [Line Items]
Amounts of transaction with related party	19	249	$ 0
PharmaSophia, LLC - research and development agreement
Related Party Transaction [Line Items]
Related party receivables - short term	0	1,081
Rondo Partners LLC
Related Party Transaction [Line Items]
Related party receivables - short term	486	68
Related party payables - short term	442	442
Related party payables - long term	5,929	3,719
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement
Related Party Transaction [Line Items]
Related party receivables - short term	0	16
Puniska Healthcare Pvt Ltd
Related Party Transaction [Line Items]
Related party payables - short term	0	14,225
Apace Packaging, LLC - packaging agreement
Related Party Transaction [Line Items]
Related party payables - short term	756	560
AzaTech Pharma LLC - supply agreement
Related Party Transaction [Line Items]
Related party payables - short term	863	1,783
Members - tax receivable agreement
Related Party Transaction [Line Items]
Related party payables - short term	201	0
Related party payables - long term	430	0
R&S Solutions LLC - logistics services
Related Party Transaction [Line Items]
Related party payables - short term	7	0
Alkermes Plc
Related Party Transaction [Line Items]
Related party payables - short term	28	0
Tracy Properties LLC
Related Party Transaction [Line Items]
Related party payables - short term	0	0
Asana BioSciences, LLC
Related Party Transaction [Line Items]
Related party receivables - short term	$ 2	$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)

1 Months Ended

12 Months Ended

21 Months Ended

May 27, 2022

Dec. 31, 2021 USD ($) product

Nov. 02, 2021 USD ($)

Apr. 02, 2021 USD ($)

Jan. 11, 2021 USD ($)

Jun. 01, 2020 USD ($)

Dec. 31, 2022 USD ($) candidate

Oct. 31, 2022 USD ($)

Aug. 31, 2022 USD ($)

Jul. 31, 2022 USD ($)

Mar. 31, 2022 USD ($)

Feb. 28, 2022 USD ($)

Dec. 31, 2021 USD ($) product

Sep. 30, 2020 USD ($) subsidiary

Aug. 31, 2020 USD ($) product

May 31, 2020 USD ($)

Mar. 31, 2020

Jul. 31, 2019 USD ($)

Dec. 31, 2022 USD ($) building

Dec. 31, 2021 USD ($) product

Dec. 31, 2020 USD ($)

Dec. 31, 2019 USD ($)

Dec. 31, 2017 USD ($) product

Dec. 31, 2022 USD ($)

Aug. 12, 2021 product

Jan. 31, 2021

Jun. 06, 2019 USD ($) product

Related Party Transaction [Line Items]

Annual lease cost

$ 27,116,000

$ 24,371,000

$ 30,924,000

Collaborative arrangement maximum milestone paid

26,500,000

Contractually stated amount of deferred consideration

30,500,000

Contingent consideration

$ 5,900,000

$ 15,427,000

$ 5,900,000

15,427,000

5,900,000

$ 15,427,000

Related party receivables

1,179,000

500,000

1,179,000

$ 500,000

1,179,000

500,000

Acquired non-controlling interest, non-public subsidiary

$ 3,300,000

Number of non-public subsidiaries, acquired non-controlling interest | subsidiary

1

Payments to acquire additional interest in subsidiaries

$ 800,000

Acquired non-controlling interest, non-public subsidiary

$ 2,500,000

Percentage of tax receivable agreement paid to other holders of Amneal common units

85%

85%

Transition Services

Related Party Transaction [Line Items]

Amounts of transaction with related party

300,000

Kashiv BioSciences LLC

Related Party Transaction [Line Items]

Amounts of transaction with related party

$ 22,123,000

9,413,000

$ 25,058,000

Industrial Real Estate Holdings NY, LLC

Related Party Transaction [Line Items]

Lease renewal term

5 years

Industrial Real Estate Holdings NY, LLC | Rent Renewal Fee

Related Party Transaction [Line Items]

Expenses from transactions with related party

$ 100,000

Industrial Real Estate Holdings NY, LLC | Rent Expense

Related Party Transaction [Line Items]

Expenses from transactions with related party

$ 100,000

Annual rent increase (percent)

3%

Related Party | Kashiv BioSciences LLC

Related Party Transaction [Line Items]

Related party receivables

$ 14,000

12,000

$ 14,000

12,000

14,000

$ 12,000

Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Amounts of transaction with related party

$ 2,400,000

Number of generic product candidates | candidate

4

Income from related parties

$ 0

Related Party | LAX Hotel, LLC

Related Party Transaction [Line Items]

Number of buildings, financing lease | building

2

Related Party | Kanan, LLC

Related Party Transaction [Line Items]

Number of buildings, financing lease | building

2

Related Party | Kanan, LLC | Annual Rental Cost

Related Party Transaction [Line Items]

Amounts of transaction with related party

$ 2,000,000

Related Party | PharmaSophia, LLC - research and development agreement

Related Party Transaction [Line Items]

Ownership interest (percent)

50%

50%

50%

50%

Related Party | PharmaSophia, LLC - research and development agreement | Development Costs

Related Party Transaction [Line Items]

Amounts of transaction with related party

$ 1,100,000

Income from related parties

$ 6,000,000

Related Party | Fosun International Limited | Non-Refundable Fee, Net of Tax

Related Party Transaction [Line Items]

Payment received, non-refundable fee

$ 1,000,000

Related Party | Fosun International Limited | Fee Due Upon First Commercial Sale Of Products

Related Party Transaction [Line Items]

Additional amount due from related parties upon sale of each product

$ 300,000

Additional amount due from related parties upon sale of each product, number of products | product

8

Related Party | Subsidiary of Fosun International Limited

Related Party Transaction [Line Items]

Number of products in agreement | product

2

Related Party | Subsidiary of Fosun International Limited | Non-Refundable Fee, Net of Tax

Related Party Transaction [Line Items]

Payment received, non-refundable fee

$ 200,000

Related Party | Subsidiary of Fosun International Limited | Fee Due Upon First Commercial Sale Of Products

Related Party Transaction [Line Items]

Number of products in agreement | product

2

2

2

Additional amount due from related parties upon sale of each product

$ 100,000

$ 100,000

$ 100,000

Av K A R E And R S | Rondo Partners LLC

Related Party Transaction [Line Items]

Due from related parties

100,000

100,000

100,000

TPG Operations, LLC - consulting services

Related Party Transaction [Line Items]

Consulting agreement, term

7 months

Maximum | Related Party | PharmaSophia, LLC - research and development agreement | Development Costs

Related Party Transaction [Line Items]

Related party receivables

4,900,000

Minimum | Related Party | PharmaSophia, LLC - research and development agreement | Development Costs

Related Party Transaction [Line Items]

Related party receivables

$ 1,100,000

Kashiv Specialty Pharmaceuticals, LLC

Related Party Transaction [Line Items]

Voting interest acquired (percent)

98%

98%

Contractually stated amount of deferred consideration

$ 30,100,000

30,500,000

$ 30,099,000

Contingent consideration

5,900,000

$ 3,300,000

5,900,000

3,300,000

5,900,000

$ 3,300,000

Consideration paid in cash on hand

$ 100,100,000

Kashiv BioSciences LLC

Related Party Transaction [Line Items]

Voting interest acquired (percent)

98%

Annual lease cost

$ 100,000

Collaborative arrangement upfront payment

$ 183,000,000

Collaborative arrangement maximum milestone incurred

$ 15,000,000

Estimated useful life (in years)

8 years 3 months 18 days

Collaborative arrangement maximum milestone paid

$ 15,000,000

Kashiv BioSciences LLC | Maximum

Related Party Transaction [Line Items]

Collaborative arrangement upfront payment

$ 37,500,000

Filgrastim

Related Party Transaction [Line Items]

Related party transaction, selling, general and administrative expenses from transactions with related party

$ 5,000,000

Puniska Healthcare Pvt Ltd

Related Party Transaction [Line Items]

Voting interest acquired (percent)

74%

26%

26%

26%

26%

Acquired non-controlling interest, non-public subsidiary

4,300,000

Due to sellers

14,200,000

$ 14,200,000

$ 14,200,000

Consideration paid in cash on hand

$ 14,162,000

$ 72,880,000

$ 1,700,000

$ 1,700,000

Amneal Group

Related Party Transaction [Line Items]

Consideration paid in cash on hand

$ 14,200,000

Kashiv Bio Sciences License And Commercialization Agreement

Related Party Transaction [Line Items]

Number of products in agreement | product

2

Collaborative arrangement term

10 years

Collaborative arrangement, profit share (percent)

50%

Kashiv Bio Sciences License And Commercialization Agreement | Regulatory Approval

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

$ 22,500,000

Kashiv Bio Sciences License And Commercialization Agreement | Successful Delivery Of Commercial Launch Inventory

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

43,000,000

Kashiv Bio Sciences License And Commercialization Agreement | Number Of Competitors For Launch Of One Product | Maximum

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

50,000,000

Kashiv Bio Sciences License And Commercialization Agreement | Achievement Of Cumulative Net Sales | Maximum

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

67,500,000

Kashiv Bio Sciences License And Commercialization Agreement | Achievement Of Cumulative Net Sales | Minimum

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

$ 15,000,000

Ganirelix Acetate and Cetrorelix acetate | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Number of products in agreement | product

2

Collaborative arrangement upfront payment

$ 1,100,000

Ganirelix Acetate and Cetrorelix acetate | Regulatory Approval | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

300,000

Ganirelix Acetate and Cetrorelix acetate | Development Milestones | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

2,100,000

Ganirelix Acetate and Cetrorelix acetate | Development Fees | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

$ 2,600,000

Levothyroxine Sodium | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Amounts of transaction with related party

2,000,000

Additional amount due to related party, if circumstances met (up to)

$ 18,000,000

Posaconazole | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Collaborative arrangement upfront payment

$ 300,000

Posaconazole | Regulatory Approval | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

300,000

Posaconazole | Achievement Of Cumulative Net Sales | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

1,000,000

Posaconazole | Development Milestones | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

$ 800,000

K127 | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Collaborative arrangement upfront payment

$ 1,500,000

K127 | Regulatory Approval | Related Party | Kashiv BioSciences LLC | R&D Reimbursement

Related Party Transaction [Line Items]

Collaborative arrangement maximum contingent payments amount

$ 16,500,000

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Contributions to defined contribution plan		$ 9,500,000	$ 8,900,000	$ 7,700,000
Deferred compensation plan, employer contributions	$ 0

Segment Information - Additiona

Segment Information - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 segment product
Segment Reporting [Abstract]
Number of reportable segments | segment	3
Number of product families | product	250

Segment Information - Schedules

Segment Information - Schedules of Segment Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net revenue	$ 2,212,304	$ 2,093,669	$ 1,992,523
Cost of goods sold	1,416,485	1,302,004	1,329,551
Cost of goods sold impairment charges	11,111	22,692	34,579
Gross profit	784,708	768,973	628,393
Selling, general and administrative	399,700	365,504	326,727
Research and development	195,688	201,847	179,930
In-process research and development impairment charges	12,970	710	2,680
Intellectual property legal development expenses	4,358	7,716	10,655
Acquisition, transaction-related and integration expenses	709	8,055	8,988
Restructuring and other charges	1,421	1,857	2,398
Change in fair value of contingent consideration	731	200	0
(Insurance recoveries) charges for property losses and associated expenses, net	(1,911)	5,368	0
Charges related to legal matters, net	269,930	25,000	5,860
Other operating income	(3,960)	0	0
Operating (loss) income	(94,928)	152,716	91,155
Generics
Segment Reporting Information [Line Items]
Net revenue	1,432,073	1,366,338	1,343,210
AvKARE
Segment Reporting Information [Line Items]
Net revenue	406,110	349,012	293,746
Operating Segments | Generics
Segment Reporting Information [Line Items]
Net revenue	1,432,073	1,366,338	1,343,210
Cost of goods sold	890,245	825,568	894,422
Cost of goods sold impairment charges	5,786	22,692	34,579
Gross profit	536,042	518,078	414,209
Selling, general and administrative	109,781	64,500	56,134
Research and development	167,509	158,365	150,068
In-process research and development impairment charges	12,970	710	2,680
Intellectual property legal development expenses	4,251	7,562	10,647
Acquisition, transaction-related and integration expenses	25	0	328
Restructuring and other charges	821	80	(614)
Change in fair value of contingent consideration	0	0
(Insurance recoveries) charges for property losses and associated expenses, net	(1,911)	5,368
Charges related to legal matters, net	22,400	0	5,610
Other operating income	(3,960)
Operating (loss) income	224,156	281,493	189,356
Operating Segments | Specialty
Segment Reporting Information [Line Items]
Net revenue	374,121	378,319	355,567
Cost of goods sold	177,107	193,562	192,910
Cost of goods sold impairment charges	5,325	0	0
Gross profit	191,689	184,757	162,657
Selling, general and administrative	90,031	84,481	75,917
Research and development	28,179	43,482	29,862
In-process research and development impairment charges	0	0	0
Intellectual property legal development expenses	107	154	8
Acquisition, transaction-related and integration expenses	49	16	85
Restructuring and other charges	0	0	0
Change in fair value of contingent consideration	731	200
(Insurance recoveries) charges for property losses and associated expenses, net	0	0
Charges related to legal matters, net	0	0	250
Other operating income	0
Operating (loss) income	72,592	56,424	56,535
Operating Segments | AvKARE
Segment Reporting Information [Line Items]
Net revenue	406,110	349,012	293,746
Cost of goods sold	349,133	282,874	242,219
Cost of goods sold impairment charges	0	0	0
Gross profit	56,977	66,138	51,527
Selling, general and administrative	53,659	57,918	58,544
Research and development	0	0	0
In-process research and development impairment charges	0	0	0
Intellectual property legal development expenses	0	0	0
Acquisition, transaction-related and integration expenses	0	1,422	641
Restructuring and other charges	0	0	0
Change in fair value of contingent consideration	0	0
(Insurance recoveries) charges for property losses and associated expenses, net	0	0
Charges related to legal matters, net	0	0	0
Other operating income	0
Operating (loss) income	3,318	6,798	(7,658)
Corporate and Other
Segment Reporting Information [Line Items]
Net revenue	0	0	0
Cost of goods sold	0	0	0
Cost of goods sold impairment charges	0	0	0
Gross profit	0	0	0
Selling, general and administrative	146,229	158,605	136,132
Research and development	0	0	0
In-process research and development impairment charges	0	0	0
Intellectual property legal development expenses	0	0	0
Acquisition, transaction-related and integration expenses	635	6,617	7,934
Restructuring and other charges	600	1,777	3,012
Change in fair value of contingent consideration	0	0
(Insurance recoveries) charges for property losses and associated expenses, net	0	0
Charges related to legal matters, net	247,530	25,000	0
Other operating income	0
Operating (loss) income	$ (394,994)	$ (191,999)	$ (147,078)

Segment Information - Schedule

Segment Information - Schedule of Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 589,360	$ 639,003
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	354,504	388,818
India
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	180,325	189,885
Ireland
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 54,531	$ 60,300

(Insurance Recoveries) Charge_3

(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net - Narrative (Details) $ in Thousands		12 Months Ended
	Sep. 01, 2021 facility	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Unusual or Infrequent Items, or Both [Abstract]
Number of facilities damaged | facility	2
Total property losses and associated expenses		$ 0	$ 10,368
Charges (insurance recoveries) for property losses and associated expenses		$ 1,900	$ 5,000

(Insurance Recoveries) Charge_4

(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net - Charges (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Unusual or Infrequent Item, or Both [Line Items]
Total property losses and associated expenses	$ 0	$ 10,368
Less: Insurance recoveries received	(1,911)	(5,000)
(Insurance recoveries) charges for property losses and associated expenses, net	(1,911)	5,368
Impairment of equipment
Unusual or Infrequent Item, or Both [Line Items]
Total property losses and associated expenses	0	4,202
Impairment of inventory
Unusual or Infrequent Item, or Both [Line Items]
Total property losses and associated expenses	0	950
Repairs and maintenance expenses
Unusual or Infrequent Item, or Both [Line Items]
Total property losses and associated expenses	0	3,716
Salaries and benefits
Unusual or Infrequent Item, or Both [Line Items]
Total property losses and associated expenses	$ 0	$ 1,500

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event - Opana ER® antitrust litigation - Revolving Credit Facility $ in Millions	1 Months Ended
	Jan. 31, 2023 USD ($)
Subsequent Event [Line Items]
Payment for legal settlements	$ 83.9
Borrowing capacity	$ 80